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Cytosolic phospholipase A2 (cPLA2) is an important class of enzyme involved in the inflammatory 
pathway. In various disease states such as arthritis and neuroinflammation models, cPLA2 was found 
to have elevated expression or increased activity. As a result, this influenced the production of 
inflammatory markers such as prostaglandins and eicosanoids which in long-term would be 
detrimental to the disease state. Suitable pharmacological interventions for identifying cPLA2 as a 
target have been shown to relieve the effects of inflammation. In this thesis, arachidonyl 
trifluoromethyl ketone was chosen as the scaffold and a library of analogues was synthesized as 
inhibitors of cPLA2. Structure activity relationship (SAR) study was conducted with the use of a 
biochemical assay to identify new leads and effectiveness of cPLA2 inhibition in which the 
successfully developed compound was evaluated on a neuroinflammatory model. In addition, a set of 
fluorogenic inhibitors and substrate of cPLA2 were synthesized and demonstrated to be potential 
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CHAPTER 1: INTRODUCTION 
 
1.1 Phospholipase A2 and its functions 
Phospholipase A2 (PLA2) belongs to a superfamily of phospholipases catalyzing its substrate 
specifically at the sn-2 position of the acyl bond. The metabolites from the hydrolysis of PLA2 are 
lysophospholipids and long chain fatty acids which are mainly long chain polyunsaturated fatty acids 
(LCPUFA) of arachidonic acid (AA) and docosahexaenoic acid (DHA). Lysophospholipids function 
as precursors for platelet activating factors (PAF) and in other reactions ranging from metabolism of 
intracellular phospholipid to growth-factor-like extracellular mediators.
1
 LCPUFA which are found in 
various parts of the body especially in the neural membrane of the Central Nervous System (CNS), act 
as precursors for inflammatory mediators such as eicosanoids and prostaglandins. For instance, AA 
are usually found esterified on membrane phospholipids, and basal levels are converted into 
inflammatory mediators required for bodily functions.
2
 Being a part of membrane phospholipids, the 
cis nature of the double bonds on AA also affects membrane fluidity. PLA2s are therefore important 
modulators in phospholipid turnover and maintain the levels of free LCPUFA, indirectly serving its 
roles in altering membrane fluidity and permeability.  
 
It has been reported that neuroinflammation is strongly influenced by both the activity and 
downstream metabolite produced by PLA2 
2, 3
 PLA2 levels were found to be up-regulated in the event 
of neurodegenerative diseases, which generally involve a sizeable amount of inflammatory and 
oxidative components in their pathways, resulting in severe oxidative stress in the brain.
3
 Several 
neurodegenerative diseases such as ischemia, multiple sclerosis, Alzheimer’s disease, prion diseases 
and schizophrenia have been found to be attributed to neuroinflammation. Hence, it is of paramount 
importance to understand the activity of PLA2 in the CNS. Three most important classes of PLA2, 






1.1.1 Inflammation and Arachidonic Acid Cascade 




A large proportion of phospholipids, in particular phosphatidylcholine, have an arachidonate ester at 
the sn-2 position of phospholipids. After their hydrolysis by PLA2, free fatty acid AA is commonly 
released and acts as the main precursor to the formation of pro-inflammatory eicosanoids such as 
prostaglandins and leukotrienes. Upon the release of AA, 5-lipoxygenase (5-LOX) converts it into 5-
hydroperoxyeicosatetraenoic acid (5-HETE), which is then converted into leukotrienes. Similarly, 
other lipoxygenases (8-LOX, 12-LOX, 15-LOX) also act on AA to produce different isomers of 
HETE as shown in Scheme 1-1.
4,5
 On the other hand, production of prostaglandin PGH2, is controlled 
by the activity of COX1/COX2. This highly unstable endoperoxide is rapidly converted to PGE2, 
PGD2, PGF2α.
6
 Strict control of the levels of AA and lysophospholipids is therefore crucial to 
maintain normal brain function. This implies that PLA2 activity also needs to be strictly modulated so 





1.1.2 Secretory Phospholipase A2 
Secretary phospholipase A2 (sPLA2) is one of the most well-studied class of PLA2 with lower 
molecular weight ranging from 14-18kDa.
7
 They contain 6-8 disulphide bridges and are originally 
isolated and characterized from both cobra and rattlesnake venom.
8
 sPLA2 is calcium dependent and 
possess calcium binding sites for activation. By having a conserved calcium binding loop and a 
catalytic site involving histidine and aspartic acid, they differ from the typical serine proteases which 
utilized acyl enzyme intermediate in the hydrolysis.
8
 A water molecule is first polarized in the dyad 
via a calcium dependent mechanism, which then attacks the carbonyl ester of the phospholipid 
substrates. This class of enzyme has no distinct preference for its substrates, unlike cPLA2 which are 
highly specific for arachidonyl substrate at the sn-2 of phospholipids.  
 
In general, sPLA2 was found to be implicated in various inflammatory and autoimmune diseases. 
Among the various isoforms, sPLA2-IIA is the most extensively studied. This isoform was first 
discovered in atherosclerotic lesions and has its role as inflammatory marker protein in 
atherosclerosis.
8 
Synovial fluids of people suffering from rheumatoid arthritis also had elevated levels 
of sPLA2-IIA while mice which were deficient of this enzyme had reduced symptoms of arthritis.
9
 In 
addition to eicosanoid and prostaglandins production, this class of enzyme was also capable of 
inducing various proinflammatory mediators generation from many cells types such as neutrophils, 




1.1.3 Calcium-independent Phospholipase A2 
Calcium-independent Phospholipase A2 (iPLA2) was originally isolated from macrophage. Calcium 
binding is not a necessary condition for its activation however; its activity can still be regulated by 
calcium binding proteins such as calmodulin or ATP for stabilization. 
11
 Structurally, the catalytic site 
of iPLA2 is similar to cPLA2 bearing an active serine that participates in the hydrolysis. However, the 
serine in iPLA2 lies in a more exposed position, resulting itself to be more accessible to solvents as 
compared to cPLA2. This could shed light on the low substrate specificity of iPLA2 towards AA.
7
 
iPLA2 does not require calcium for its activation, and is regulated in processes such as iPLA2 
 4 
 
oligomerization, caspase cleavage and ATP binding resulting in iPLA2 activation. iPLA2 has several 
isoforms such as iPLA2β, iPLA2γ, iPLA2δ, iPLA2ε, iPLA2ζ, iPLA2η with iPLA2β being the most well-





1.1.4 Cytosolic Phospholipase A2 
Cytosolic phospholipase A2 (cPLA2) is a widely distributed phospholipase that is ubiquitous 
throughout the body. Among the three major phospholipases (sPLA2, iPLA2, cPLA2) mentioned, 
cPLA2 play a vital role in releasing AA specifically in the pro-inflammatory signalling pathway. 
Though sPLA2 and iPLA2 are also capable of mediating such release, selectivity in particular fatty 
acyl chain could not be identified. This selectivity might arise due to the structures of the different 
PLA2 isoforms.  
 











Figure 1-1: Simplified structure of different isoforms of cPLA2. Close structural resemblance was 
observed in C2 and α/β domains among the isoforms bearing a catalytic dyad of Ser and Asp. Red 






cPLA2 contains 6 subgroups, namely α, β, δ, γ, ε and ζ. In the brain, 3 specific paralogs, cPLA2α, 
cPLA2β and cPLA2γ are present.
6, 7 
They are specifically expressed in the amygdale, corpus callosum, 
hippocampus, susbtantia nigra, subthalamic nucleus and thalamus.
13
 cPLA2α is the most well-studied 
among the isoforms and is ubiquitously expressed in most human tissues.
6
 Structurally, they contain 
the same catalytic dyad of serine and aspartic acid enabling their role as phospholipase. However, the 
molecular weight of the various enzyme isoforms ranges from 61kDa in cPLA2γ to 114kDa for 
cPLA2β. The crystal structure of cPLA2α derived from E5-CHO cells had been published.
14
 A novel 
structure containing a C2 domain which exhibits lipid-binding and calcium-dependency characteristic 
in cPLA2α was identified from the crystal structure together with a catalytic domain. This topology 
revealed the presence of a flexible lid that regulates the access of its substrate to the catalytic domain 
bearing the active site. A deep hydrophobic funnel selectively limits arachidonyl substrate entrance 
into the enzyme, while actual catalysis of the substrate occurs at the heart of this funnel. Comparing 
with other serine proteases, cPLA2α differs in that it contained a catalytic dyad consisting of Ser and 
Asp instead of the normal Ser-His-Asp triad. Presence of Ca
2+
 binding on the C2 domain is important 
in promoting the translocation of cPLA2 to approach the membrane. Upon a series of phosphorylation 
and subunit binding, repositioning of the catalytic domain to the membrane surface will then occur, 
leading to the catalytic action of cPLA2.
15
 Among the different paralogs, only cPLA2γ does not 
contain the calcium binding C2 domain. This might also explain why it is calcium independent for its 
activation. The catalytic dyad of Ser and Asp are conserved for all the paralogs.  
 
1.1.4.2 Activation mechanism of cPLA2 
Previous studies reported that cPLA2 perform important functions related to membrane regulation.
7
 
Thus, cPLA2 activity is tightly regulated. One major approach to control cPLA2 activity is by 
regulating the activation of cPLA2. There are several proposed models of cPLA2 activation. Most of 
them are in agreement that cPLA2 activation involves two key post-translational modifications: the 
binding of calcium and phosphorylation of key residues. The presence of calcium has been shown to 
be essential for cPLA2 activity.
16
 For example, production of AA, a product of cPLA2, has been 
demonstrated to be triggered by calcium mobilizing agonists.
17
 Research has also shown that calcium 
 6 
 
binds to the C2 domain of cPLA2, triggering a Ca
2+
 dependent translocation from the cytosol to the 
intracellular membranes in order of preference of the Golgi apparatus, endoplasmic reticulum and the 
nucleus.
15, 18
 This does the essential function of bringing cPLA2 into contact with its substrates; 
membrane phospholipids. There are two known stages of calcium release.
16
 Firstly, a rapid 
intracellular release of calcium triggers the translocation of cPLA2 to the intracellular membranes. The 
second stage involves a sustained influx of external Ca
2+
 which results in stable binding to membrane. 
This mechanism has been supported by studies illustrating that both stages of calcium release are 
needed for cPLA2 function. The application of a serum that increases intracellular calcium stimulates 
the release of AA. However, this effect is inhibited by the addition of chelators that remove 
extracellular calcium.
19
 Likewise, external release of calcium alone results in a slow rate of cPLA2 
translocation with a corresponding low cPLA2 activity and low release of AA.  
 
cPLA2 activity can also be regulated by phosphorylation of key serine residues in the catalytic domain, 
namely Ser505, Ser727 and Ser515. This is supported by the association of several kinases with 
cPLA2 activation in a variety of cell types, and the loss of cPLA2 activity in the presence of 
phosphatases.
17
 Ser505 is the site of action for mitogen activated protein kinases (MAPK).
20
 
Phosphorylation of Ser505 leads to an increase in catalytic activity of cPLA2, thereby resulting in 
enhanced release of arachidonic acid.
20, 21
 Studies have suggested that phosphorylation at Ser505 
enables cPLA2 to achieve its optimal orientation, and increases its binding affinity to phospholipids at 
low calcium levels.
17
 Phosphorylation at Ser727 is the site of action for MAPK downstream kinases. 
Ser727 has been shown to be a functionally important residue that regulates protein-protein 
interaction. One method to demonstrate phosphorylation at Ser727 regulates cPLA2 activity is by 
relieving the inhibition by the p11-annexin A2 complex.
22
 Studies done on rabbit vascular smooth 
muscle cells have also established the crucial role of Ser515 phosphorylation on cPLA2 activity.
23
 
Mutant S515A reduced phosphorylation at Ser505, suggesting that Ser515 phosphorylation is 
upstream of Ser505 phosphorylation and that phosphorylation at both sites are needed for cPLA2 
activity.
24






1.2 cPLA2 in neuroinflammation 
Various reports have surfaced recently on the link between cPLA2 and neuroinflammation.
 3, 25-27
 It  
has been shown that overexpression of cPLA2 led to an increase in pro-inflammatory cytokine 
production, leading to subsequent pathological changes in the neurodegenerative process.
3
 Aberrant 
activation of cPLA2 has been demonstrated in various examples such as stimulation of the MAPK 
signalling pathway for cPLA2 activation via reactive oxygen species (ROS), S-nitrosylation of cPLA2 
and COX-2 by inducible nitric oxide synthase (iNOS) to magnify inflammatory responses etc.
13
 By 
attacking membrane phospholipids, cPLA2 produces pro-inflammatory precursors of 
lysophospholipids and free fatty acids.
28
 In particular, cPLA2 cleaves phosphatidylcholine to form 
lysophosphatidylcholine and arachidonic acid.
29
 Sundaram et al. has demonstrated that an increase in 
cPLA2 activity could result in an increase production of lysophosphatidylcholine. Being a soluble 
lipid mediator released by neurons, cPLA2 could activate glia cells and release pro-inflammatory 





AA itself also plays a role in neuroinflammation. AA is a free fatty acid that is an important 
component of neuronal membranes.
31
 Therefore an overproduction of AA would potentially result in a 
huge increase in prostaglandin and leukotrienes which in long-term would lead to neurodegeneration. 
Studies have shown such elevated levels of prostaglandin E2 in patients with probable Alzheimer's 
Disease (AD), while beneficial effects on the development of AD was observed when downstream 
COX inhibitors was used. Animal studies have also shown that deletion of prostaglandin receptors 
lead to decrease oxidative damage and αβ peptides, indicating that immune-activated oxidative 
damage is present in neuroinflammation.
32,33
 In addition to being a precursor, AA has been shown to 
be involved in mitochondrial dysfunction, and acting as a retrograde messenger implicated in memory 
function.
34
 Toxic and trophic effects were found on neurons after exposure and this also include 
membrane fluidity alteration, protein kinases activation and regulation of gene expression. cPLA2 is 




Membrane phospholipids which are substrates of cPLA2 could be affected when a change in cPLA2 
activity occur. As a result, this causes phospholipid remodelling and membrane perturbations, 
ultimately affecting membrane protein functions.  For instance, prolonged activation of cPLA2 can 
potentially skew the balance of membrane phospholipids in the CNS resulting in their long-term 
destruction. Electron transport chain and other related protein would be directly impacted. Finally, 
alterations in membrane phospholipids can result in increasing membrane permeability and synaptic 
loss.
2, 28
 Curtailing cPLA2 activation to only basal level might therefore be important in reversing the 
harmful effects of long-term neuroinflammation.  
 
1.3 cPLA2 in Alzheimer's Disease 
cPLA2 is known as a contributing factor to neurodegenerative diseases such as AD, Parkinson’s 
disease and multiple sclerosis.
2, 25, 35-36
 Activity of cPLA2 showed to increase in brain fractions of AD 
patients  as compared to that of healthy controls.
37
 In addition, changes in cPLA2 expression had been 
localized to areas of the brain such as the hippocampus and amygdala. The hippocampus, in particular, 
is an area that suffers significant neuronal damage in AD. Conversely, iPLA2 and sPLA2 are 
ubiquitously expressed throughout the brain with sPLA2 largely localized to synaptic vesicles.
25
 
Traditional models which associated cPLA2 overactivation in AD with αβ and NMDA receptors have 
been proposed.  There is a strong case supporting the involvement of αβ in cPLA2 activation - the 
inhibition of αβ leading to a decrease in cPLA2 activity. This is further supported by evidences of αβ 
inducing reactive oxygen species (ROS) production and calcium influx in astrocytes.
38
 As cPLA2 
activation has a similar effect of triggering inflammatory processes and the production of ROS, cPLA2 
may be a downstream effector of αβ pathology. αβ and NMDA receptor stimulation have been shown 





In addition, αβ exposure leading to downstream glutamate excitotoxicity and neuronal damages was 
shown to activate cPLA2. 
13, 41, 42
 This established a link between oxidative/nitrosative pathway to that 
of αβ cytotoxicity and inflammatory response from cPLA2 activation. Re-examining the pathology of 
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Alzheimer’s disease also suggested direct implications of αβ neurotoxicity, arising from cPLA2 
dysregulation.
25, 42, 43 
One possible mechanism to explain the aberrant activation of cPLA2 has been 
proposed by Shelat et al.
44
 Shelat et al illustrated that αβ and NMDA receptors are associated with 
ROS production through NADPH oxidase, presenting a parallel pathway to cPLA2 activation. αβ acts 
on NADPH oxidase, producing ROS that activates ERK1/2, a known activator of cPLA2.  
 
Figure 1-2: Cascade of neurotoxic events leading to neuroinflammation 
 
Nevertheless apart from αβ, Sundaram et al. have also elucidated a novel pathway involving cPLA2 
and p25/Cdk5 mediated neuroinflammation (Figure 1-2).
3
 Sundaram et al. established the link 
between  hyperactivated p25/Cdk5 complex to neuroinflammation through cPLA2. Neurotoxic insults 
lead to an influx of calcium ions, activating Calpain. Calpain cleaves p35, the physiological regulator 
of Cdk5, to form p25, resulting in the formation of the p25/Cdk5 complex. This activates downstream 
signalling events which in turn result in an increased cPLA2 activity. As cPLA2 catalyses the 
formation of lysophosphatidylcholine (LPC) from phosphatidylcholine (PC), the release of LPC 
leading to glia cell activation was observed by detecting an upregulation of glial fibrillary acidic 
protein (GFAP) expression.
45
 Currently, it is not yet known if these pathways occur independently of 
each other, or are linked in an upstream or downstream manner. Nevertheless, this evidence of linking 
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the increased activation of cPLA2 to neurodegeneration has highlighted the need to understand the 
role of cPLA2 in AD pathology as well as the potential of cPLA2 as a promising therapeutic target.  
 
1.4 Current developments in cPLA2 inhibitors 
Identifying cPLA2 as a potential therapeutic target is important as this allows for pharmacological 
intervention that could reduce the harmful effects brought about in a dysregulated system. Inhibition 
can thus be readily achieved using small molecules with high selectivity against cPLA2. Currently, 
considerable efforts had been targeted at generating different scaffolds which could exhibit high 
potency and selectivity on cPLA2 against other phospholipases. Given the ubiquity of this 
phospholipase, various classes of compound synthesized were tested on different cell-lines containing 
the same enzyme to investigate their pharmacokinetic properties. A brief summary of these classes of 
compounds is shown in the following section. 
 
1.4.1 Trifluoromethyl ketones 
 
Scheme 1-2: Structure of trifluoromethyl ketones inhibitors of cPLA2 
 
Arachidonyl trifluoromethyl ketone (AACOCF3), is a trifluoromethyl ketone known to be a potent 
inhibitor of phospholipase A2. Capable of inhibiting cPLA2 and iPLA2 with IC50 values of 1.5 μM and 
6 μM respectively, AACOCF3 is also 500 fold more selective for cPLA2 over sPLA2 in terms of 
potency.
2
  AACOCF3 is widely used as a standard during the screening of inhibitors for in vitro or in 
vivo studies on cPLA2 inhibition. The high potency of AACOCF3 could be due to its close structural 
resemblance with the AA, which was generated after cPLA2 hydrolysis of the membrane substrate. 
Replacing the carboxylic acid with a trifluoromethyl ketone increases the electrophilicity of the 
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carbonyl carbon, resulting in a different form of interaction with the nucleophilic Ser228 residue at 
the catalytic site as compared with the membrane phospholipid substrate. AACOCF3 forms a new 
covalent bond after a nucleophilic attack by Ser228 OH in cPLA2 providing a negatively charged 
hemiketal that is stabilized by two positive arginine residues, hence achieving cPLA2 inhibition. 
 
Inhibition of cPLA2 by AACOCF3 has been demonstrated to have high potencies in various cells, 
providing anti-inflammatory protection to downstream targets. In primary neuronal culture containing 
short-chain peptide oligomers, a dose-dependent and time-dependent increase in phosphorylated 
cPLA2 was detected when treated with synthetic αβ.
43
 This resulted in an increase in AA 
concentration. Pre-treatment with AACOCF3 caused a reduction in AA release and an increase in αβ 
induced cell death while treatment with the iPLA2 inhibitor, bromoenol lactone (BEL) had no effects. 
These results demonstrated the selectivity of AACOCF3 and its ability to provide neuroprotection by 
inhibiting cPLA2. In another series of experiments, treatment of AACOCF3 on rat dorsal root ganglion 
neuron culture prevented growth cone collapse when stimulated by the repellent Semaphorin 3A 
(Sema3A).
46
 Growth cones are axons containing amoeboid tips, which under the actions of eicosanoid 
such as 12(S)-HETE, downstream kinase activation and phosphorylation leading to cone detachment 
occur. As a competitive inhibitor to cPLA2, AACOCF3 prevented the stimulation of phospholipase 
activity by Sema3A, thereby limiting the extent of growth cone collapse.  
 
Other trifluoromethylketone analogues have also been synthesized and tested for their inhibitory 
activity against cPLA2. Amongst them are close structural analogues such as gamma-linolenic acid, 
palmitoyl trifluoromethyl ketone and linoleic acid which were tested on different assay systems 
including mixed-micelle, DOPM/GLU vesicle as well as natural membrane systems from U937 
cells.
47
 It was found that they have a certain degree of selectivity towards iPLA2 instead of cPLA2 








Scheme 1-3: Structures of potent oxoamides inhibitors of cPLA2 
Table 1-1: In vitro and in vivo activities of 2-oxoamides tested on Edema induced rats.
48-50










10a 0.025 ± 0.013 0.01 33 
31b 0.025 ± 0.012 0.0165 11 
AX006 0.017 ± 0.009 0.01 93 
AX012 0.017 ± 0.006 0.008 69 
39 0.011 ± 0.003 0.0001 53 
AX007 0.009 ± 0.004 0.1 63 
38 0.008 ± 0.003 0.008 65 
17b 0.005 ± 0.002 0.00005 71 
a
AX074 0.003 ± 0.001 - - 
a




 XI(50) refers to the inhibitor’s concentration giving rise to 50% inhibition with units of mole 
fractions determined by taking the moles of inhibitor divided by total moles of substrate plus inhibitor 
plus detergent. 
In 2002, G. Kokotos and E.A. Dennis et al developed 2-oxoamides as a novel class of cPLA2 
inhibitor.
51
 Its structure mimics the substrate phosphatidylchloline by possessing isosteric replacement 
of various functional groups. The sn-2 ester of the phosphatidylcholine is replaced by an oxoamide 
functionality which could interact with the OH of Ser228 in cPLA2 while the phosphate on the 
substrate is changed to a carboxylate moiety. In addition, incorporation of two alkyl chains resembles 
the two fatty acid segments on phosphatidycholine, enabling penetration of the molecule into 
hydrophobic regions within cPLA2.
52
 Various modifications on this class of inhibitor have so far been 
carried out. The lead compound AX007 containing a L-γ-norleucine moiety was found while 
screening a library of novel 2-oxoamides and gave a highly potent XI(50) of 0.009 mole fraction.
51
 
Such a biological evaluation was performed by determining XI(50) in a Phospholipase A2 assay 
containing mixed micelles of substrate instead of the conventional IC50 and Ki. XI(50) measurement is 
a more appropriate technique as surface concentration of the inhibitor is more important than the bulk 
concentration due to the primary activity of cPLA2 on the interface. Extensive studies which were 
subsequently performed led to the discovery of more potent analogues such as AX007, 17b and 
AX074.
52
  In addition to the need for a non-bulky side chain beside the nitrogen, chirality beside the 
amide was also an important feature to achieve high potency. It was also found that 2-oxoamide have 
a certain degree of inhibition for sPLA2 while iPLA2 inhibition was minimal. Analogues possessing 






1.4.3 Indoles and derivatives
 
Scheme 1-4: Structure of indole inhibitors of cPLA2 
 
This class of analogues was first reported by Lehr et al. when a library of indole-2-carboxylic acid 
was screened.
54
 By measuring AA release from calcium ionophore A23187-induced bovine platelets, 
1-1 was identified with an IC50 of 8 μM. The extent of cell lysis by the compounds was also reported 
to prevent false positives due to reduced AA formation from lysed cells. Subsequently, further 
investigative studies showed that the carboxylic acid group was important for inhibition. This implies 
that a positive residual in the vicinity of the binding pocket while the acyl containing the carbon chain 
were important for the interaction with OH of Ser228 in cPLA2. Indole N must also be substituted for 
potency to be observed. This substitution required carbon of a certain number, at the same time 
possessing a polar moiety at the chain end such as carboxylic acid giving rise to 1-2 and 1-3 with 
potency of 1.6 μM and 0.5 μM respectively.55 
 
Functionalized indole sulfonamide was developed from Wyeth, starting off as a substrate mimetic 
exercise on indole compounds.
55
 Compounds possessing good pharmacokinetic (PK) properties were 
evaluated with a primary “coumarin assay” and cell-based assays, identifying 1-4 as a lead with good 
potency and PK parameters. IC50 values obtained from the coumarin assay reached 0.8 μM while a 
mast cell line, MC-9 assay similarly gives 0.8 μM.56 Compound 1-5 and 1-6 bearing the sulfoxide 
moiety were subsequently found to have IC50 of 0.8 μM and 0.5 μM respectively in a GLU micelle 
assay.
57
 To further enhance the interaction of the compound with cPLA2, substitution on the C2 of 
indole was extensively explored. The result was the development of a sulfonamide class of compound 
with the following pharmacophore, N-benzhydryl moiety, C2 sulfonamide and C3 benzoic acid. With 
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the eventual aim of reducing plasma clearance, ecopladib was synthesized and found to exhibit high 
potency of 150 nM in a GLU assay
58
(Scheme 1-5). Further explorations gave Efipladib and WAY-
196025 which were capable of achieving an even better potency. Good PK properties were also 
displayed.
59
 Selectivity tests conducted on the compounds found out that they were selective 
inhibitors for cPLA2α while inactive to other isoforms such as cPLA2β and cPLA2γ. Under the same 
assay conditions, strong selectivity of cPLA2 over sPLA2 was observed. A 16% inhibition of sPLA2 at 
high concentration of Ecopladib was obtained while 73% inhibition of cPLA2 was achieved at 
submicro molar concentration. In the case of Efipladib and WAY-196025, no inhibition was detected 
for sPLA2 at 0.5 μM while successful inhibition of cPLA2α was achieved at nanomolar concentrations, 
illustrating high selectivity of the compound for cPLA2α.
59, 60
 Giripladib (also known as PLA-695) 
was another compound exhibiting good potency (Scheme 1-5). However it failed the phase II clinical 
trial (NCT00396955) when a 4 dose regimen of the compound was compared with naproxen and 





Scheme 1-5: Structures of Ecopaldib, WAY-196025, Efipladib and Giripladib 
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Table 1-2: In vitro and in vivo studies for functionalized sulfonamide analogues 
Compound IC50/μM %F
c







  (mL/min/kg) 
1-4 160 >400 63(10mg/Kg) - 
1-5 0.8 2.0 39
d
 44 
1-6 0.5 0.8 11
d
 47 




Efipladib 0.040 0.070 1.0(25mg/kg) 5.0 
WAY-196025 0.010 0.030 6.0(25mg/kg) 6.1 
Giripladib 0.27 0.15 - - 
a
 GLU micelle assay 
b 
Rat Whole Blood assay 
c
 Oral Bioavailability of compound on rats using 
MC/Tween formulation 
d 
Dosage was not stated 
e
Clearance level 
Efipladib was found to have applications in cancer research in terms of preventing the proliferation 
and angiogenesis of cancer via eicosanoid pathways.
62
 Treatment of Efipladib on prostate cancer cell 
lines caused a surge in COX-1 protein and PGE2 level as well as a reduction in lipoxygenase products. 
The possible induced production of COX-1 could enable the mechanism of prostate cancer cell 
survival and proliferation to be elucidated.
63
 WAY-196025, on the other hand, was found to be useful 
such as in asthma treatment. In vitro allergen stimulation on human blood samples obtained from 
asthmatic and healthy individuals were performed in assay added with the inhibitor to block 5-
lipoxyegnase production. It was reported that although allergen regulated gene expression was not 














Scheme 1-6: Structures of Pyrrole derivatives as inhibitors of cPLA2 
 
Lehr first introduced the pyrrole series of inhibitor as a structure mimetic of cPLA2 substrates, 
achieving 1-7 which gave an inhibition value of 24 μM when the AA released from bovine platelets 
was measured after A23187 calcium ionophore stimulation.
54, 65
 Further SAR studies showed that the 
introduction of an acyl group on N led to loss in potency, leading to the use of solely alkyl 
substitution to preserved activity.
54
 An extensive SAR exercise was conducted by varying the long 
alkyl chain at the C3 positions, length of the carboxylic acid at C2 as well as length of the alkyl 
moiety at the 2 remaining sites on the pyrrole. It was found that a propionic acid chain was the 
optimum length for C2 while substitution on the N experienced a significant increase in potency when 
it ends with a carboxylic acid moiety giving compounds 1-8 to 1-11  with IC50 ranging between 3.9-
3.3 μM.66, 67 The methyl group which is less hindered is important to maintain potency of the series.67  
Due to the close structural similarity of indole analogues from the same group, they were postulated to 












Scheme 1-7: Structures of 1-12, Pyrroxyphene, RSC-3388 and Pyrropheneone 
 
Table 1-3: IC50 of pyrrolidene derived inhibitors in different assay conditions 
Name IC50/nM 
 PC/DOG THP-1 PGE2 LTC4 
1-12 165 ± 20 670 ± 70 410 ± 70 370 ± 70 
Pyrroxyphene 78 ± 9 320 ± 30 260 ± 110 260 ± 60 
RSC-3388 1.8 ± 0.5 22 ± 1 31 ± 43 13 ± 1 
Pyrropheneone 4.2 ± 2.6 24 ± 1.7 25 ± 19 14 ± 6.7 
 
Ono and co-workers have developed pyrrolidine derivatives as potential cPLA2 inhibitors.
68
 By 
incorporating a thiazolidinedione into the molecule, this serves as an acid-base interaction with Arg 
200. In addition, the carbonyl on the o-(benzoyl)-benzoyl moiety, which was bonded to N of 
pyrrolidine, binds with the OH of Ser228, thus occupying the catalytic site of cPLA2 entirely. Highly 
potent inhibitors were developed from this scaffold with 1-12 bearing an IC50 value of 670 nM in AA 
production inhibition assays derived from THP-1 cells, surpassing the commercial inhibitor. Further 
modifications of the pharmacophores which include the introduction of F on the benzene, increasing 
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the steric bulkiness on the biphenyl as well as lengthening the thiazolidinedione via double bond 
insertion gave pyrroxyphene and RSC-3388 which gave IC50 values of 320 nM and 22 nM 
respectively under the same assay condition. Furthermore, the cPLA2 activity was evaluated with the 




Due to the promising results obtained, pyrrophenone was synthesized by replacing the biphenyl 
functionality on the first three analogues with an S-trityl group to provide a sterically crowded and 
lipophilic moiety. This enabled pyrrophenone to achieve potency comparable to RSC-3388. (Table 1-
3).
69, 70
 Computational studies performed on docked cPLA2 using pyrrophenone also suggested that 
steric bulkiness in functionally allowed region could increase the potency of the drug.
71
 Moreover, the 
compound was also a selective cPLA2 inhibitor over sPLA2 and porcine pancreatic lipase.
70
 
Pyrrophenone has since been used as a commercial inhibitor for cPLA2, finding applications in 
various biological experiments, such as regulating intercellular adhesion molecule 1 expression, 
mitochondrial Ca
2+




1.4.6 Other Inhibitors 
Scheme 1-8: Structures of 1,3-disubstituted propanones derivatives as inhibitors of cPLA2 
Connolly et al have developed various novel inhibitors mimicking the substrate in terms of its 
phosphate group, arachidonic acid as well as a serine trap. Such characteristics led to the design of 
compounds bearing a carboxylate, aromatic backbone as well as an electrophilic ketone moiety. 
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Extensive work were then performed to probe the pharmacophore of the inhibitor, in terms of 
lipophilicity of the aromatic backbone, electrophilicity of the ketone and acidity of the carboxylate, 
etc.
75
 This gave rise to 1-13 and 1-14 which showed nanomolar inhibition of cPLA2 in a bilayer assay 
and low nanomolar inhibition in a soluble substrate assay. Efforts to reduce the lipophilicity of the 
scaffold was achieved by introducing heterocyclic moiety into the structure in 1-15, giving 
comparable potency in soluble substrate assay while low micromolar inhibition was achieved in HL90 
cell assay for 1-16.
76 
 






HL 90 cell assay 
IC50/ μM 
1-13 8 30 2.8 
1-14 4 80 - 
1-15 - 560 1.0 
1-16 - 50 1.3 
 
With the high potency achieved for the 1,3-disubstituted propanone series, indonyl propanone 
analogues 1-17 was first synthesized and found to have IC50 of 35 nM. SAR studies resulted in the 
highly potent 1-18 and 1-19 when tested by vesicle assay on purified enzymes and cellular assay 
containing human platelets. IC50 of less than 5 nM was reported for both compounds in the vesicle 
assay while less than 2 nM inhibition was achieved in the cellular assay with phorbolester (TPA) as 
stimulant.
77
 Further modifications involving bioisosteric replacement of the carboxylic acid with 
amide, sulfonamide, thiazoldine and oxadiazole etc did not improve the potency satisfactorily.
78
 In a 
bid to improve the solubility of the compound in water, a novel class utilizing the attachment of the 
propanone to other sites on the benzene ring rather than substitution on the indole-N was developed. 
Although the IC50 values and metabolic stability of 1-20 and 1-21 in an in vitro environment of rat 






Scheme 1-9: Structures of 1-17 to 1-23 as cPLA2 inhibitors 
 
Table 1-5:  Inhibition data and pharmacokinetic parameters of indonyl propanone inhibitors
 
 
Compound Vesicle assay with 
isolated enzyme 
IC50/nM 









1-17 35 18 <5 8.4 ± 2.0 
1-18 4.3 0.9 - - 
1-19 4.9 1.1 - - 
1-20 400 300 <5 30 ± 2.5 
1-21 600 500 <5 17 ± 0.6 
1-22 12 - 30 212 ± 15 
1-23 2.1 - 81 <1 
a
TPA (phorbolester 12-O-tetradecanoylphorbol-13-acetate) 
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1-22 and 1-23 with low nanomolar inhibitory activities of 12nM and 2.1nM respectively were also 





22 possessed a modest metabolic stability but an excellent solubility of 212μg/ml while 1-23 had a 
high metabolic stability of 81% but relatively low solubility.  
 
Scheme 1-10: Structure of methyl arachidonyl fluorophosponate, a non-selective PLA2 inhibitor 
 
Based on arachidonyl selectivity of cPLA2 and the need for a Ser residue involvement during 
hydrolysis, Huang et al developed methyl arachidonyl fluorophosphonate (MAFP) which was shown 
to have good blocking effects for cPLA2.
84
 Being an irreversible inhibitor, a covalent phosphonoester 
bond would likely be formed when the OH of Ser228 was substituted with the F on MAFP. As a 
result, MAFP was also a good active site titrator of cPLA2 activities.
84
 Although it possesses high 
inhibitory action on cPLA2 (IC50 = 0.5 μM), it could similarly inhibit iPLA2 in a time-dose dependent 
manner of up to 0.75 μM, making it an unselective inhibitor.2 In addition, it was also a potent 
irreversible antagonist of the anandamide amidase whose substrate is arachidonyl ethanolamide.
84
 Due 
to its non-specificity, this property of dual inhibition of iPLA2 and cPLA2 is also frequently utilized to 
quench effects of phospholipase A2 entirely.  
 
1.5 Fluorogenic inhibitors and substrates of PLA2 
 
1.5.1 Principle of Fluorescence  
 
Photoluminescence refers to the phenomenon where the excitation of an electron from the ground 
state to a higher energy state via absorption of electromagnetic radiation resulted in the emission of 
photons. Whether the excitation of the electron into higher electronic states actually leads to an 
eventual emission of light is dependent on various factors. Emission of light may not occur when 
 23 
 
excited electron relaxes to the ground state through non-radiative means such as interconversion, 
intersystem crossing and vibrational relaxation, as illustrated via the Perrin-Jablonski diagram (Figure 
1-3).
85
 When the electronic transition from the excited state to the ground state proceeds via radiative 
means, photoluminescence could be observed. This could broadly be classified into florescence and 
phosphorescence. Due to the difference in the type of excited state the electron is residing in, there is 
a difference in the timescale for light emission to occur. Fluorescence occurs when electronic 
transition to the ground state proceeds readily upon electronic excitation while a delayed one is 








1.5.2 Fluorophores and immunofluorescence 
Fluorophores are compounds which produce fluorescence when excited by light. Organic molecules 
in particular possessing extended conjugated ᴨ-system are typical examples of fluorophores. The use 
of fluorophores is especially important in the field of bio-imaging. Ideal fluorophores should possess 
the following requirements. They should have high quantum yield with large extinction coefficient at 
the excitation wavelength. In addition, photo-stability of the molecule is important to reduce the 





In the field of immunofluorescence, fluorophores conjugated to antibodies are frequently used to label 
target antigenic sites. This powerful imaging technique picks up the emitted fluorescence by imaging 
instruments such as fluorescence/confocal microscopy, array scanner and flow cytometers, enabling 
researchers to elucidate cellular structures and visualize intracellular processes.
88 
Under the umbrella 
of immunofluorescence, labelling of antigens on cells is termed as immunocytochemistry (ICC) while 
tissue staining is known as immunohistochemistry (IHC). Immunofluorescence could be performed 
via a direct method or indirect method. For direct immunofluorescence, primary antibodies of target 
antigens are directly conjugated with the desired fluorophores. This has advantages of shorter 
labelling time and reduced procedures while handling the sample. However, this method suffers from 
high cost and lower signal strength. On the contrary, the indirect method involves an initial use of an 
unlabelled primary antibody, followed by incubation of the sample with a secondary anti-
immunoglobulin antibody that is conjugated with a fluorescent dye. With the second method, signal 
amplification could be achieved as one primary antibody had multiple binding sites for the secondary 
to attach itself on. A wide array of different coloured dyes could be chosen from different secondary 
antibodies that could be attached to the same primary. It has thus found widespread uses accompanied 
with its huge economical saving.  
 
On the side-line, nuclear staining technology also plays an important role in bio-imaging. Cell-
penetrant nuclei selective probes allow cells to be stained without much processing required. In 
addition, these probes have minimal effects on cell functions, enabling nuclear processes such as 
mitosis or cytokinesis to be monitored real-time. By using contrasting dyes to label different 
organelles, eg. Nuclei and mitochondria, multicolour images could be generated, allowing a complete 
visualization of the cell. Commonly used nuclear acid stains include DAPI (4’,6-diamidino-2-
phenylindole) and Hoechst stains (bis-benzimides derivatives) which intercalates with AT regions of 
the DNA.
89
 Researchers commonly use such probes together with immunofluorescence to visualize 
localizations of cellular processes. For example in Figure 1-4, the use of a secondary antibody 
conjugated to Alexafluor® 488 and DAPI enables the simultaneous staining of both the cellular nuclei 
as well as cPLA2 in SHSY5Y cells. Both dyes have distinctly different excitation and emission, as 
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such it could be detected at different wavelength upon applying the right type of filter. Visualization 
of the location of cPLA2 (appeared green in Figure 1-4) was observed to be at the cytoplasm, 
separated from the nuclei (appeared blue), with distinctly defined neurites-like structures. 
(A) 
     
(B) 
 
(C)                                               







Figure 1-4: Fluorescence images of cells (A) Overlay image of Immunofluorescence of SHSY5Y 
cells between two channels. (B)(Left) Stained cPLA2 on SHSY5Y cells via secondary antibody 
conjugated to Alexafluor 488. Image captured via FITC channel. (Right)Stained nuclei of SHSY5Y 
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cells via DAPI. Image captured via DAPI channel. Images were obtained from control experiments 
performed in chapter 4. (C) Absorption and Emission spectra of Alexa Fluor ® 488 and DAPI.
90, 91 
 
1.5.3 Fluorogenic PLA2 probes 
 
Scheme 1-11: Structures of Fluorogenic substrates of PLA2: DBPC, RED-PED6, PENN/SATE 1, 






Various fluorogenic probes of PLA2 had been previously synthesized.
 92-96 
They are substrates of PLA2 
bearing fluorophores which could be used to track the real-time activity of PLA2 and localization of 
the enzyme. At the same time, such compounds could also be utilized in fluorogenic assays. In the 
past, radiometric assay measuring the level of released radioactive fatty acid from cells was used to 
measure PLA2 activities. This technique was dangerous and failed to give unambiguous determination 
of the type of PLA2 responsible for the reaction. On the other hand, fluorogenic probes assays are 
rapid and highly sensitive, aiding in high throughput screening of enzyme samples or synthesized 
compounds. This would be important for in vitro drug discovery and research of PLA2 in cellular 
signalling applications. There were a few strategies that were employed when designing the substrates. 
DBPC and Red-PED6 were designed by attaching quencher groups on the tail end of sn-1 acyl 
group.
92-93
 Fluorophores attached on the sn-2 tail end were quenched due to the close proximity of the 
quencher such as the DABCYL group on DBPC and the multiple nitro groups on Red-PED6.
93 
Upon 
PLA2 hydrolysis, the non-quenched fluorogenic carboxylic acid would be able to exhibit fluorescence, 
thus giving a direct indication of enzymatic activity. A 25-fold increase in fluorescence level by bee 
venom PLA2 was observed upon hydrolysis of DBPC with bee venom PLA2.
92
 Activity of cPLA2 was 
subsequently visualized in bradykinin-inducible canine kidney cell line (MDCK-D1) with confocal 
microscopy. 
 
FRET transition was another strategy employed. By pairing two different fluorophores of overlapping 
absorption and emission spectra, detection of hydrolytic changes could be done at two different 
channels, eg increase in intensity of donor emission or drop in intensity of acceptor emission. Probes 
such as PENN/SATE 1 and BODIPY FR-PC are good examples of this. PENN/SATE 1 contains a 
NBD as a FRET donor and Nile red moiety as the acceptor. NBD has an emission at 543 nm, which 
coincides with the excitation of Nile red at 540 nm. With an emission at 640 nm, an excitation at 
NBD’s absorption will lead to a FRET transition leading to this emission in the probe.  The authors 
were able to demonstrate the probe as cell penetrant and tracked the expression of PLA2 in the growth 
of Medaka fish embryos.
94-95
 The BODIPY FR-PC utilized 2 derivatives of the BODIPY group having 
absorption and emission of 505/512 and 558/568 respectively. It had been shown to be capable of 
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tracking endogenous PLA2 activity in zebrafish.
93
 Recently, the group from Chen et al had 
demonstrated the use of FRET using NBD-PC and quantum dot loaded cluster of CdSe/ZnS 
compacted within a phospholipid micelles. A low background fluorescence with a low limit of 
detection of 3UL
-1




1.6 Objectives of Research 
The aim of this thesis is therefore to synthesize small molecule inhibitors of cPLA2 which are 
structurally similar to its natural substrate. By evaluating the biological activity of these compounds, 
our aim is to determine the structure activity relationship (SAR) of the inhibitors on cPLA2 to better 
understand the active site and binding pocket of the enzyme. This could provide future insight to 
develop a more potent and selective inhibitor. Molecular modelling would be an essential part to 
rationalize and further identify the possible residues involve in the inhibition. From the hit compound, 
selectivity and cytotoxicity tests would be performed to evaluate its feasibility as a drug and 
subsequently in a neuroinflammatory model. 
 
Another objective of this thesis is to develop fluorogenic inhibitors and substrate of cPLA2. Current 
design of fluorogenic substrates are based on criteria such as cell-permeability and the quantum yield 
of the respective fluorophores. This thesis aimed to develop a library of fluorogenic inhibitors of 
cPLA2 which could perform its function as an inhibitor and at the same time as a tool in bio-imaging. 
From the most potent inhibitor obtained from biochemical screening, the fluorophore was 
incorporated into the substrate that was synthesised. This aimed to provide a more guided approach to 
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CHAPTER 2: CHEMICAL SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP 




Phospholipases A2 (PLA2s) are a superfamily of enzymes characterized by their ability to hydrolyze 
the acyl ester bond at the sn-2 position of glycerophospholipids to yield polyunsaturated fatty acids 
(PUFAs) and a lysophospholipid.
1
 The mammalian PLA2 family comprises five main types of 





-independent iPLA2, the platelet-activating factor acetylhydrolases PAF-AH and the 
lysosomal PLA2. Of these PLA2 enzymes, the ubiquitous cPLA2 is found to be responsible for the 
release of arachidonic acid (AA), an important PUFA which serves as the precursor for the synthesis 
of eicosanoids and prostanoids that mediate a wide variety of inflammatory responses.
2
 In the central 
nervous system, cPLA2 activation has been implicated in the pathogenesis of a number of 
neurodegenerative (Alzheimer’s disease, Parkinson’s disease and prion diseases) and neuropsychiatric 
(schizophrenia and depressive disorder) diseases.
3
 Effects of inflammation and its involvement in 
nitrosative/oxidative signaling pathways for example had been frequently cited as a pathogenetic link 
to Aβ-amyloid production due to the actions of cPLA2. A direct effect of a sustained, abberant cPLA2 
activation could result in enhanced neural membrane destruction eventually comprising functions on 
membranal ion receptors, leading to cell death.
3 
Thus cPLA2 is an important target for drug discovery, 
and for the development of new therapeutics to treat neurodegenerative and neuropsychiatric 
disorders. An ideal cPLA2 inhibitor should not only reach the site where inflammatory processes are 
taking place (this may be achieved through improved drug delivery systems), they should also inhibit 
inflammation, block oxidative stress and cross the blood-brain barrier. To-date, various organic 
compounds have been shown to inhibit cPLA2 selectively.
4
 However, some of these compounds 
provide unfavorable side-effects
5 
while others suffer from solubility and metabolic stability 
problems.
6
 Thus there is a need to examine other compounds for their activities and suitability as 
cPLA2 inhibitor. As part of our efforts to develop cPLA2 inhibitors as potential drug candidates for the 
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treatment of neurological disorders, we have synthesized a new series of AA analogues and evaluated 
them for their inhibitory activities. In our inhibitor design, we have included the arachidonyl 
trifluoromethyl keto pharmacophore, as earlier studies have shown that arachidonyl trifluoromethyl 
ketone (AACOCF3) is a potent but non-selective inhibitor of cPLA2 that has been applied to various 
neurological studies.
7
 Bearing close structural resemblance with the substrate of cPLA2 - 
phosphatidylcholine (PC), it had been shown to be cell-penetrant and effective in reducing the 
undesirable effects of a dysregulated cPLA2 system.
8
 These include cell models, lysate systems as 
well as in vivo studies of CNS systems demonstrating its potential in breaching the blood brain 
barrier.
8-9
  We hoped to utilize the relevant pharmacophores of AACOCF3 to achieve its potent and 
cell-penetrant capability, at the same time develop a selective inhibitor of cPLA2 through our study. 
We herein present the synthesis of AA analogues 1a-o, 2a-q and 20c as well as the investigation of 
these compounds for their (i) inhibition of cPLA2, (ii) cytotoxicity, (iii) specific functionality to the 
inhibitory function, and (iv) ability to cross the blood-brain barrier.  
2.2 Chemical Synthesis 
2.2.1 Retrosynthetic Analysis of AACOCF3 
 
Scheme 2-1: Retrosynthesis of 2-1 
 
The retrosynthetic analysis of 2-1 (AACOCF3) and its analgoues was envisioned to be synthesized 
from 2-2, where ester could be subsequently converted into a trifluoromethylketone group. 2-2 could 
be synthesized from 2-3, via a controlled hydrogenation to form the all-cis tetraene functionality. 
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Disconnection at the appropriate positions on the skipped alkyne 2-3 could form the individual alkyne 
fragments 2-8, 2-10 and 2-11, which are commercially available. Through a series of cross-coupling 
and bromination reactions as shown in earlier studies, 2-1 and its analogues could be synthesized.
10
 
Using AA as a scaffold, we sought to enhance the potency and selectivity of the cPLA2 inhibitors. The 
inhibitor design involves the modification of AA at different selected positions of the compound 
(Figure 2-1).  
 
 
     D         C              B            A   
 
Figure 2-1: Functionalities on AA that could be varied: A – tail length, B – number of double bonds, 
C – number of methylene groups between the first double bond and the carbonyl group, and D – 













2.2.2 Synthesis of AACOCF3 and trifluoromethylketone based analogues 
Scheme 2-2. Synthesis of AACOCF3 and analogues (a) 4-Chloro-2-butyn-1-ol, CuI, NaI, K2CO3, 




C, 1 h (c) Propargyl alcohol, CuI, NaI, 




C, 1 h (e) Methyl 6-hexynoate, CuI, 
NaI, K2CO3, DMF, rt, overnight (f) Propyl 5-pentynoate, CuI, NaI, K2CO3, DMF, rt, overnight (g) H2, 
Ni(OAc)2.4H2O, NaBH4, en, 95% EtOH, rt, 2 h (h) i) NaOH, MW 120
o
C, 1 h ii) Trifluoroacetic 
anhydride, Pyridine, , CH2Cl2, rt, 2 h (i) Propargyl alcohol, n-BuLi, HMPA, THF, -78
o
C to rt, 
overnight 
Modification of the tail length (A): AACOCF3 1a was prepared by assembling alkynes together 
through a series of coupling and bromination reactions according to the synthetic strategy shown in 
Scheme 2-2a.
10 
A total of 3 coupling and 2 bromination reactions were performed to reach the skipped 
diyne 8a. 8a was initially hydrogenated with Brown’s P2 nickel catalyst in ethanol according to a 
published procedure.
10d
 However this did not provide the desired compound 9a (Table 2-1, entry 1). It 
was observed that decreasing reaction time improved the yield as over-hydrogenated side products 
were being reduced (Table 2-1, entry 2-4). Optimization of the hydrogenation reaction by varying the 
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equivalent of the catalyst and reaction conditions (Table 2-1) eventually provided 9a in 68% yield. 
Initial attempts to trifluoromethylate 9a by stirring TMSCF3 and CsF as a TMS activator with the 
ester in CHCl3 at room temperature did not yield 1a.
11a
 Replacing CsF with TBAF also failed to 
provide the desired compound.
11b
 We attempted to convert 9a to the corresponding carboxylic acid 
and then treating it with LDA and EtO2CCF3.
11c
 However this too did not yield 1a. Finally we tried to 
trifluoromethylate the intermediate carboxylic acid with pyridine and TFAA
12
 and gratifyingly this 
gave 1a in 48% yield (over 2 steps). Analogues 1b - 1d containing the tetraene was synthesized in the 
same manner by varying the alkyne 3 in the first step of the reaction. Analogues 1f - 1h containing the 
triene was synthesized by reducing the number of coupling and bromination steps to reach a skipped 
diyne 10a-c before hydrogenation and trifluoromethylation to obtain the respective compounds. 
Table 2-1: Optimization for the hydrogenation of compound 8a 
Entry 
Equivalents of Brown’s 
P2 nickel catalyst
 
Solvent Time (h) Yield (%) 
1
9d 
0.32 Pure EtOH 8 - 
2
 
2.24 95:5 EtOH-2 M NaOH 8 - 
3
 
2.24 95:5 EtOH-2 M NaOH 3 19 
4
 
2.24 95:5 EtOH-2 M NaOH 1 63 
5
 
1.5 95:5 EtOH-2 M NaOH 1 68 
 
Modification of the number of double bonds (B): In the synthesis of analogues 1i-l which contain two 
double bonds, the precursor intermediate 13a-d is not commercially available and was synthesized by 
treating alkyl halide 12a-d with propargyl alcohol in the presence of butyllithium and an additive as a 
solvating agent. Initially N,N’-dimethylpropyleneurea (DMPU) was used as the additive but it gave 
13b in only 20% yield. Hence we tried hexamethylphosphoramide (HMPA) which provided 13b in 86% 
yield. This may be attributed to the increased polarity of the P=O bond in HMPA as compared to the 
C=O in DMPU, which stabilizes the acetylide to a greater extent. HMPA was thus used as an additive 
for the synthesis of intermediate 13a-d.  
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Modification of the number of methylene groups between the first double bond and the carbonyl 
group (C): The synthesis of 1a-d and 1f-l involved the coupling of methyl 6-hexynoate to the 
brominated intermediate before hydrogenation. To synthesize 1e with reduced carbons between the 
carbonyl and first double bond, coupling of 7e to propyl 5-pentynoate yielded the skipped diyne 8e 
which was hydrogenated and trifluoromethylated to give 1e. 
Scheme 2-3. Synthesis of 1m to 1o (a) NH3, Mg(OMe)2, MeOH, 80
o
C, overnight (b) i) NaOH, MW 
120
o
C, 1 h ii) Chlorodifluoroacetic anhydride, Pyridine , CH2Cl2, rt, overnight (c) i) NaOH, MW 
120
o
C, 1 h ii) Difluoroacetic anhydride, Pyridine , CH2Cl2, rt, overnight. 
Modification of the functionality on the carbonyl group (D): To form a primary amide 1m, tetraene 9a 
underwent amidation by heating it with a solution of ammonia dissolved in methanol and Mg(OMe)2 
overnight at 80
o
C. The chlorodifluroketone and difluoroketone functionalities in 1n and 1o were 
respectively synthesized by hydrolyzing the ester 9a to the corresponding carboxylic acid followed by 









2.2.3 Synthesis of Arachidonyl based amide analogues 
 
Scheme 2-4. Synthesis of Arachidonyl based amide analogues (a) CH≡C-(CH2)qCO2R
2
, CuI, NaI, 
K2CO3, DMF, rt, overnight (b) H2, Ni(OAc)2.4H2O, NaBH4, en, 95% EtOH, rt, 2 h (c) MeOH/NaOH, 
rt, 3 h (d) NH2-Alk-CO2Me or NH2-Ar-CO2Me or NH2-Ar-CONH2, EDC.HCl, HOBt, TEA, DMF, rt, 
overnight (e)i) (COCl2), catalytic DMF, CH2Cl2, rt, 1 h ii) NH2-Ar-CO2Me, TEA, THF, rt, overnight 




Scheme 2-5. Synthesis of 2p and 2q (a) 3-aminobenzenesulfonamide, EDC.HCl, TEA, MeCN, 4
o
C, 
overnight (b) Methyl 5-aminopentanoate hydrochloride, EDC.HCl, HOBt, TEA, DMF, rt, overnight  
(c) 22, CuI, NaI, K2CO3, DMF, rt, overnight (d) H2, Ni(OAc)2.4H2O, NaBH4, en, 95% EtOH, rt, 2 h 
(e) MeOH/NaOH, rt, 3 h 
 
Modification of the functionality on the carbonyl group (D)continued: To synthesize 2 which differs 
from the rest of the class via an extension from the carbonyl amide, the skipped dyne 7a and 7b were 
coupled with the respective alkyne ester to form 8a and 17a-c (Scheme 2-4). Upon hydrogenation and 
ester hydrolysis, the corresponding carboxylic acids 19a-d were coupled to the appropriate amines via 
an amide coupling involving EDC.HCl, HOBt, TEA to give 20a – 20k, 2l – 2m and 2p. The amines 
involved are primary amines which are not deactivated by electron-withdrawing groups. For example, 
Methyl 3-aminobenzoate involved in synthesizing 20d, 20i and 20j has sufficient electron density to 
be coupled with the carboxylic acid in the presence of the electron-withdrawing methyl ester at the 
meta position. 20a-20k possessing a methyl ester was then hydrolyzed to release a free carboxylic 
acid as the final analogue. 2l and 2m possess a primary amide instead of ester hence they do not 
require further hydrolysis after the amide coupling step and could be screened for their inhibitory 
activity. To synthesize 2n and 2o, the acid 19a had to be converted into an acid chloride with oxalyl 
chloride before reacting it with the respective amines to form 20n and 20o. This was due to 
conjugative electron-withdrawing effects from the methyl ester on the benzene ring, resulting in a 
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huge decrease in electron density of the amine, affecting its reactivity. As such, a harsher amidation 
condition was required. 20n and 20o were then hydrolyzed to the free acid form 2n and 2o. 2q was 
synthesized by coupling 7a with the amine 23 followed by hydrogenation and hydrolysis. The full 




Figure 2-2: Structures of all synthesized inhibitors 
 
2.3 Biological Results of cPLA2 Assay 
Tables 2-2 and 2-3 show the results of the inhibitory function tests of the compounds on cPLA2. The 
compounds were evaluated with a fluorogenic PLA2 assay kit (EnzChek® Phospholipase A2 Assay 
Kit, Catalog No: E10217) at a standard 10 μM concentration to filter out potential inhibitors. Potential 
inhibitors were determined by their ability to lower cPLA2 activity which could be translated to the 
percentage inhibition values.  
Modification of the tail length (A): To investigate the effects of the alkyl chain length on the 
compound’s inhibitory activity, analogues 1b and 1c were synthesized. A phenyl moiety was 
introduced in 1d to explore the change it had on the potency.  From Table 2-2, it can be seen that 
varying the tail length did not provide any significant improvement in potency as compared to 1a 
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(Table 2-2, Cpd 1a-1c). Nevertheless, a slight increase in potency was seen when the C8 (1c) alkyl 
chain was decrease to a C3 (1b) chain. The same trend was also observed for the diene series (1i – 1l). 
Increasing the alkyl chain length from C5 (1i) to C13 (1l) chain length resulted in a huge decrease in 
potency from 63.6% inhibition to 27.6%. A small increase in the potency from C5 (1i) to C7 (1j) was 
visibly detected although the increase is within the margin of error. 1d possessing a phenyl moiety 
instead of the alkyl chain has the highest potency within the trifluoromethylketone series (Table 2-2). 
The highest potency could be attributed to additional interactions with cPLA2 (vide infra). 
Modification of the number of double bonds (B): The skipped alkene functionality in the arachidonyl 
backbone causes 1a to be light and oxygen sensitive.
13 
We hypothesized that reducing the number of 
skipped alkenes on the backbone would improve the compound’s stability. Hence analogues with a 
reduced number of double bonds 1f-l were synthesized (Schemes 2-2a and 2-2b). Comparing their 
potencies with 1a, the improvement in the potencies were less impressive. Nevertheless an increase in 
potency was detected when the number of double bonds increased from two (1k) to four (1a) while 
maintaining the number of carbons unchanged. A plausible explanation could be an increased in 
rigidity of the compound with more double bonds, making it less rotatable hence improving its 
binding affinity with the enzyme pocket.  
Modification of the number of methylene groups between the first double bond and the carbonyl 
group (C): Earlier studies have shown that the number of methylene groups between the carbonyl 
carbon and the first double bond (Figure 2-1) is important for enzyme recognition.
14
 To better 
understand the effects of these methylene groups on the inhibitory properties of the compound, 1e 
with two methylene groups was synthesized. Results obtained showed that 1e had the same potency as 
1a (Table 2-2). This suggested that the position of the double bonds from the carbonyl for enzyme 
recognition might not be as important as it was previously postulated.
14
  
Modification of the functionality on the carbonyl group (D): Earlier studies have shown that the 
presence of a trifluoro moiety confers a very high electrophilicity on AA.
15
 This can result in the keto 
existing largely in the hydrated form, thus reducing the concentration of the active species. To vary 
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the electrophilicity of the carbonyl group, we have modulated the number of fluorine atoms or 
replaced the trifluoro moiety with other functionalities (Table 2-2, Cpd 1m-1o). Reducing the 
electrophilicity of the carbonyl group by reducing the number of fluorine atoms on the trifluoromethyl 
moiety also did not result in a more potent cPLA2 inhibitor (Table 2-2, Cpd 1n-1o). Similarly a drop 
in potency to 39.3% inhibition was observed in 1m when the carbonyl was converted into a primary 
amide.  
Studies by Pickard et al
16
 have shown that site-directed mutagenesis of Arg200 in cPLA2 severely 
affected its catalytic property. Since this amino acid residue is positioned near the mouth of the active 
site cleft, it was proposed that Arg200 plays a stabilizing role by interacting with the phosphate group 
on phosphatidylcholine, a glycerophospholipid that is hydrolysed by cPLA2.
17
 We postulated that 
replacing the trifluoromethyl moiety with a group containing a negatively charged functionality that 
can interact with Arg200 would improve the compound’s potency. Encouraged by these results, we 
decide to pursue the synthesis of amide analogues containing functionalities that could stabilize 
Arg200. Various analogues containing an alkyl extension ending with either a carboxylic acid, ester 
or amide functionality were thus synthesized (Schemes 2-4 and 2-5). 
 
Table 2-2: Potency of 1 at 10 μM and their physicochemical properties   
   
Cpd R
2






1a CF3 2 4 C5H11 40.0 ± 0.9 60.0 
1b CF3 2 4 C3H7 37.0 ± 3.9 63.0 
1c CF3 2 4 C8H17 45.0  ± 3.5 55.0 
1d CF3 2 4 phenyl 31.8  ± 2.0 68.2 
1e CF3 1 4 C6H13 40.5  ± 3.6 59.5 
1f CF3 2 3 C5H11 33.8 ± 2.2 66.2 









We started the investigation by synthesizing 2a-2c which contained an extra carboxylic acid to 
provide additional interaction with Arg200 (Scheme 2-4). 2b containing 4 methylene groups between 
the free carboxylic acid and amide was synthesized as the distance of these 4 methylene groups is 
approximately equal to the distance between the arachidonate ester and phosphate group of the 
substrate phosphatidylcholine. Such consideration ensures that 2b fit into the binding pocket of cPLA2 
in the same manner as what the natural substrate does. A SAR on the carbon length between the 
carboxylic acid to the amide was performed by changing the number of methylene groups from 3 to 5 
for 2a and 2c respectively. As anticipated, 2b possessed the highest potency (Table 2-3). This 
suggests that an optimum number of methylene groups between the amide and carboxyl is 4, while 
deviating from this number cause the potency to drop. To examine if the carboxylic acid’s interaction 
with Arg 200 was responsible for increasing potency, 20c containing the ester instead of the 
carboxylic acid was also screened. A huge decrease in potency to 15.2% inhibition occurred, 
confirming the hypothesis. Next, our efforts were directed at determining the importance of number of 
methylene groups between the first double bond and the carbonyl group. Although it was concluded 
in previous section that this effect is insignificant, presence of the extension to reach out to Arg 200 
has resulted in a distinct elongation of the molecule with respect to compounds 1a - o in general. 
Comparing between 2b, 2g, 2k and 2q when methylene groups increase from 2 to 5, potency 
increased tremendously peaking at 4 methylene groups (2g) but dropped again when it was further 
1h CF3 2 3 C8H17 45.6  ± 2.8 54.4 
1i CF3 2 2 C5H11 36.4 ± 3.3 63.6 
1j CF3 2 2 C7H15 33.9 ± 4.8 66.1 
1k CF3 2 2 C11H23 54.0 ± 6.9 46.0 
1l CF3 2 2 C13H27 72.4 ± 12.9 27.6 
1m NH2 2 4 C5H11 60.7  ± 1.9 39.3 
1n CClF2 2 4 C5H11 49.2  ± 4.5 50.8 
1o CHF2 2 4 C5H11 40.2  ± 0.5 59.8 
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increase to 5 (2k). This point towards 4 methylene groups as the number for optimal interactions with 
the enzyme. Changing the tail length from C5 to C3 in 2h didn’t improve the potency.  
At the same time, further rigidification of the molecule in hope of improving potency was achieved by 
introducing phenyl moiety instead of alkyl chains to link the amide and carboxylic acid together. 3 
analogues containing a meta-directed (2d), para-directed (2n) and ortho-directed (2o) carboxylic acid 
were designed. Ortho substitution suffers from a huge loss in cPLA2 inhibition. Meta-substitution (2d) 
was found to give the best result, providing a 2.5 fold higher potency than 1a. When the free 
carboxylic acid was replaced by an amide, a lower potency was seen. Similar trend was also observed 
in the meta- and para-substituted amide where the meta amide 2m has a higher potency than 2n. To 
further improve the cell-penetrant ability of the compound, allosteric replacement of the carboxylic 
acid was made with sulphonamide 2p. However an improvement of potency compared with 1a was 
not observed. Since it was determined that 4 methylene groups between the amide and first double 
bond was optimum for binding, 2i and 2j with different alkyl tail end was synthesized. 2i having a 
potency of 88.5% inhibition was discovered as the most potent compound. From the 2 tables, three 
compounds 2d, 2g and 2i which significantly decreased the cPLA2 activity, were identified (Table 2-
3). Since 2d and 2i are structurally analogous, only the stronger inhibitor 2i was selected for further 
studies. Thus using the fluorogenic PLA2 assay and recombinant cPLA2, the IC50 of 2g and 2i were 
determined to be 5.3 ± 0.3 and 2.9 ± 0.2 μM respectively, indicating that these compounds are more 
potent against cPLA2 than 1a (IC50 = 16.5 ± 3.0 μM) (Figure 2-2). This increase in potency of the 
compounds supported our hypothesis that the presence of a carboxylate group could interact with 
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Figure 2-3: Dose-dependent inhibitory plot of 1a, 2g and 2i. 
 
2.4 MTS Assay 
MTS assay were conducted with 1a, 2g and 2i at 48 h and 72 h using BV-2 cells, a murine microglial 
cell derived from post-natal mouse cerebella, and HEK293T cells which are from the human 
embroyonic kidney (Figure 2-4). Vehicule control, dimethyl sulfoxide (DMSO), was also included to 
serve as control as the compounds were dissolved in DMSO. The amount of DMSO used in the assay 
was limited to 1% of the total volume to ensure that it does not result in cytotoxicity of cells. Both 2g 
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Figure 2-4: MTS assay - conducted on the 1a, 2g and 2i on 2 different cell lines at different time 
points. Compounds were adjusted to a final concentration of 10 μM. Results were obtained from three 






2.5 Selectivity against sPLA2 
To further explore their selectivity towards cPLA2, compounds 2g and 2i were evaluated for their 
activities against sPLA2 at 10 μM concentration using a fluorogenic PLA2 assay and recombinant 
sPLA2 (Figure 2-5). Thioetheramide-PC, a specific inhibitor of sPLA2 (IC50 = 2 μM)
18
 was used as a 
comparison and showed a 62% reduction of sPLA2 activity. Compound 2i did not provide a 
significant change in sPLA2 activity, indicating that it is not sPLA2 selective. However compound 2g 
showed a significant increase of sPLA2 activity to 184%, implying that it could possibly be a sPLA2 
agonist. With the elimination of compound 2g as a potential inhibitor of cPLA2 through the sPLA2 





























Figure 2-5:  sPLA2 activity of the respective compounds at 10 μM. Control refers to the set when 
only enzyme and substrate are present. Thio-PC refers to the sPLA2 selective inhibitor 
thioetheramide-PC. Data analyzed by one-way ANOVA with Bonferroni's Multiple Comparison Test 






2.6 Inhibition of iNOS Production via LPS Stimulation of BV-2 Cells  
It is well established that reactive oxygen species (ROS) and nitric oxide (NO), produced during 
microglia activation, contribute to inflammatory response and cytotoxic damage to surrounding 
neurons and neighboring cells.
19
 Recent studies have shown that BV-2 microglial cell could serve as 
an in vitro  model to mimic such neuroinflammatory states when stimulated with lipopolysaccharide 
(LPS).
20 
LPS activates BV-2 cells by triggering a cascade of inflammatory events which includes the 
production of NO. This event is characterized by the generation of the biomarker, inducible nitric 
oxide synthase (iNOS), as well as reactive oxygen species (ROS). Chuang et al
21 
have also shown that 
cPLA2 is a major contributor in this pathway and inhibiting this enzyme reduces the production of the 
neurotoxic mediators and provide neuroprotective effects. Thus to investigate the ability of 2i to 
inhibit cPLA2 in a neuroinflammatory model, BV-2 cells were treated with LPS (2 μg/mL), incubated 
for different timepoints, collected and lysed for protein extraction. Western blots conducted showed 
that the iNOS level was highest between 8-14 h (Figure 2-6A). Densitometry analysis showed that 
there were no statistical differences in the iNOS levels between the 8 and 14 h timepoints (Figure 2-
6B). The cPLA2 level was also determined and found to be constant throughout the entire activation 
process (Figure 2-6C). Next, compound 2i (20 μM) was incubated together with LPS in the BV-2 
cells for 14 h. Under the same condition, the LPS-induced iNOS expression was significantly reduced 
by 50% (Figure 2-7). Varying the concentration of 2i from 1-20 μM showed a dose-dependent 
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Figure 2-6: Time point changes of protein expression level in BV-2 cells after 2 μg/mL of LPS 
stimulation. BV-2 cells were lysed at the respective time points, protein levels were normalized and 
western blot was performed (A) - Representative western blot out of 3 independent experiments 
showing protein bands of iNOS, cPLA2 and GAPDH. (B) - Densitometry analysis of iNOS. (C) -
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Figure 2-7: Changes in protein expression level of BV-2 cells at 14 h after 2 μg/mL of LPS 
stimulation with different dose treatment of 2i. BV-2 cells were lysed and protein levels were 
normalized and western blot was performed. (A) - Representative western blot out of 3 independent 
experiments showing protein bands of iNOS, cPLA2 and GAPDH. (B) - Densitometry analysis of 
iNOS. . Data analyzed by one-way ANOVA with Dunnett's Multiple Comparison Test indicates 





2.7 ROS Production  
CM-H2DCFDA was used as the main detection reagent for ROS for this study. Being a chloromethyl 
derivative of the conventional H2DCFDA, it is better retained in the cells due to the reactions of its 
chloromethyl group with intracellular thiol species. In addition, esterase present in the cells would 
convert acetate group found in CM-H2DCFDA into carboxylic acid, further retaining it in the cell. To 
investigate the ROS production by BV-2 cell stimulated with LPS, intracellular ROS was measured 
14 h post-stimulation with CM-H2DCFDA fluorescence. A 2-fold increase in ROS was detected as 
compared to the control. When compound 2i at 3 different concentrations (2-20 μM) was incubated 
together with LPS with the BV-2 cells for 14 h, a dose-dependent decrease in ROS was observed 
(Figure 2-8), indicating the compounds 2i could reduce ROS production under neurotoxic conditions. 
However, residual ROS might still be observed for samples treated with compound 2i. This could be 
because the activation of ROS production might not be solely due to the inflammatory pathway 
mechanism involving cPLA2. It was reported in previous studies that a multitude of several other 






























































Figure 2-8: ROS production of BV-2 cells at 14 h after 2 μg/mL of LPS stimulation. Respective 
concentrations of 2i was dissolved together with LPS in DMEM. Control set was added with vehicle 
DMSO.  Data analyzed by one-way ANOVA with Bonferroni's Multiple Comparison Test indicate 
statistical difference when comparing between LPS-treated versus LPS-treated with respective 
concentration of 2i (**P<0.01, *P<0.05). 
 




This part of the project was carried out in collaboration with Prof. Go Mei Lin 
(Department of Pharmacy, NUS).  
 
A major requirement for the development of a successful drug for the treatment of central nervous 
system (CNS) disorder is its ability to passage through the BBB to reach the therapeutic target. Hence 
screening for its ability to penetrate the BBB is of great importance. To explore whether compound 2i 
is able to penetrate into the brain, we used a parallel artificial membrane permeation assay 
(PAMPA)
23
 to assess its BBB permeability. 
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Since poor water solubility and insoluble precipitates can cause false positives in bioassays, we 
carried out a kinetic solubility test to determine the aqueous solubility of compound 2i before 
proceeding to the PAMPA assay. Using the multiscreen filter plates from Millipore, the solubility of 
2i was found to be 65.6 + 5.1 μM (28.7 + 2.2 μg/mL) and >100 μM (>43.8 μg/mL) at 3 h and 24 h 
respectively, at pH 7.4. Next, the in vitro permeability (Pe) of 2i and five standard compounds 
(caffeine, carbamazepine, quinidine, dopamine and propranolol) were determined at 6 h and 16 h 
(Table 2-4). Compound 2i was found to have much greater permeability (12.34 + 1.46 x 10
-6
 cm/s) at 
16 h than the other compounds tested. Since earlier studies have shown that
 
compounds with a 
permeability >7.0 x 10
-6
 cm/s would be able to cross the BBB by passive permeation,
23 
this implies 
that 2i has the potential to across the BBB. 
 
Table 2-4: Effective Permeabilities (Pe) of test compounds at 6 h and 16 h 
 
Compound Pe (pH 7.4) (10
-6
 cm/s) Log Pe 





Time  6 h 16 h 
2i 2.19 ± 0.22 -5.66 ± 0.04 12.34 ± 1.46 -4.91 ± 0.02 
Propranolol 11.67 ± 0.29 -4.93 ± 0.01 11.26 ± 0.74 -4.95 ± 0.03 
Carbamazepine 10.24 ± 0.28 -4.99 ± 0.01 9.86 ± 0.28 -5.01 ± 0.01 
Quinidine 2.93 ± 0.12 -5.53 ± 0.02 4.14 ± 0.32 -5.38 ± 0.03 
Caffeine 0.64 ± 0.40 -6.27 ± 0.33 2.12 ± 0.54 -5.69 ± 0.25 
Dopamine 1.27 ± 0.18 -5.90 ± 0.06 0.46 ± 0.07 -6.34 ± 0.06 
All values were obtained from 3 separate determinations made from a single stock solution of test 
compound 
 




This part of the project was carried out in collaboration with Prof. Chandra S Verma 
(Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR)).  
 
A docking study was performed to rationalize the inhibitory activities and to identify the possible 
binding sites of compounds 2g and 2i on the cPLA2 enzyme. The crystal structure of cPLA2 in its apo 
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form and with a few missing regions was obtained from the protein data bank.
24
 The missing regions 
were modelled and the complete structure was subjected to molecular dynamics (MD) simulations. 
The complete mode of cPLA2 remained stable during simulation. The conformations sampled during 
the last 50 ns of the MD simulations were clustered into conformational sub-states using the Kclust 
programe from the MMTSB tool set, with an rmsd of 2 Å set as cutoff. The cluster centroids of the 
top 5 most populated clusters were used for docking calculations. The cPLA2 binding has distinct 
properties - highly negatively charged at one side, slightly positive charged at the other side and a 
long, narrow and hydrophobic tunnel that connects both the charge ends. Since there are no co-crystal 
structures of cPLA2-inhibitor available, various analogues of 1 and 2 were docked and the results 
obtained were compared to the experimental data to understand the binding of the designed 
compounds.  
From the docking calculations, a binding site was defined around the catalytic important residue 
Ser228.
16
 Docking calculations with 1a showed the compound penetrating into the deep hydrophobic 
pocket of cPLA2 and the carbonyl group interacting with Ser 228 to provide a slow and tight binding 
via hydrogen bonds and van der Waals contacts (Figure 2-9A). Using this docking protocol, 
analogues of 1 and 2 were docked around this region. Docking calculations were repeated with 
different conformations of cPLA2 as identified through clustering the MD simulation trajectories.  Ten 
poses for each compound were computed and the best docking pose for each compound was chosen 
by ranking the computed binding energy (docking score).  Analysis of the top scored solutions (lowest 
energy solutions) showed that all the compounds bind similarly in the active sites of cPLA2 with (i) 
the electrophilic carbon of the substituted ketone in 1 or amide in 2 being in close proximity to Ser228, 
and (ii) Gly197/198 interacting with the carbonyl oxygen of 1 or the amide oxygen of 2. In addition, 
docking analysis of 2 shows the carboxylic acid moiety interacting with the side chains of Arg200. 
For the aminobenzoic acid analogues 2d and 2n, the carboxylic acid functionality is in closer 
proximity to Arg200 when it is in the meta position than the para position (Figures 2-9B and 2-9C). 
This results in a stronger attractive interaction which could contribute to the stronger inhibitory 
property of 2d. Furthermore, the interactions between the carboxylic acid moiety, Arg200 provide a 
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tighter binding for 2g and 2i than 1a (Figures 2-9D and 2-9E). Compound 2i, which has its carboxylic 
acid moiety closest to Arg200, has the most favourable interaction with cPLA2. These results support 
our experimental cPLA2 inhibition assay data which show 2i as the strongest cPLA2 inhibitor. 
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Figure 2-9: Predicted binding mode of compound 1a, 2d, 2g, 2i, 2n docked into cPLA2 with key 
interacting residues highlighted. Residues in the active sites are shown as lines; hydrogen bonds are 
indicated by dashed lines (magenta); protein residues involved in hydrogen bond interactions are 
labelled accordingly.  
 
2.10 Conclusion 
cPLA2 activation has been shown to be critically important in the regulation of homeostatic processes 
and disease pathogenesis. Thus, cPLA2 represents a potential novel therapeutic target to treat a wide 
range of diseases from cancer to neurodegenerative diseases such as Alzheimer’s disease and multiple 
sclerosis.
25
 In our efforts to develop potential drug candidates to treat neurological disorders, we have 
synthesized a new class of AA analogues and identified one compound 2i that is a non-cytotoxic, 
cPLA2-selective inhibitor which inhibits the enzyme more potently than AACOCF3. Compound 2i is 
also brain penetrant and able to reduce ROS and NO production in LPS-stimulated BV-2 microglial 
cells. Further studies are presently ongoing to develop the compound as a lead compound. 
Understanding its in vivo effect will be crucial in evaluating its clinical potential.     
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2.11 Experimental - Chemistry 
Commercially available reagents were bought from Sigma Aldrich, Alfa Aesar, Acros and Tokyo 
Chemical Industry and used without purification. Solvents such as hexane, ethyl acetate, 
dichloromethane, and methanol were pre-distilled while others were used without further purification. 
Flash column chromatography was carried out on Merck silica gel 60. Thin-layer chromatography 
(TLC) was performed on precoated F254 silica plates from Merck and visualized with UV light. TLC 
were heated with potassium permanganate stain whenever necessary. Prep TLC were from Analtech 




C NMR spectra were recorded on Bruker ACF300 (300MHz) or 
AMX 500 (500MHz) spectrometer at 298K. All J values are reported in Hz and chemical shift (δ) 
reported in parts per million (ppm) relative to tetramethylsilane (TMS). Mass spectra were determined 
by high resolution mass spectrometry (HRMS) electron impact ionization (EI) or electrospray 
ionization (ESI) or atmospheric-pressure chemical ionization (APCI). 
 
General procedure for the synthesis of 4a-e, 6a-e, 8a-e, 10a-c, 15a-d, 17a-d and 23 
A mixture of the terminal alkyne (17.41 mmol), allylic halide (11.61 mmol), CuI (3.32 g, 17.41 
mmol), NaI (2.61 g, 17.41 mmol) and K2CO3 (2.41 g, 17.41 mmol) were dissolved in DMF (36 mL) 
and stirred overnight at room temperature. The reaction mixture was then quenched by adding an 
equal volume of ethyl acetate and the organic layer was washed with saturated NH4Cl (3 x 20 mL) 
and brine (3 x 20 mL). The organic layer was then dried using anhydrous MgSO4, concentrated and 
purified using flash column chromatography to afford the product as either a yellow oil or a yellow 
solid. The following cross-coupled products, 8a-e, 10a-c, 15a-d, 17a-d and 23, were not isolated and 
were used directly for the next step of the reaction. 
 
 
Undeca-2,5-diyn-1-ol (4a): Yellow oil, 88% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (500 
MHz, CDCl3) δ 4.26 (t, J = 2.1 Hz, 2 H), 3.23 – 3.14 (m, 2 H), 2.22 (s, 1 H), 2.15 (tt, J = 7.1, 2.3 Hz, 
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1 H), 1.56 – 1.43 (m, 1 H), 1.39 – 1.24 (m, 2 H), 0.89 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, 
CDCl3): δ 81.12, 80.71, 78.37, 73.23, 51.14, 31.02, 28.77, 22.15, 18.64, 13.97, 9.71. 
 
 
Nona-2,5-diyn-1-ol (4b): Pale yellow oil, 96% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (300 
MHz, CDCl3) δ 4.19 (t, J = 2.2 Hz, 2H), 3.13 (dd, J = 4.6, 2.3 Hz, 2H), 2.77 (s, 1H), 2.11 – 2.00 (m, 
2H), 1.54 – 1.34 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 80.76, 80.35, 78.25, 
73.38, 50.78, 21.91, 20.44, 13.27, 9.59. 
 
 
Tetradeca-2,5-diyn-1-ol (4c): Yellow oil, 74% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (300 
MHz, CDCl3) δ 4.17 (t, J = 2.1 Hz, 2 H), 3.11 (dd, J = 4.5, 2.2 Hz, 2 H), 2.07 (tt, J = 7.1, 2.3 Hz, 2 H), 
1.39 (dd, J = 14.6, 7.1 Hz, 2 H), 1.32 – 1.08 (m, 10 H), 0.80 (t, J = 6.7 Hz, 3 H); 13C NMR (75 MHz, 




6-phenylhexa-2,5-diyn-1-ol (4d): Yellow oil, 79% yield, eluent system: 5:1 hexane-EA, 
1
H NMR 
(500 MHz, CDCl3) δ 7.44– 7.42 (m, 2H), 7.30 – 7.29 (m, 3H), 4.29 (t, J = 2.1 Hz, 2H), 3.45 (t, J = 2.1 
Hz, 2H), 1.83 (s, 1H).
 13
C NMR (126 MHz, CDCl3) δ 131.72(2C), 128.26(2C), 128.21, 122.93, 83.06, 







Dodeca-2,5-diyn-1-ol (4e): Pale yellow oil, 86% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (300 
MHz, CDCl3) δ 4.21 (t, J = 2.2 Hz, 2H), 3.14 (p, J = 2.3 Hz, 2H), 2.61 (s, 1H), 2.10 (tt, J = 7.2, 2.4 Hz, 
2H), 1.48 – 1.34 (m, 2H), 1.33 – 1.21 (m, 6H), 0.84 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
81.05, 80.49, 78.28, 73.23, 50.89, 31.21, 28.53, 28.44, 22.41, 18.53, 13.89, 9.67. 
 
 
Tetradeca-2,5,8-triyn-1-ol (6a): Yellow oil, 87% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (300 
MHz, CDCl3) δ 4.23 (t, J = 1.9 Hz, 2 H), 3.27 – 3.00 (m, 4 H), 2.11 (ddd, J = 9.2, 4.6, 2.3 Hz, 2 H), 
1.45 (dd, J = 13.9, 6.9 Hz, 2 H), 1.37 – 1.14 (m, 4 H), 0.87 (t, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, 
CDCl3) δ 80.87, 79.71, 78.63, 75.40, 73.61, 73.44, 50.79, 30.93, 28.26, 22.06, 18.50, 13.81, 9.70, 9.55. 
 
 
Dodeca-2,5,8-triyn-1-ol (6b): Yellow oil, 66% yield, eluent system: 5:1 hexane-EA,
 1
H NMR (300 
MHz, CDCl3) δ 4.25 (t, J = 2.1 Hz, 2H), 3.38 – 2.95 (m, 4H), 2.13 (tt, J = 7.1, 2.4 Hz, 2H), 1.91 (s, 
1H), 1.51 (dd, J = 14.5, 7.2 Hz, 2H), 0.96 (dd, J = 9.7, 5.0 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
80.83, 80.11, 78.64, 75.55, 73.62, 51.21, 22.09, 20.65, 13.47, 9.87, 9.71. 
 
 
Heptadeca-2,5,8-triyn-1-ol (6c): Pale yellow solid, 62% yield, eluent system: 5:1 hexane-EA,
1
H 
NMR (300 MHz, CDCl3) δ 4.20 (dd, J = 7.6, 6.1 Hz, 2 H), 3.19 – 2.97 (m, 4 H), 2.43 (s, 1 H), 2.08 
(ddd, J = 11.7, 9.3, 7.1 Hz, 2 H), 1.51 – 1.00 (m, 12 H), 0.91 – 0.67 (m, 3 H); 13C NMR (126 MHz, 
CDCl3) δ 81.33, 81.08, 75.80, 75.57, 73.42, 73.13, 31.84, 29.19, 29.11, 28.90, 28.71, 22.66, 18.70, 





9-phenylnona-2,5,8-triyn-1-ol (6d): Yellow oil,  75% yield, eluent system: 5:1 hexane-EA, 
1
H NMR 
(500 MHz, CDCl3) δ 7.43 – 7.41 (m, 2H), 7.30 – 7.26 (m, 3H), 4.25 (t, J = 2.1 Hz, 2H), 3.39 (t, J = 
2.3 Hz, 2H), 3.24 – 3.22 (m, 2H), 2.46 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 131.73(2C), 
128.27(2C), 128.18, 123.00, 83.44, 80.78, 79.84, 78.94, 74.68, 74.41, 51.07, 10.51, 9.93. 
 
 
Pentadeca-2,5,8-triyn-1-ol (6e): Yellow oil, 77% yield, eluent system: 5:1 hexane-EA, 
1
H NMR (500 
MHz, CDCl3) δ 4.26 (s, 2H), 3.21-3.19 (m, 2H), 3.14 (p, J = 2.3 Hz, 2H), 2.16 – 2.13 (m, 2H), 1.51 – 
1.45 (m, 2H), 1.38 – 1.35 (m, 2H), 1.34 – 1.24 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 81.05, 80.14, 78.66, 77.26, 77.00, 76.75, 75.57, 73.61, 73.47, 51.25, 31.33, 28.66, 28.55, 
22.53, 18.69, 14.03, 9.88, 9.74. 
 
General procedure for the synthesis of 5a-e, 7a-e and 14a-d 
The respective alcohol (6.124 mmol) and CBr4 (4.062 g, 12.25 mmol) were dissolved in CH2Cl2 (5.2 
mL) and cooled to -40
o
C. PPh3 (3.213 g, 12.25 mmol) was dissolved in CH2Cl2 (5.2 mL) and added 
dropwise via a canella to the reaction mixture, which was then stirred for 1h at -20
o
C. Upon 
completion of the reaction, hexane was added to the reaction mixture, resulting in the precipitation of 
PPh3O. The resulting suspension was filtered through Celite, concentrated and purified by flash 
column chromatography using a 99:1 hexane-ethyl acetate eluent system to afford the respective 
product as either a yellow or colourless oil. 
 
 
1-bromoundeca-2,5-diyne (5a): Yellow oil, 73% yield. 
1
H NMR (500 MHz, CDCl3) δ 3.91 (dd, J = 
3.0, 1.5 Hz, 2 H), 3.20 (dd, J = 3.2, 1.5 Hz, 2 H), 2.17 – 2.08 (m, 2 H), 1.51 – 1.43 (m, 2 H), 1.38 – 
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1.24 (m, 4 H), 0.86 (t, J = 6.95 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 82.10, 81.38, 75.23, 72.77, 
31.04, 28.35, 22.20, 18.62, 14.85, 13.96, 10.07. 
 
 
1-bromonona-2,5-diyne (5b): Yellow oil, 77% yield. 
1
H NMR (500 MHz, CDCl3) δ 3.90 (t, J = 2.3 
Hz, 2H), 3.29 – 3.14 (m, 2H), 2.11 (tt, J = 7.1, 2.4 Hz, 2H), 1.59 – 1.35 (m, 2H), 0.94 (t, J = 7.4 Hz, 
3H).
 13
C NMR (125 MHz, CDCl3) δ 81.98, 81.07, 75.12, 72.83, 21.96, 20.52, 14.76, 13.35, 9.95. 
 
 
1-bromotetradeca-2,5-diyne (5c): Yellow oil, 60% yield. 
1
H NMR (300 MHz, CDCl3) δ 3.88 (t, J = 
2.3 Hz, 2 H), 3.17 (dd, J = 4.6, 2.3 Hz, 2 H), 2.10 (tt, J = 7.1, 2.3 Hz, 2 H), 1.43 (dd, J = 14.5, 7.1 Hz, 
2 H), 1.37 – 1.13 (m, 10 H), 0.84 (t, J = 6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 81.94, 81.22, 
75.09, 72.62, 31.71, 29.07, 28.98, 28.75, 28.54, 22.54, 18.53, 14.69, 13.96, 9.94. 
 
 
(6-bromohexa-1,4-diyn-1-yl)benzene (5d): Yellow oil, 65% yield. 
1
H NMR (500 MHz, CDCl3) δ 
7.44 – 7.42 (m, 2H), 7.30 (dd, J = 5.0, 1.8 Hz, 3H), 3.94 (t, J = 2.3 Hz, 2H), 3.48 (t, J = 2.3 Hz, 2H). 
13




1-bromododeca-2,5-diyne (5e): Yellow oil, 69% yield. 
1
H NMR (500 MHz, CDCl3) δ 3.93 (t, J = 2.3 
Hz, 2H), 3.23 – 3.22 (m, 2H), 2.16 (tt, J = 7.2, 2.4 Hz, 2H), 1.49 (dd, J = 15.0, 7.4 Hz, 2H), 1.40 – 
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1.36 (m, 2H), 1.30 (ddd, J = 14.4, 8.8, 2.8 Hz, 4H), 0.90 (t, J = 7.0 Hz, 3H).
 13
C NMR (126 MHz, 
CDCl3) δ 82.08, 81.40, 75.17, 72.71, 31.28, 28.57, 28.49, 22.50, 18.62, 14.82, 14.00, 10.05. 
 
 
1-bromotetradeca-2,5,8-triyne (7a): Yellow oil, 71% yield. 
1
H NMR (500 MHz, CDCl3) δ 3.90 (dd, 
J = 3.1, 1.4 Hz, 2 H), 3.22 (dd, J = 4.6, 2.2 Hz, 2 H), 3.12 (dd, J = 4.7, 2.4 Hz, 2 H), 2.13 (tt, J = 7.1, 
2.3 Hz, 2 H), 1.52 – 1.41 (m, 2 H), 1.39 – 1.25 (m, 4 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (125 




1-bromododeca-2,5,8-triyne (7b): Yellow oil, 70% yield. 
1
H NMR (300 MHz, CDCl3) δ 3.89 (t, J = 
2.3 Hz, 2H), 3.21 (p, J = 2.3 Hz, 2H), 3.12 (p, J = 2.4 Hz, 2H), 2.11 (tt, J = 7.1, 2.4 Hz, 2H), 1.58 – 
1.39 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). δ. 13C NMR (75 MHz, CDCl3) δ 81.27, 80.80, 75.72, 75.50, 
73.54, 73.08, 22.05, 20.60, 14.65, 13.43, 10.06, 9.66. 
 
 
1-bromoheptadeca-2,5,8-triyne (7c): Yellow oil, 77% yield. 
1
H NMR (300 MHz, CDCl3) δ 3.90 (t, J 
= 2.3 Hz, 2 H), 3.26 – 3.17 (m, 2 H), 3.17 – 3.05 (m, 2 H), 2.13 (tt, J = 7.1, 2.4 Hz, 2 H), 1.46 (dd, J = 
14.6, 7.2 Hz, 2 H), 1.40 – 1.15 (m, 10 H), 0.87 (t, J = 6.7 Hz, 3 H); 13C NMR (126 MHz, CDCl3) δ 
81.33, 81.08, 77.30, 77.04, 76.79, 75.80, 75.57, 73.43, 73.13, 31.84, 29.19, 29.11, 28.90, 28.71, 22.66, 






(9-bromonona-1,4,7-triyn-1-yl)benzene (7d): Yellow oil, 77% yield.
 1
H NMR (500 MHz, CDCl3) δ 
7.45 – 7.43 (m, 2H), 7.30 (dd, J = 4.4, 2.1 Hz, 3H), 3.91 (d, J = 2.5 Hz, 2H), 3.40 (d, J = 2.5 Hz, 2H), 
3.26 (d, , J = 2.5 Hz, 2H).
 13
C NMR (126 MHz, CDCl3) δ 131.55(2C), 128.09(2C), 127.99, 122.83, 
83.19, 81.07, 80.64, 75.60, 74.74, 73.67, 14.63, 10.36, 10.02. 
 
 
1-bromopentadeca-2,5,8-triyne (7e): Yellow oil, 67% yield. 
1
H NMR (500 MHz, CDCl3) δ 3.90 (t, J 
= 2.3 Hz, 2H), 3.23 – 3.22 (m, 2H), 3.13 (d, J = 3.0, Hz, 2H), 2.16 – 2.13 (m, 2H), 1.50 – 1.45 (m, 
2H), 1.39 – 1.31 (m, 2H), 1.30-1.25 (m, 4H), 0.88 (t, J = 6.9 Hz, 3H) 13C NMR (126 MHz, CDCl3) δ 
81.14, 80.86, 75.62, 75.43, 73.28, 72.97, 31.20, 28.52, 28.41, 22.41, 18.53, 14.59, 13.89, 9.95, 9.56. 
 
 
1-bromooct-2-yne (14a): Colourless oil, 97% yield. 
1
H NMR (500 MHz, CDCl3) δ 4.34 (t, J = 2.3 Hz, 
2H), 2.65 (ddt, J = 9.3, 4.7, 2.2 Hz, 2H), 1.94 – 1.91 (m, 2H), 1.77 – 1.72 (m, 4H), 1.31 (t, J = 7.1 Hz, 
5H).
 13
C NMR (126 MHz, CDCl3) δ 88.28, 75.23, 30.92, 27.97, 22.09, 18.87, 15.76, 13.93. 
 
 
1-bromodec-2-yne (14b): Colourless oil, quantitative yield. 
1
H NMR (500 MHz, CDCl3) δ 3.94 (t, J 
= 2.4 Hz, 2 H), 2.24 (tt, J = 7.2, 2.3 Hz, 2 H), 1.56 – 1.46 (m, 2 H), 1.38 (dt, J = 15.3, 6.8 Hz, 2 H), 
1.34 – 1.23 (m, 6 H), 0.90 (t, J = 6.9 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 88.32, 75.27, 31.72, 






1-bromotetradec-2-yne (14c): Colourless oil, quantitative yield. 
1
H NMR (500 MHz, CDCl3) δ 3.94 
(s, 2 H), 2.24 (tt, J = 7.1, 2.3 Hz, 2 H), 1.56 – 1.47 (m, 2 H), 1.42 – 1.34 (m, 2 H), 1.30 (d, J = 24.3 Hz, 
14 H), 0.89 (t, J = 6.9 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 88.31, 75.29, 31.94, 29.64 (2 C), 
29.53, 29.38, 29.13, 28.86, 28.40, 22.72, 18.98, 15.73, 14.15. 
 
 
1-bromohexadec-2-yne (14d): Colourless oil, quantitative yield. 
1
H NMR (300 MHz, CDCl3) δ 3.96 
(t, J = 2.2 Hz, 2 H), 2.27 (tt, J = 7.0, 2.2 Hz, 2 H), 1.62 – 1.46 (m, 2 H), 1.46 – 1.16 (m, 20 H), 0.92 (t, 
J = 6.6 Hz, 3 H); 
13
C NMR (75 MHz, CDCl3) δ 88.24, 75.17, 31.85, 29.61 (2 C), 29.58, 29.53, 29.42, 
29.28, 29.02, 28.75, 28.30, 22.61, 18.87, 15.64, 14.03. 
 
General procedure for the synthesis of 9a-e, 11a-c, 16a-d, 18b-d and 24 
The hydrogenation procedure employed was adapted from the procedure described by Qi et al.
9d
 
Ni(OAc)2.4H2O (0.119 g, 0.4773 mmol) was dissolved in a 95% EtOH : 5% 2M NaOH solution and 
saturated with hydrogen gas through bubbling. 0.4773 mL of 1M NaBH4 (0.4773 mmol) solution was 
then added to the Ni(OAc)2.4H2O mixture under a H2 atmosphere and stirred vigorously to yield a 
black suspension. Ethylenediamine (0.032 mL, 0.4773 mmol) was then added to the mixture and H2 
gas was bubbled through it for another 15 – 20 min. The alkyne (0.3182 mmol) was then dissolved in 
CH2Cl2 (2 mL) and added to the reaction mixture. The reaction mixture was stirred under positive 
hydrogen pressure for 2 h, quenched by passing the mixture through Celite, concentrated and purified 
via flash column chromatography to afford the respective product as a yellow oil. Prep TLC was 







(5Z,8Z,11Z,14Z)-methyl icosa-5,8,11,14-tetraenoate (9a): Yellow oil, 58% yield (over 2 steps), 
eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.54 – 5.29 (m, 8 H), 3.68 (s, 3 H), 
2.80 – 2.83 (m, 6 H), 2.34 (t, J = 7.5 Hz, 2 H), 2.13 (dd, J = 14.0, 7.1 Hz, 2 H), 2.07 (dd, J = 14.2, 7.0 
Hz, 2 H), 1.79 – 1.66 (m, 2 H), 1.45 – 1.23 (m, 6 H), 0.91 (t, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 174.04, 130.48, 128.92, 128.87, 128.57, 128.20, 128.16, 127.86, 127.54, 51.47, 33.43, 31.52, 
29.33, 27.22, 26.55, 25.64, 25.63, 25.61, 24.78, 22.58, 14.07. 
 
 
(5Z,8Z,11Z,14Z)-methyl octadeca-5,8,11,14-tetraenoate (9b): Yellow oil, 48% yield (over 2 steps), 
eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.67 – 5.18 (m, 8H), 3.67 (s, 3H), 2.82 
(dt, J = 17.1, 5.7 Hz, 6H), 2.32 (t, J = 7.5 Hz, 2H), 2.08 (ddd, J = 33.9, 13.9, 6.9 Hz, 4H), 1.83 – 1.62 
(m, 2H), 1.39 (dd, J = 14.8, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ174.05, 
130.21, 128.92, 128.88, 128.58, 128.20, 128.17, 127.87, 127.77, 51.46, 33.45, 29.30, 26.56, 25.65, 
25.63, 25.61, 24.79, 22.77, 13.77. 
 
 
(5Z,8Z,11Z,14Z)-methyl tricosa-5,8,11,14-tetraenoate (9c): Yellow oil, 50% yield (over 2 steps), 
eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.50 – 5.28 (m, 8 H), 3.69 (s, 3 H), 
2.85 (dt, J = 10.3, 5.5 Hz, 6 H), 2.35 (dd, J = 9.5, 5.6 Hz, 2 H), 2.11 (ddd, J = 28.7, 14.1, 7.0 Hz, 6 H), 
1.79 – 1.66 (m, 2 H), 1.44 – 1.24 (m, 10 H), 0.91 (t, J = 6.7 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 
191.44, 130.37, 129.54, 128.53, 128.29, 128.04, 127.73, 127.64, 127.40, 52.03, 35.47, 33.12, 31.81, 





(5Z,8Z,11Z,14Z)-methyl 15-phenylpentadeca-5,8,11,14-tetraenoate (9d): Yellow oil,  46% yield 
(over 2 steps), eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 7.37 (t, J = 7.6 Hz, 2H), 
7.32 (d, J = 7.4 Hz, 2H), 7.29 – 7.21 (m, 1H) , 6.51 (d, J = 11.4 Hz, 1H), 5.69 (dd, J = 7.4, 4.1 Hz, 
1H), 5.53 – 5.44 (m, 2H), 5.43 – 5.36 (m, 4H), 3.70 (s, 3H), 3.14 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 5.8 
Hz, 2H), 2.80 (t, J = 5.2 Hz, 2H), 2.35 (dd, J = 9.4, 5.5 Hz, 2H), 2.13 (dd, J = 13.3, 6.7 Hz, 2H), 1.77 
– 1.71 (m, 2H). 13C NMR (126 MHz, CDCl3) δ173.92, 137.31, 130.53, 129.27, 128.87, 128.77, 128.70, 
128.66, 128.23, 128.106, 128.00, 127.90, 126.60, 51.63, 33.63, 26.91, 26.49, 25.67, 25.54, 24.72. 
 
 
(4Z,7Z,10Z,13Z)-propyl icosa-4,7,10,13-tetraenoate (9e): Yellow oil, 37% yield (over 2 steps), 
eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.41 – 5.37 (m, 8H), 4.05 (dd, J = 8.7, 
4.7 Hz, 2H), 2.86 – 2.79 (m, 6H), 2.42 – 2.37 (m, 4H), 2.09 – 2.05 (m, 2H), 1.67 (dd, J = 14.2, 7.0 Hz, 
2H), 1.37 – 1.30 (m, 8H), 0.96 (t, J = 7.4 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 173.13, 130.42, 129.20, 128.55, 128.28, 127.98, 127.94, 127.80, 127.50, 65.94, 34.22, 31.73, 
29.58, 28.94, 27.22, 25.59, 25.55, 22.81, 22.60, 21.96, 14.04, 10.34. 
 
 
(5Z,8Z,11Z)-methyl heptadeca-5,8,11-trienoate (11a): Yellow oil, 52% yield (over 2 steps), eluent 
system: 98:2 hexane-EA, 
1
H NMR (300 MHz, CDCl3) δ 5.50 – 5.21 (m, 6 H), 3.65 (s, 3 H), 2.79 (t, J 
= 5.4 Hz, 2 H), 2.31 (t, J = 7.5 Hz, 2 H), 2.19 – 1.90 (m, 4 H), 1.69 (dt, J = 14.4, 7.2 Hz, 2 H), 1.29 (s, 
8 H), 0.88 (t, J = 6.4 Hz, 3 H); 
13
C NMR (75 MHz, CDCl3) δ 173.93, 130.36, 128.86, 128.75, 128.39, 





(5Z,8Z,11Z)-methyl pentadeca-5,8,11-trienoate (11b): Yellow oil, 30% yield (over 2 steps), eluent 
system: 98:2 hexane-EA, 
1
H NMR (300 MHz, CDCl3) δ 5.44 – 5.38 (m, 6H), 3.70 (s, 3H), 2.82 (d, J 
= 5.3 Hz, 4H), 2.36 (t, J = 7.5 Hz, 4H), 2.16 – 2.04 (m, 2H), 1.76 – 1.72 (m, 2H), 1.42 (dd, J = 14.7, 
7.3 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 174.02, 130.14, 128.90, 128.81, 
128.45, 127.88, 127.73, 51.42, 33.39, 29.25, 26.50, 25.59, 25.55, 24.74, 22.73, 13.74. 
 
 
(5Z,8Z,11Z)-methyl icosa-5,8,11-trienoate (11c): Yellow oil, 40% yield (over 2 steps), eluent 
system: 98:2 hexane-EA, 
1
H NMR (300 MHz, CDCl3) δ 5.46 – 5.22 (m, 5H), 3.65 (s, 3H), 2.78 (t, J = 
5.4 Hz, 1H), 2.31 (t, J = 7.5 Hz, 1H), 2.17 – 1.91 (m, 2H), 1.76 – 1.59 (m, 1H), 1.26 (s, 5H), 0.86 (t, J 
= 6.3 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 173.95, 130.38, 128.88, 128.77, 128.41, 127.84, 127.46, 
51.37, 33.34, 31.83, 29.59, 29.46, 29.25 (2 C), 27.19, 26.47, 25.52 (2 C), 24.70, 22.61, 14.03. 
 
 
(5Z,8Z)-methyl tetradeca-5,8-dienoate (16a): Pale yellow oil, 29% yield (over 2 steps), eluent 
system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.40 – 5.31 (m, 4H), 3.67 (s, 3H), 2.77 (t, J = 
6.7 Hz, 2H), 2.33 (dd, J = 9.8, 5.3 Hz, 2H), 2.13 – 2.09 (m, 2H), 2.06 – 2.03 (m, 2H), 1.72 (dd, J = 
14.9, 7.5 Hz, 2H), 1.37 – 1.30 (m, 6H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 








(5Z,8Z)-methyl hexadeca-5,8-dienoate (16b): Yellow oil, 40% yield (over 2 steps), eluent system: 
98:2 hexane-EA,
1
H NMR (500 MHz, CDCl3) δ 5.43 – 5.25 (m, 4 H), 3.65 (s, 3 H), 2.75 (t, J = 6.7 Hz, 
2 H), 2.36 – 2.25 (m, 2 H), 2.09 (dd, J = 14.2, 7.1 Hz, 2 H), 2.03 (dd, J = 14.0, 7.0 Hz, 2 H), 1.73 – 
1.65 (m, 2 H), 1.38 – 1.19 (m, 10 H), 0.87 (t, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 174.04, 




(5Z,8Z)-methyl icosa-5,8-dienoate (16c): Yellow oil, 23% yield (over 2 steps), eluent system: 98:2 
hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.45 – 5.25 (m, 4 H), 3.68 (s, 3 H), 2.78 (t, J = 6.8 Hz, 2 
H), 2.39 – 2.26 (m, 2 H), 2.12 (dd, J = 14.2, 7.1 Hz, 2 H), 2.06 (dd, J = 14.0, 7.0 Hz, 2 H), 1.78 – 1.62 
(m, 2 H), 1.44 – 1.17 (m, 18 H), 0.90 (t, J = 6.9 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 174.01, 
130.38, 129.26, 128.60, 127.60, 51.40, 33.43, 31.92, 29.68 (2 C), 29.65 (2 C), 29.56, 29.35, 29.32, 
27.24, 26.53, 25.59, 24.80, 22.68, 14.08. 
 
 
(5Z,8Z)-methyl docosa-5,8-dienoate (16d): Yellow oil, 70% yield (over 2 steps), eluent system: 98:2 
hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.49 – 5.27 (m, 4 H), 3.68 (s, 3 H), 2.78 (t, J = 6.8 Hz, 2 
H), 2.38 – 2.29 (m, 2 H), 2.12 (dd, J = 14.2, 7.0 Hz, 2 H), 2.06 (dd, J = 14.0, 7.0 Hz, 2 H), 1.77 – 1.67 
(m, 2 H), 1.40 – 1.32 (m, 2 H), 1.30 (d, J = 18.6 Hz, 20 H), 0.89 (t, J = 6.9 Hz, 3 H); 13C NMR (75 
MHz, CDCl3) δ 
13
C NMR (75 MHz, CDCl3) δ 173.65, 130.13, 129.10, 128.41, 127.46, 51.12, 33.20, 






(6Z,9Z,12Z,15Z)-ethyl henicosa-6,9,12,15-tetraenoate (18b): Pale yellow liquid, 48% yield (over 2 
steps), eluent system: 98:2 hexane-EA, 
1
H NMR (300 MHz, CDCl3) δ 5.41 – 5.38 (m, 7H), 4.15 (q, J 
= 7.1 Hz, 2H), 2.86 – 2.80 (m, 4H), 2.32 (t, J = 7.5 Hz, 2H), 2.10 – 2.05 (m, 6H), 1.70 – 1.62 (m, 2H), 
1.40 – 1.33 (m, 4H), 1.32 – 1.25 (m, 7H), 0.92 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
173.56, 130.36, 129.60, 128.45, 128.22, 128.06, 128.01, 127.82, 127.49, 60.08, 34.16, 31.45, 29.26, 
29.03, 27.15, 27.05, 26.80, 25.56(2C), 24.54, 22.50, 14.17, 13.99. 
 
 
(6Z,9Z,12Z,15Z)-ethyl nonadeca-6,9,12,15-tetraenoate (18c): Pale yellow liquid, 55% yield (over 2 
steps), eluent system: 98:2 hexane-EA,
1
H NMR (500 MHz, CDCl3) δ 5.40 – 5.38 (m, 8H), 4.15 (q, J 
= 7.1 Hz, 2H), 2.87 – 2.84 (m, 6H), 2.32 (t, J = 7.5 Hz, 2H), 2.12 – 2.04 (m, 4H), 1.69 – 1.64 (m, 2H), 
1.42 (ddd, J = 11.8, 7.4, 2.1 Hz, 4H), 1.28 (t, J = 7.1 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H).
 13
C NMR (126 
MHz, CDCl3) δ 173.63, 130.16, 129.68, 128.54, 128.31, 128.13, 128.10, 127.90, 127.78, 60.14, 34.24, 
29.29, 29.08, 26.86, 25.65, 25.63(2C), 24.60, 22.75, 14.22, 13.74. 
 
 
(7Z,10Z,13Z,16Z)-methyl docosa-7,10,13,16-tetraenoate (18d): Yellow liquid,  25% yield (over 2 
steps), eluent system: 98:2 hexane-EA, 
1
H NMR (500 MHz, CDCl3) δ 5.39 – 5.34 (m, 8H), 3.67 (s, 
3H), 2.85 – 2.77 (m, 6H), 2.31 (t, J = 7.5 Hz, 2H), 2.07 – 2.03 (m, 4H), 1.65 – 1.60 (m, 2H), 1.39 – 
1.33 (m, 6H), 1.32 – 1.25 (m, 4H), 0.88 (dd, J = 9.1, 4.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
174.20, 130.47, 130.03, 128.53, 128.39, 128.06, 127.93, 127.90, 127.57, 51.43, 34.05, 31.52, 29.32, 





Methyl 5-((4Z,7Z,10Z,13Z)-nonadeca-4,7,10,13-tetraenamido)pentanoate (24): Pale yellow solid, 
43% yield (over 2 steps), eluent system: 3:1 hexane-EA, 
1H NMR (500 MHz, DMSO) δ 7.77 – 7.76 
(m, 1H), 5.35 – 5.30 (m, 7H), 3.57 (s, 3H), 3.02 – 3.01 (m, 2H), 2.82 – 2.74 (m, 4H), 2.29 (t, J = 7.4 
Hz, 2H), 2.09 – 2.04 (m, 2H), 2.03 – 1.99 (m, 2H), 1.51 – 1.48 (m, 2H), 1.39 -1.36 (m, 2H), 1.31 – 
1.30 (m, 4H), 1.26 – 1.23 (m, 6H), 0.85 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 173.20, 
171.19, 129.92, 128.86, 128.08, 128.03, 128.00, 127.74, 127.66, 127.50, 51.13, 37.91, 35.21, 32.88, 
30.85, 28.69, 28.53, 26.57, 25.18, 25.17, 25.13, 23.16, 21.94, 21.84, 13.88. HRMS (ESI): calculated 
for C25H41NO3Na (M+Na) 426.2979, found 426.2995. 
 
General procedure for the synthesis of 1a-l and 1n-o 
To the respective ester (0.31 mmol) was added 4M NaOH (5 mL) and the reaction mixture was 
microwaved for 1 h at 120
o
C. Upon cooling to ambient temperature, the reaction mixture was 
quenched with 3M HCl (7 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic phase 
was dried with anhydrous MgSO4, concentrated and used for the next step of the reaction without 
further purification. Trifluoromethylation was performed by adapting the procedure reported by 
Ackermann et al.
11b
 The acid obtained in the aforementioned reaction (0.31 mmol) was dissolved in 
CH2Cl2 (5 mL). Thereafter, pyridine (0.26 mL, 3.20 mmol) and trifluoroacetic/chlorodifluoroacetic 
anhydride (0.44 mL, 3.123 mmol) were added. For compounds 1a-h, the reaction mixture was stirred 
for 2 h. For compound 1n and 1o, the mixture was stirred overnight. Upon completion of reaction 
(based on TLC), the reaction was quenched by shaking the mixture with saturated NaHCO3 (50 mL) 
and subsequently extracting the aqueous layer with ethyl acetate (3 x 20 mL). The combined organic 
layer was then dried with anhydrous MgSO4, concentrated and purified using flash column 






(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one (1a): Yellow oil, 48% yield (over 
2 steps). 
1
H NMR (500 MHz, CDCl3) δ 5.57 – 5.26 (m, 8H), 2.97 – 2.79 (m, 6 H), 2.74 (t, J = 7.1 Hz, 
2 H), 2.23 – 2.12 (m, 2 H), 2.08 (dd, J = 13.9, 6.8 Hz, 2 H), 1.80 (dd, J = 14.4, 7.2 Hz, 2 H), 1.50 – 
1.22 (m, 6 H), 0.94 (t, J = 6.95 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 191.42 (d, J = 3.5 Hz)
a
, 
130.51, 129.65, 128.65, 128.41, 128.16, 127.85, 127.76, 127.50, 115.57 (q, J = 291 Hz), 35.60, 31.51, 
29.31, 27.21, 26.01, 25.63, 25.59 (2 C), 22.55, 22.17, 14.02. HRMS (APCI): calculated for C21H32F3O 
(M+1) 357.2400, found 357.2384. 
 
 
(6Z,9Z,12Z,15Z)-1,1,1-trifluorononadeca-6,9,12,15-tetraen-2-one (1b): Yellow oil, 46% yield 
(over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 5.44 – 5.34 (m, 8H), 2.82 (dt, J = 19.3, 6.7 Hz, 6H), 
2.72 (t, J = 7.2 Hz, 2H), 2.14 (dd, J = 14.4, 7.2 Hz, 2H), 2.05 (dd, J = 14.1, 7.1 Hz, 2H), 1.76 (dd, J = 
14.4, 7.2 Hz, 2H), 1.38 (dt, J = 14.6, 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 191.40 (d, J = 34.7 Hz, 1H), 130.24, 129.67, 128.66, 128.43, 128.16, 127.86, 127.78, 127.75, 
115.59 (q, J = 292.1 Hz, 2H), 35.62, 29.31, 26.04, 25.66, 25.65, 25.61, 22.76, 22.20, 13.74. HRMS 
(APCI): calculated for C19H28F3O (M+1): 329.2087; found 329.2086. 
 
 
(6Z,9Z,12Z,15Z)-1,1,1-trifluorotetracosa-6,9,12,15-tetraen-2-one (1c): Yellow oil, 52% yield (over 
2 steps). 
1
H NMR (300 MHz, CDCl3) δ 5.44 (tt, J = 8.5, 4.6 Hz, 8H), 2.96 – 2.67 (m, 6 H), 2.14 (ddd, 
J = 19.1, 13.4, 6.5 Hz, 6 H), 1.81 (dt, J = 13.6, 6.8 Hz, 2 H), 1.48 – 1.21 (m, 14 H), 0.93 (t, J = 8.9, 3 
H); 
13
C NMR (75 MHz, CDCl3) δ 191.21 (d, J = 34 Hz), 130.37, 129.54, 128.53, 128.29, 128.04, 
127.73, 127.64, 127.40, 115.49 (q, J = 291 Hz), 35.47, 31.81, 29.56 (2 C), 29.43, 29.23, 27.16, 25.91 
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(6Z,9Z,12Z,15Z)-1,1,1-trifluoro-16-phenylhexadeca-6,9,12,15-tetraen-2-one (1d): Yellow oil,  60% 
yield (over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.30 (ddt, J = 14.5, 7.4, 4.4 Hz, 5H), 6.49 (d, J = 
11.5 Hz, 1H), 5.68 (dt, J = 11.5, 7.5 Hz, 1H), 5.53 – 5.34 (m, 6H), 3.12 (t, J = 6.9 Hz, 2H), 2.83 – 
2.71 (m, 6H), 2.14 (dd, J = 14.5, 7.3 Hz, 3H), 1.78 (dd, J = 14.5, 7.2 Hz, 2H). 
13
C NMR (126 MHz, 
CDCl3) δ 191.56 (d, J = 35 Hz), 137.35, 130.54, 129.57, 129.32, 128.71, 128.63, 128.15, 128.11, 
127.96, 126.64, 115.55 (d, J = 292 Hz), 35.58, 26.95, 25.97, 25.71, 25.56, 22.13. HRMS (APCI): 
calculated for C22H26F3O (M+1): 363.1930; found 363.1917. 
 
 
(5Z,8Z,11Z,14Z)-1,1,1-trifluorohenicosa-5,8,11,14-tetraen-2-one (1e): Yellow oil, 64% yield (over 
2 steps). 
1
H NMR (500 MHz, CDCl3) δ 5.41 – 5.32 (m, 8H), 2.85 – 2.77 (m, 6H), 2.47-2.43 (m, 2H), 
2.05 (dd, J = 13.8, 6.9 Hz, 2H), 1.30– 1.26 (m, 10H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ δ 190.85 (d, J = 35.2 Hz), 130.53, 130.36, 128.70, 128.62, 127.69, 127.61, 127.48, 126.47, 
115.52 (d, J = 292.1 Hz), 36.33, 31.76, 29.60, 28.98, 27.26, 25.64, 25.63, 25.57, 22.63, 20.30, 14.06. 
HRMS (APCI): calculated for C21H32F3O (M+1): 357.2400; found 357.2411. 
 
 
(6Z,9Z,12Z)-1,1,1-trifluorooctadeca-6,9,12-trien-2-one (1f): Yellow oil, 58% yield (over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 5.53 – 5.26 (m, 6 H), 2.83 (s, 2 H), 2.75 (t, J = 7.1 Hz, 2 H), 2.15 (dt, J 
= 12.5, 7.3 Hz, 2 H), 2.13 – 1.98 (m, 2 H), 1.85 – 1.72 (m, 2 H), 1.42 – 1.22 (m, 8 H), 0.92 (t, J = 6.7 
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Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 191.44 (d, J = 35 Hz)
c
, 130.53, 129.71, 128.69, 128.10, 
127.61, 127.44, 115.57 (d, J = 291 Hz)
d
, 35.59, 31.52, 29.32, 27.22, 25.99, 25.63, 25.58, 22.57, 22.14, 
14.03. HRMS (APCI): calculated for C18H26F3O (M-1): 315.1941; found 315.1939. 
 
 
(6Z,9Z,12Z)-1,1,1-trifluorohexadeca-6,9,12-trien-2-one (1g): Yellow oil, 51% yield (over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 5.44 – 5.33 (m, 6H), 2.82 – 2.79 (m, 4H), 2.72 (t, J = 7.2 Hz, 2H), 2.14 
(dd, J = 14.6, 7.3 Hz, 2H), 2.04 (dd, J = 14.0, 7.6 Hz, 2H), 1.76 (m, 2H), 1.39 (dd, J = 14.7, 7.4 Hz, 
2H), 0.91 (t, J = 7.4 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 191.41 (q, J = 34.9 Hz, 4H), 130.23, 
129.71, 128.68, 128.08, 127.65, 127.61, 115.56 (d, J = 292.3 Hz, 1H), 35.59, 29.29, 25.99, 25.63, 




(6Z,9Z,12Z)-1,1,1-trifluorohenicosa-6,9,12-trien-2-one (1h): Yellow oil, 60% yield (over 2 steps). 
1
H NMR (300 MHz, CDCl3) δ 5.49 – 5.24 (m, 6 H), 2.76 (dt, J = 14.2, 6.7 Hz, 6 H), 2.10 (ddd, J = 
20.1, 13.7, 6.8 Hz, 4 H), 1.84 – 1.68 (m, 2 H), 1.19 – 1.41 (s, 12 H), 0.88 (t, J = 5.8 Hz, 3 H); 13C 
NMR (125 MHz, CDCl3) δ 191.43 (d, J = 35 Hz)
e
, 130.54, 129.72, 128.70, 128.10, 127.61, 127.43, 
115.57 (d, J = 290 Hz)
f
, 35.60, 31.90, 29.65, 29.52, 29.33, 29.31, 27.26, 26.00, 25.63, 25.59, 22.68, 
22.15, 14.08. HRMS (APCI): calculated for C21H32F3O (M-1): 357.2411; found 357.2399. 
 
 
(6Z,9Z)-1,1,1-trifluoropentadeca-6,9-dien-2-one (1i): Pale yellow oil, 75% yield (over 2 steps). 
1
H 
NMR (500 MHz, CDCl3) δ 5.46 – 5.37 (m, 2H), 5.36 – 5.28 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H), 2.72 (t, 
J = 7.2 Hz, 2H), 2.14 (dd, J = 14.5, 7.2 Hz, 2H), 2.04 (dd, J = 14.2, 7.1 Hz, 2H), 1.76 (p, J = 7.2 Hz, 
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2H), 1.34 – 1.28 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 191.45 (d, J = 34.8 
Hz), 130.61, 130.03, 127.86, 127.30, 115.57 (q, J = 292.3 Hz), 35.61, 31.50, 29.28, 27.21, 25.99, 




(6Z,9Z)-1,1,1-trifluoroheptadeca-6,9-dien-2-one (1j): Yellow oil, 65% yield (over 2 steps). 
1
H 
NMR (500 MHz, CDCl3) δ 5.52 – 5.28 (m, 4 H), 2.79 (t, J = 7.2 Hz, 2 H), 2.74 (t, J = 7.2 Hz, 2 H), 
2.16 (dd, J = 14.3, 7.1 Hz, 2 H), 2.07 (dd, J = 14.1, 7.0 Hz, 2 H), 1.79 (p, J = 7.2 Hz, 2 H), 1.42 – 1.22 
(m,  10 H), 0.91 (t, J = 6.9 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 191.43 (d, J = 34 Hz)
h
, 130.59, 
130.02, 127.85, 127.28, 115.57 (q, J = 291 Hz), 35.58, 31.86, 29.62, 29.27, 29.21, 27.25, 25.98, 25.58, 
22.65, 22.15, 14.04. HRMS (APCI): calculated for C17H26F3O (M-1) 303.1941, found 303.1946. 
 
 
(6Z,9Z)-1,1,1-trifluorohenicosa-6,9-dien-2-one (1k): Yellow oil, 47% yield (over 2 steps). 
1
H NMR 
(500 MHz, CDCl3) δ 5.53 – 5.24 (m, 4 H), 2.77 (dt, J = 21.1, 7.1 Hz, 4 H), 2.16 (dd, J = 14.2, 7.0 Hz, 
2 H), 2.07 (dd, J = 13.9, 6.9 Hz, 2 H), 1.83 – 1.73 (m, 2 H), 1.29 (s, 18 H), 0.91 (t, J = 6.9 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 191.45 (q, J = 36 Hz), 130.62, 130.04, 127.86, 127.28, 115.57 (d, J = 
290 Hz)
i
, 35.60, 31.92, 29.68 (2 C), 29.64 (2 C), 29.56, 29.35, 29.32, 27.26, 25.99, 25.59, 22.69, 
22.17, 14.08. HRMS (APCI): calculated for C21H34F3O (M-1) 359.2567, found 359.2551. 
 
 
(6Z,9Z)-1,1,1-trifluorotricosa-6,9-dien-2-one (1l): Yellow oil, 46% yield (over 2 steps). 
1
H NMR 
(500 MHz, CDCl3) δ 5.50 – 5.39 (m, 2 H), 5.39 – 5.29 (m, 2 H), 2.79 (t, J = 7.2 Hz, 2 H), 2.74 (t, J = 
7.2 Hz, 2 H), 2.17 (q, J = 7.1 Hz, 2 H), 2.11 – 1.99 (m, 2 H), 1.79 (p, J = 7.2 Hz, 2 H), 1.37 (dd, J = 
15.9, 8.5 Hz, 2 H), 1.31 (d, J = 19.3 Hz, 20 H), 0.91 (t, J = 6.9 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) 
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δ 191.42 (q, J = 34 Hz), 130.61, 130.04, 127.85, 127.28, 115.58 (q, J = 291 Hz), 35.60, 31.92, 29.69 
(2 C), 29.67, 29.65, 29.64, 29.63, 29.55, 29.36, 29.32, 27.26, 25.99, 25.59, 22.68, 22.18, 14.07; 
HRMS (APCI): calculated for C23H38F3O (M-1) 387.2880, found 387.2863. 
 
 
(6Z,9Z,12Z,15Z)-1-chloro-1,1-difluorohenicosa-6,9,12,15-tetraen-2-one (1n): Yellow oil, 46% 
yield. 
1
H NMR (500 MHz, CDCl3) δ 5.54 – 5.27 (m, 6 H), 2.91 – 2.71 (m, 6 H), 2.16 (dt, J = 12.1, 7.5 
Hz, 2 H), 2.08 (dd, J = 14.1, 7.0 Hz, 2 H), 1.87 – 1.73 (m, 2 H), 1.44 – 1.22 (m, 8 H), 0.88 (t, J = 3.15 
Hz. 3 H); 
13
C NMR (125 MHz, CDCl3) δ 191.77, 130.52, 129.58, 128.64, 128.39, 128.25, 127.90, 
127.78, 127.51, 119.81 (t, J = 304 Hz), 34.36, 31.53, 29.32, 27.23, 26.07, 25.64 (2 C), 25.62, 22.68, 
22.57, 14.05. HRMS (APCI): calculated for C21H32ClF2O (M+1) 373.2104, found 373.2117. 
 
 
(6Z,9Z,12Z,15Z)-1,1-difluorohenicosa-6,9,12,15-tetraen-2-one (1o): Yellow oil, 51% yield.
 1
H 
NMR (500 MHz, CDCl3) δ 5.67 (t, J = 54.1 Hz, 1H), 5.40 – 5.34 (m, 8H), 2.85 – 2.80 (m, 6H), 2.69 – 
2.66 (m, 2H), 2.15 – 2.12 (m, 2H), 2.06 (t, J = 7.2 Hz, 2H), 1.77 – 1.71 (m, 2H), 1.37 – 1.33 (m, 2H), 
1.31 – 1.28 (m, 4H), 0.89 (dd, J = 9.0, 4.7 Hz, 5H). 13C NMR (75 MHz, CDCl3) δ
13
C NMR (126 MHz, 
CDCl3) δ 199.72, 130.50, 130.36, 129.31, 128.61, 128.54, 128.32, 127.97, 127.80, 127.51, 109.87 (t, J 
= 253.0 Hz, 1H)., 35.29, 31.51, 29.31, 29.27, 27.21, 26.22, 25.62, 25.60, 22.56, 22.13, 14.04. HRMS 
(APCI): calculated for C21H31F2O (M-1) 337.2348; found 337.2345. 
 
General procedure for the alkylation of 12a-d to form 13a-d. 
The general procedure employed was adapted from the protocol reported by Yoshida et al.
26
 To 
propargyl alcohol (116 μL, 2.00 mmol) in THF (3 mL) was added HMPA (1.1 mL, 6.3 mmol) and the 
reaction mixture was cooled to -78
o
C. 2 M n-Butyllithium in cyclohexane (2.0 mL, 4 mmol) was then 
added to the mixture via a canella and stirred vigorously. Thereafter, the respective compound 12 
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(1.00 mmol) dissolved in THF (3 mL) was transferred to the reaction mixture via a canella. The 
temperature of the reaction mixture was allowed to rise to room temperature while stirring overnight. 
Upon completion of the reaction (based on TLC), the reaction was quenched by adding an equivalent 
amount of ethyl acetate and washed with saturated NH4Cl (3 x 20 mL). The organic layer was dried 
with MgSO4, concentrated and purified by flash column chromatography using a 5:1 hexane-ethyl 
acetate eluent system to afford the respective product as a colourless oil or white solid. 
 
 
Oct-2-yn-1-ol (13a): Colourless oil, 47% yield. 
1
H NMR (300 MHz, CDCl3) δ 4.24 (t, J = 2.1 Hz, 
2H), 2.61 (s, 1H), 2.20 (tt, J = 7.2, 2.1 Hz, 2H), 1.49 (dd, J = 14.2, 7.1 Hz, 2H), 1.41 – 1.28 (m, 4H), 
0.89 (t, J = 6.5 Hz, 3H).
 13




Dec-2-yn-1-ol (13b): Colourless oil, 86% yield. 
1
H NMR (500 MHz, CDCl3) δ 4.21 (s, 2 H), 2.29 (s, 
1 H), 2.24 (tt, J = 7.2, 1.9 Hz, 2 H), 1.52 – 1.41 (m, 2 H), 1.37 (dt, J = 15.3, 6.8 Hz, 2 H), 1.32 – 1.19 
(m, 6 H), 0.85 (t, J = 6.9 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 87.06, 78.96, 51.81, 32.34, 29.45, 
29.41, 29.25, 23.23, 19.34, 14.64. 
 
 
Tetradec-2-yn-1-ol (13c): White solid, 50% yield. 
1
H NMR (500 MHz, CDCl3) δ 4.22 (s, 2 H), 2.19 
(ddd, J = 9.2, 4.8, 2.0 Hz, 2 H), 1.89 (d, J = 5.4 Hz, 1 H), 1.49 (dt, J = 14.4, 7.1 Hz, 2 H), 1.38 – 1.16 
(m, 16 H), 0.86 (t, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, CDCl3) δ 86.55, 78.31, 51.31, 31.90, 29.62, 





Hexadec-2-yn-1-ol (13d): White solid, 65% yield. 
1
H NMR (500 MHz, CDCl3) δ 4.22 (s, 2 H), 2.18 
(tt, J = 7.1, 2.1 Hz, 2 H), 2.09 (s, 1 H), 1.48 (dt, J = 15.1, 7.1 Hz, 2 H), 1.40 – 1.17 (m, 20 H), 0.86 (t, 
J = 7.0 Hz, 3 H); 
13
C NMR (125 MHz, CDCl3) δ 86.49, 78.31, 51.26, 31.92, 29.68, 29.66 (2 C), 29.65, 
29.53, 29.35, 29.16, 28.89, 28.63, 22.68, 18.72, 14.08. 
 
 
Synthesis of (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamide (1m): To 9a (67 mg, 0.21 mmol) was 
added 7M ammonia in methanol (0.30 mL, 2.1 mmol) and 7% magnesium methoxide in methanol 
(0.32 mL, 0.21 mmol) and the reaction mixture was heated in a sealed tube at 80
o
C overnight. When 
no starting material was observed, the mixture was cooled to room temperature, quenched with 
saturated NaCl and extracted with ethyl acetate. The combined organic phase was dried with MgSO4, 
concentrated and purified by flash column chromatography with a gradient elution of 3:1 hexane-ethyl 
acetate to 1:2 hexane-ethyl acetate system to afford 1m as a yellow oil (20 mg, 31%). 
1
H NMR (500 
MHz, CDCl3) δ 5.62 (s, 1H), 5.42 – 5.29 (m, 8H), 2.84 – 2.79 (m, 4H), 2.24 – 2.21 (m, 2H), 2.16 – 
2.11 (m, 2H), 2.05 (dd, J = 14.0, 6.9 Hz, 2H), 1.72 (dt, J = 14.7, 7.4 Hz, 2H), 1.35 – 1.27 (m, 8H), 
0.88 (dd, J = 8.8, 4.7 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ
13
C NMR (126 MHz, CDCl3) δ 175.33, 
130.53, 129.01, 128.90, 128.62, 128.26, 128.16, 127.86, 127.53, 35.16, 31.51, 29.31, 27.22, 26.58, 
25.65(2C), 25.26, 22.56, 14.09, 14.05. HRMS (APCI): calculated for C20H34NO(M+1) 304.2640; 
found 304.2645. 
 
General procedure amidation reaction to afford 2l-m, 20a-k and 22 
EDC.HCl (0.029 g, 0.15 mmol), HOBt (0.017 g, 0.120 mmol), the respective compound 19 (30.6 mg, 
0.100 mmol), TEA (15 μL, 0.105 mmol) and the respective amine (0.105 mmol) were dissolved in 
DMF (1.5 mL) and stirred for 3 h at room temperature. Upon the completion of reaction, the reaction 
was quenched by adding an equivalent amount of ethyl acetate and washed with aqueous NaHCO3 (3 
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Methyl 4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)butanoate (20a): Pale yellow liquid, 53% 
yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
1
H NMR (300 MHz, CDCl3) δ 5.73 (s, 1 
H), 5.36 – 5.09 (m, 8 H), 3.66 (s, 3 H), 3.27 (dd, J = 12.9, 6.7 Hz, 2 H), 2.92 – 2.64 (m, 6 H), 2.34 (q, 
J = 7.0 Hz, 2 H), 2.09 (ddd, J = 22.9, 14.5, 7.1 Hz, 6 H), 1.88 – 1.76 (m, 4 H), 1.69 (dt, J = 14.5, 7.4 
Hz, 2 H), 1.41 – 1.17 (m, 8 H), 0.87 (t, J = 6.7 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 173.87, 172.93, 
130.47, 129.07, 128.70, 128.55, 128.18, 128.12, 127.81, 127.47, 51.68, 38.86, 36.05, 31.44, 29.72, 
29.66, 29.27, 27.17, 26.63, 25.58 (2 C), 25.47, 24.61, 22.52, 14.02. HRMS (ESI): calculated for 
C25H40NO3 (M-1) 402.3008, found 402.3019 
 
 
Methyl 5-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)pentanoate (20b): Pale yellow liquid, 53% 
yield (over 2 steps), eluent system: 3:1 hexane- ethyl acetate. 
1
H NMR (500 MHz, CDCl3) δ 5.62 (s, 1 
H), 5.47 – 5.29 (m, 8 H), 3.68 (s, 3 H), 3.27 (q, J = 6.6 Hz, 2 H), 2.89 – 2.77 (m, 4 H), 2.35 (t, J = 7.2 
Hz, 2 H), 2.21 – 2.16 (m, 2 H), 2.12 (dd, J = 13.4, 6.9 Hz, 2 H), 2.07 (dd, J = 14.2, 7.1 Hz, 2 H), 1.73 
(dt, J = 14.9, 7.5 Hz, 2 H), 1.66 (dd, J = 15.2, 7.4 Hz, 2 H), 1.59 – 1.51 (m, 2 H), 1.42 – 1.25 (m, 8 H), 
0.90 (t, J = 6.7 Hz, 3 H);
 13
C NMR (125 MHz, CDCl3) δ 173.91, 172.85, 130.51, 129.15, 128.73, 
128.60, 128.22, 128.18, 127.86, 127.53, 51.55, 38.96, 36.12, 33.46, 31.50, 29.31, 29.06, 27.21, 26.69 
(2 C), 25.63, 25.56 (2 C), 22.55, 22.05, 14.04. HRMS (ESI): calculated for C26H43NO3 (M-1) 





Methyl 6-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)hexanoate (20c): Pale yellow liquid, 62% 
yield (over 2 steps), eluent system: 3:1 hexane- ethyl acetate. 
1
H NMR (300 MHz, CDCl3) δ 5.55 (s, 
1H), 5.38 – 5.34 (m, 8H), 3.65 (s, 3H), 3.23 (dd, J = 13.1, 6.8 Hz, 2H), 2.82 – 2.80 (m, 6H), 2.30 (t, J 
= 7.4 Hz, 2H), 2.14 (dd, J = 14.9, 7.0 Hz, 2H), 2.08 – 2.00 (m, 4H), 1.66 (ddt, J = 22.6, 15.1, 7.6 Hz, 
4H), 1.52 – 1.47 (m, 2H), 1.36 –  1.28 (m, 8H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
174.00, 172.78, 130.46, 129.10, 128.66, 128.54, 128.17, 128.12, 127.80, 127.46, 51.45, 39.14, 36.10, 
33.77, 31.45, 29.25(2C), 27.16, 26.63, 26.28, 25.58(3C), 25.52, 24.38, 22.51, 14.01. HRMS (ESI): 
calculated for C27H45NO3Na (M+23) 454.3292, found 454.3302. 
 
 
Methyl 3-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoate (20d):  white solid, 55% yield 
(over 2 steps), eluent system: 3:1 hexane- ethyl acetate. 
1H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 
8.28 (s, 1H), 7.85 (d, J = 7.3 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 5.39 – 5.29 
(m, 8H), 3.85 (s, 3H), 2.76 (dd, J = 11.3, 5.4 Hz, 5H), 2.34 (t, J = 7.4 Hz, 2H), 2.11 – 2.07 (m, 2H), 
2.01 – 1.97 (m, 3H), 1.69 – 1.64 (m, 2H), 1.29 – 1.24 (m, 6H), 0.83 (t, J = 5.6 Hz, 3H). 13C NMR (75 
MHz, DMSO) δ 171.27, 166.09, 139.68, 129.99, 129.87, 129.26, 129.04, 128.19, 128.05, 127.94, 
127.75, 127.60, 127.45, 123.48, 123.36, 119.46, 52.09, 35.71, 30.87, 28.70, 26.58, 26.17, 25.16(3C), 
24.87, 21.96, 13.87. HRMS (ESI): calculated for C28H37NO3 (M-1) 436.2857, found 436.2848. 
 
 
Methyl 4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamidomethyl)benzoate (20e): Pale yellow solid, 
76% yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
1
H NMR (300 MHz, CDCl3) δ 7.96 
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(d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 6.02 (s, 1H), 5.39 – 5.34 (m, 8H), 4.46 (d, J = 5.8 Hz, 
2H), 3.89 (s, 3H), 2.82 – 2.78 (m, 6H), 2.30 – 2.21 (m, 2H), 2.15 – 2.11(m, 2H), 2.08 – 2.01 (m, 2H), 
1.75 (dd, J = 14.8, 7.4 Hz, 2H), 1.34 – 1.29 (m, 6H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 172.85, 166.74, 143.61, 130.46, 129.89(2C), 129.19, 128.93, 128.78, 128.53, 128.18, 
128.04, 127.76, 127.44(3C), 52.04, 43.08, 35.89, 31.43, 29.24, 27.14, 26.59, 25.56(3C), 25.42, 22.49, 
14.00, HRMS (ESI): calculated for C29H40NO3 (M-1) 450.3014, found 450.3015. 
 
 
Methyl 3-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamidomethyl)benzoate (20f): Pale yellow solid, 
70% yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
 1
H NMR (300 MHz, CDCl3) δ 7.97 
(dd, J = 6.8, 1.4 Hz, 2H), 7.52 (d, J = 7.8 Hz, 1H), 7.43 (dd, J = 11.2, 4.8 Hz, 1H), 5.91 (s, 1H), 5.42 – 
5.38 (m, 8H), 4.52 (d, J = 5.8 Hz, 2H), 3.94 (s, 3H), 2.86 – 2.82 (m, 6H), 2.30 – 2.25 (m, 2H), 2.15 – 
2.13 (m, 2H), 2.09 – 2.07 (m, 2H), 1.84 – 1.76 (m, 2H), 1.34 – 1.29 (m, 6H), 0.92 (t, J = 6.8 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.79, 166.82, 138.81, 132.34(2C), 130.50, 129.01, 128.79(2C), 
128.66(2C), 128.57, 128.21, 128.10, 127.81, 127.48, 52.15, 43.12, 35.97, 31.47, 29.28, 27.18, 26.63, 




Methyl 5-((6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraenamido)pentanoate (20g):  Pale yellow solid, 
45% yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
1
H NMR (500 MHz, CDCl3) δ 5.67 
(s, 1H), 5.35 – 5.34 (m, 8H), 3.65 (s, 3H), 3.23 (dd, J = 12.9, 6.6 Hz, 2H), 2.82 – 2.75 (m, 4H), 2.33 (t, 
J = 7.2 Hz, 2H), 2.15 (t, J = 7.5 Hz, 2H), 2.07 – 2.01 (m, 6H), 1.65 – 1.61 (m, 4H), 1.53 – 1.50 (m, 
2H), 1.39 – 1.35 (m, 2H), 1.34 – 1.27 (m, 6H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 173.93, 173.00, 130.43, 129.67, 128.49, 128.25, 128.04(2C), 127.83, 127.48, 51.53, 38.89, 36.63, 
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33.39, 31.45, 29.26, 29.19, 28.96, 27.15, 27.07, 26.87, 25.57(2C), 25.34, 22.51, 21.97, 14.01. HRMS 
(ESI): calculated for C27H44NO3 (M-1) 430.3316, found 4330.3317. 
 
 
Methyl 5-((6Z,9Z,12Z,15Z)-nonadeca-6,9,12,15-tetraenamido)pentanoate (20h): Pale yellow solid, 
41% yield (over 2 steps)，eluent system: 3:1 hexane-ethyl acetate. 1H NMR (500 MHz, CDCl3) δ 
5.55 (s, 1H), 5.37 – 5.36 (m, 8H), 3.67 (s, 3H), 3.25 (dd, J = 12.8, 6.6 Hz, 2H), 2.83 – 2.80 (m, 6H), 
2.34 (t, J = 7.2 Hz, 2H), 2.16 (t, J = 7.6 Hz, 2H), 2.09 – 2.03 (m, 4H), 1.67 – 1.64 (m, 4H), 1.53 (t, J = 
7.0 Hz, 2H), 1.38 (q, J = 7.6 Hz, 4H), 0.91 (t, J = 7.4 Hz, 3H).
 13
C NMR (126 MHz, CDCl3) δ 173.92, 
172.97, 130.20, 129.73, 128.56, 128.33, 128.12(2C), 127.90, 127.78, 51.53, 38.96, 36.70, 33.46, 
29.30, 29.25, 29.05, 26.93, 25.65, 25.64(2C), 25.38, 22.75, 22.04, 13.75. HRMS (ESI): calculated for 
C25H41NNaO3 (M+Na) 426.2979, found 426.2989. 
 
 
Methyl 3-((6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraenamido)benzoate (20i): Pale yellow solid, 66% 
yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
1
H NMR (300 MHz, CDCl3) δ 8.01 (s, 
1H), 7.90 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 5.41 – 5.35 (m, 8H), 
3.91 (s, 3H), 2.86 – 2.79 (m, 6H), 2.38 (t, J = 7.5 Hz, 2H), 2.13 – 2.02 (m, 4H), 1.76 (dt, J = 15.3, 7.5 
Hz, 2H), 1.44 (dt, J = 15.0, 7.5 Hz, 2H), 1.30 – 1.26 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 171.28, 166.69, 138.12, 130.91, 130.51, 129.57, 129.17, 128.59, 128.30, 128.27, 
128.17, 127.88, 127.54, 125.25, 124.28, 120.53, 52.19, 37.59, 31.51, 29.31, 29.16, 27.22, 26.92, 






Methyl 3-((6Z,9Z,12Z,15Z)-nonadeca-6,9,12,15-tetraenamido)benzoate (20j): Pale yellow solid, 
50% (over  2 steps), eluent system: 3:1 hexane-ethyl acetate.
1
H NMR (500 MHz, CDCl3) δ 8.01 (s, 
1H), 7.91 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.29 (s, 1H), 5.39 – 
5.37 (m, 8H), 3.91 (s, 3H), 2.84 – 2.81 (m, 6H), 2.38 (t, J = 7.5 Hz, 2H), 2.12 (dd, J = 13.2, 7.1 Hz, 
2H), 2.04 (dd, J = 14.1, 6.9 Hz, 2H), 1.76 (dt, J = 15.3, 7.6 Hz, 2H), 1.47 (dt, J = 15.1, 7.5 Hz, 2H), 
1.38 (dd, J = 14.7, 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz,3H).
 13
C NMR (126 MHz, CDCl3) δ 171.25, 166.67, 
138.16, 130.94, 130.22, 129.57, 129.16, 128.59, 128.32, 128.28, 128.18, 127.89, 127.78, 125.24, 
124.30, 120.57, 52.17, 37.59, 29.31, 29.17, 26.92, 25.67(3C), 25.10, 22.76, 13.75. HRMS (ESI): 
calculated for C27H36NO3 (M-1) 422.2701, found 422.2707. 
 
 
Methyl 5-((7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenamido)pentanoate (20k): Pale yellow solid, 
47% yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
 1
H NMR (500 MHz, CDCl3) δ 5.56 
(s, 1H), 5.38 – 5.36 (m, 8H), 3.67 (s, 3H), 3.28 – 3.25 (m, 2H), 2.84 – 2.80 (m, 6H), 2.34 (t, J = 7.2 
Hz, 2H), 2.18 – 2.15 (m, 2H), 207 – 2.03 (m, 6H), 1.55 – 1.52 (m, 2H), 1.34 – 1.32 (m, 6H), 1.32 – 
1.29 (dd, J = 11.6, 8.3 Hz, 4H), 1.28 – 1.27 (m, 2H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 178.76, 173.96, 130.49, 130.07, 128.55, 128.39, 128.07, 127.93, 127.88, 127.56, 51.57, 
38.99, 36.77, 33.45, 31.51, 29.68, 29.34, 29.32, 29.04, 28.95, 27.22, 27.07, 25.67, 25.64, 25.56, 22.56, 
22.02, 14.04, HRMS (ESI): calculated for C28H37NO3 (M-1) 445.3556, found 445.3559. 
 
 
4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzamide (2l): Pale yellow solid, 34% yield, 
eluent system: 1:3 hexane-ethyl acetate. 
1H NMR (500 MHz, MeOD) δ 7.86 (d, J = 8.8 Hz, 2 H), 7.70 
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(d, J = 8.8 Hz, 2 H), 5.60 – 5.22 (m, 8 H), 2.98 – 2.71 (m, 6 H), 2.44 (t, J = 7.4 Hz, 2 H), 2.20 (dd, J = 
13.2, 7.3 Hz, 2 H), 2.07 (dd, J = 13.7, 6.6 Hz, 2 H), 1.80 (dt, J = 14.8, 7.4 Hz, 2 H), 1.55 – 1.20 (m, 8 




C NMR (126 MHz, CDCl3) δ 173.22, 170.39, 142.07, 129.80, 128.72, 
128.51, 128.37, 128.24 (2 C), 128.04, 127.76, 127.74 (2 C), 127.46, 127.35, 118.82, 35.96, 31.24, 
29.04, 26.77, 26.25, 25.19, 25.16, 25.15 (2 C), 22.21, 13.02; HRMS (ESI): calculated for C27H37N2O2 
(M-1) 421.2861, found 421.2873. 
 
 
3-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzamide (2m): white solid, 74% yield (over 2 
steps), eluent system: 1:3 hexane-ethyl acetate. 
1H NMR (300 MHz, DMSO) δ 8.04 (s, 1H), 7.76 (dd, 
J = 8.1, 1.0 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 5.42 – 5.38 (m, 2H), 5.37 – 
5.31 (m, 5H), 2.85 – 2.77 (m, 4H), 2.41 (t, J = 7.5, 2H), 2.19 – 2.15 (m, 2H), 2.06 – 2.02 (m, 3H), 
1.80 – 1.75 (m, 2H), 1.37 – 1.30 (m, 6H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 
174.45, 172.11, 140.23, 135.76, 131.17, 130.12, 129.96, 129.88, 129.43, 129.15, 129.13, 128.86, 
128.74, 124.37, 123.95, 120.38, 37.29, 32.65, 30.46, 28.18, 27.68, 26.65, 26.58,  26.54(2C), 23.63, 
14.46. HRMS (ESI): calculated for C27H37N2O2 (M-1) 421.2861, found 421.2842 
 
 
Methyl 5-(pent-4-ynamido)pentanoate (22): Colourless liquid, 96% yield, eluent system: 4:1 
hexane-ethyl acetate.
1
H NMR (500 MHz, CDCl3) δ 6.69 (s, 1H), 3.50 (s, 3H), 3.10 (dd, J = 13.0, 6.6 
Hz, 2H), 2.35 (dd, J = 8.8, 4.7 Hz, 2H), 2.26 (t, J = 7.2 Hz, 2H), 2.18 (t, J = 7.3 Hz, 2H), 1.88 (t, J 
=2.6 Hz, 1H), 1.51 (t, J =7.4 Hz, 2H), 1.39 (t, J = 7.0 Hz, 2H).
 13
C NMR (126 MHz, CDCl3) δ 173.53, 
170.93, 82.66, 68.90, 51.13, 38.65, 34.79, 33.13, 28.52, 21.75, 14.57. HRMS (ESI): calculated for 
C11H16NO3 (M-1) 210.1136, found 210.1135. 
 91 
 
General procedure for the synthesis of 20n and 20o 
The respective acid 19 (0.12mmol) was dissolved in CH2Cl2 (3.5 mL). Thereafter, oxalyl chloride 
(21.2 μL, 0.243 mmol) and 1 drop of DMF were added and the mixture was stirred for 1 h at room 
temperature. After which, the solvent was removed. The formed acid chloride was re-dissolved in 
DMF (1.0 mL), the respective amine (0.243 mmol) and TEA (34 μL, 0.243 mmol) and stirred at room 
temperature overnight. When no more starting material was observed, ethyl acetate and brine were 
added to quench the reaction. The mixture was extracted with ethyl acetate (3x 20mL) and the organic 
layer was combined, dried with MgSO4 and purified by flash column chromatography  
 
 
Methyl 4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoate (20n): White solid, 64 % yield 
(over 2 steps), eluent system: 3:1 hexane-ethyl acetate.
 1
H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.7 
Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.38 (s, 1H), 5.42 – 5.34 (m, 7H), 3.89 (s, 3H), 2.83 – 2.78 (m, 6H), 
2.40 – 2.37 (m, 2H), 2.18 – 2.15 (m, 2H), 2.09 – 2.02 (m, 2H), 1.84 – 1.82 (m, 2H), 1.35 – 1.34 (m, 
2H), 1.29 – 1.25 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.24, 166.58, 
142.08, 130.83(2C), 130.53(2C), 129.12, 128.83, 128.62, 128.31, 128.04, 127.78, 127.48, 125.50, 
118.68, 51.98, 37.04, 31.49, 29.29, 27.20, 26.50, 25.65, 25.62(2C), 25.09, 22.55, 14.04. HRMS (ESI): 
calculated for C28H37NO3 (M-1) 436.2857, found 436.2838. 
 
 
Methyl 2-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoate (20o): Pale yellow solid, 32% 
yield (over 2 steps), eluent system: 3:1 hexane-ethyl acetate. 
1
H NMR (500 MHz, CDCl3) δ 11.07 (s, 
1H), 8.73 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.07 (t, J = 7.6 Hz, 
1H), 5.42 – 5.34 (m, 8H), 3.93 (s, 3H), 2.81 (dd, J = 11.1, 4.8 Hz, 6H), 2.46 (t, J = 7.6 Hz, 2H), 2.19 – 
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2.17 (m, 2H), 2.06 – 2.02 (m, 2H), 1.86 – 1.83 (m, 2H), 1.35 – 1.26 (m, 6H), 0.88 (t, J = 6.7 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.94, 168.77, 141.69, 134.69, 130.79, 130.47, 129.05, 128.90, 
128.56, 128.21, 128.19, 127.89, 127.57, 122.31, 120.39, 114.75, 52.29, 38.01, 31.51, 29.69, 29.32, 
27.21, 26.64, 25.66, 25.64, 25.30, 22.56, 14.05.HRMS (ESI): calculated for C28H37NO3 (M-1) 
436.2857, found 436.2856. 
 
 
Synthesis of (5Z,8Z,11Z,14Z)-N-(3-sulfamoylphenyl)icosa-5,8,11,14-tetraenamide (2p): EDC.HCl 
(13 mg, 0.07 mmol), 19a (18 mg, 0.06 mmol), TEA (9 μL, 0.07 mmol) and 3-
aminobenzenesulfonamide (11 mg, 0.07 mmol) were dissolved in MeCN (1.5 mL) and stirred 
overnight at 4
o
C. The reaction was quenched with ethyl acetate and the mixture was washed with 
aqueous NaHCO3 (3 x 20 mL) and brine (3 x 20 mL). The organic layer was dried, concentrated and 
purified by flash column chromatography using a 1:1 hexane-ethyl acetate eluent system to yield 2p 
as a pale yellow solid (13 mg, 47% yield).  
1H NMR (500 MHz, DMSO) δ 10.18 (s, 1H), 8.17 (s, 1H), 
7.76 – 7.74 (m, 1H), 7.48 – 7.46 (m, 2H), 7.34 (s, 2H), 5.40 – 5.31 (m, 8H), 2.82 – 2.77 (m, 6H), 2.35 
(t, J = 7.4 Hz, 2H), 2.11 (dd, J = 13.9, 6.9 Hz, 2H), 2.03 – 2.00 (m, 2H), 1.70 – 1.64 (m, 2H), 1.32 – 
1.29 (m, 2H), 1.28 – 1.24 (m, 4H), 0.85 (t, J = 6.2 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.85, 
145.02, 140.05, 130.39(2C), 129.74, 128.67, 128.57, 128.41, 128.29, 128.10, 127.95, 122.24, 120.46, 
116.47, 36.24, 31.31, 29.42, 29.13, 27.04, 26.66, 25.66(2C), 25.38, 22.38, 14.33. HRMS (ESI): 
calculated for C26H37NO3S (M-1) 457.2530, found 457.2537. 
 
General hydrolysis procedure to yield 2a-k, 2n-o and 2q 
The respective ester 20 or 24 (0.03 mmol) was dissolved in 2M methanolic NaOH (2.0 mL) and 
stirred at room temperature for 3 h. When no more starting material was observed, the reaction was 
quenched with 1M HCl and then extracted with ethyl acetate (3x20 mL). The organic layer was 
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4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)butanoic acid (2a): Pale yellow solid, 59% yield, 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1
H NMR (500 MHz, CDCl3) δ 5.73 (s, 1 H), 5.83 
– 5.33 (m, 8 H), 3.37 – 3.33 (dd, J = 12.9, 6.7 Hz, 2 H), 2.92 – 2.64 (m, 4 H), 2.41 (t, J = 7.0 Hz, 2 H), 
2.09 (ddd, J = 22.9, 14.5, 7.1 Hz, 6 H), 1.87 (dt, J = 14.5, 7.4 Hz, 2 H), 1.69 (dt, J = 14.5, 7.4 Hz, 2 H), 
1.41 – 1.17 (m, 8 H), 0.90 (t, J = 6.7 Hz, 3 H)k; 13C NMR (125 MHz, CDCl3) δ 177.15, 173.72, 
130.54, 129.01, 128.87, 128.63, 128.29, 128.14, 127.85, 127.53, 38.83, 36.05, 31.51, 29.69, 29.64, 
29.31, 27.22, 26.65, 25.64 (2 C), 25.49, 24.83, 22.57, 14.05. HRMS (ESI): calculated for 
C24H39NO3Na (M+Na) 412.2822, found 412.2830. 
 
 
5-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)pentanoic acid (2b): Pale yellow solid, 52% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1
H NMR (500 MHz, CDCl3) δ 5.67 (s, 1 
H), 5.50 – 5.28 (m, 8 H), 3.29 (d, J = 5.9 Hz, 2 H), 2.91 – 2.72 (m, 4 H), 2.40 (t, J = 7.1 Hz, 2 H), 
2.24 – 2.17 (m, 2 H), 2.13 (dd, J = 13.1, 6.6 Hz, 2 H), 2.07 (dd, J = 14.2, 7.1 Hz, 2 H), 1.71 – 1.62 (m, 
4 H), 1.59 (dd, J = 14.3, 6.9 Hz, 2 H), 1.44 – 1.24 (m, 8 H), 0.91 (t, J = 7.0 Hz, 3 H)j; 13C NMR (125 
MHz, CDCl3) δ 178.06, 173.30, 130.53, 129.09, 128.79, 128.62, 128.25, 128.17, 127.86, 127.53, 
39.05, 36.14, 33.41, 31.51, 29.31, 28.99, 27.22, 26.68, 25.64 (2 C), 25.56 (2 C), 22.56, 21.88, 14.05. 






6-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)hexanoic acid (2c): Pale yellow solid, 98% yield, 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1
H NMR (500 MHz, CDCl3) δ 5.57 (s, 1H), 5.38 
– 5.34 (m, 8H), 3.25 (dd, J = 13.3, 6.8 Hz, 2H), 2.84 – 2.75 (m, 6H), 2.34 (t, J = 7.3 Hz, 2H), 2.18 – 
2.15 (m, 2H), 2.11 – 2.08 (m, 2H), 2.07 – 2.02 (m, 2H), 1.72 – 1.63 (m, 4H), 1.53 – 1.50 (m, 2H), 
1.39 – 1.34 (m, 4H), 1.32 – 1.25 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
178.25, 173.14, 130.50, 129.09, 128.73, 128.58, 128.22, 128.14, 127.83, 127.50, 39.25, 36.12, 33.77, 
31.48, 29.29, 29.24, 27.19, 26.64, 26.24, 25.61(3C), 25.54, 24.23, 22.54, 14.03. HRMS (ESI): 
calculated for C26H42NO3 (M-1) 416.3170, found 416.3170. 
 
 
3-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoic acid (2d): Pale yellow solid, 63% yield, 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH.
 1
H NMR (500 MHz, DMSO) δ 12.91 (s, 1H), 
10.05 (s, 1H), 8.22 (s, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 
5.39 – 5.31 (m, 7H), 2.77 (dt, J = 11.5, 5.5 Hz, 4H), 2.32 (dd, J = 13.7, 6.3 Hz, 2H), 2.10 – 2.07 (m, 
2H), 2.00 – 1.98 (m, 4H), 1.67 – 1.64 (m, 2H), 1.30 – 1.27 (m, 2H), 1.24 – 1.21 (m, 4H), 0.83 (t, J = 
6.9 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 171.23, 167.18, 139.51, 131.21, 129.90, 129.29, 128.82, 
128.20, 128.07, 127.95, 127.78, 127.62, 127.48, 123.70, 123.04, 119.76, 35.74, 30.86, 28.69, 26.58, 








4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamidomethyl)benzoic acid (2e): Pale yellow solid, 95% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 12.83 (s, 
1H), 8.37 (s, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 5.36 – 5.32 (m, 9H), 4.32 (d, J = 
5.9 Hz, 2H), 2.82 – 2.77 (m, 6H), 2.16 (t, J = 7.4 Hz, 2H), 2.03 (td, J = 13.9, 7.0 Hz, 4H), 1.62 – 1.56 
(m, 2H), 1.32 – 1.28 (m, 2H), 1.27 – 1.22 (m, 4H), 0.84 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 172.48, 167.59, 145.37, 130.39, 129.83, 129.76, 129.70, 128.57, 128.51, 128.44, 128.24, 
128.13, 127.96, 127.57, 42.24, 35.22, 31.31, 29.14, 27.05, 26.74, 25.69, 25.67, 25.65(2C), 22.40, 
14.34.HRMS (ESI): calculated for C28H37NO3 (M-1) 436.2587, found 436.2861. 
 
 
3-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamidomethyl)benzoic acid (2f): Pale yellow solid, 98% 
yield,
 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH.
 1
H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 
8.1 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 5.93 (s, 1H), 5.39 – 5.33 (m, 8H), 4.51 
(d, J = 5.8 Hz, 2H), 2.83 – 2.79 (m, 6H), 2.28 – 2.25 (m, 2H), 2.12 (dd, J = 13.3, 6.8 Hz, 2H), 2.06 – 
2.02 (m, 2H), 1.78 – 1.75 (m, 2H), 1.35 – 1.33 (m, 2H), 1.29 – 1.25 (m, 4H), 0.88 (t, J = 6.9 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.21, 170.77, 138.83, 133.02, 130.50, 129.94, 129.27, 129.22, 
128.98, 128.90, 128.84, 128.58, 128.23, 128.11, 127.83, 127.49, 43.18, 35.98, 31.48, 29.28, 27.18, 








5-((6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraenamido)pentanoic acid (2g): pale yellow solid, 95% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 11.95 (s, 
1H), 7.70 (s, 1H), 5.28 (s, 8H), 2.98 – 2.96 (m, 2H), 2.77 – 2.69 (m, 4H), 2.15 (t, J = 7.2 Hz, 2H), 
1.99 – 1.98 (m, 8H), 1.45 – 1.42 (m, 4H), 1.35 – 1.32 (m, 2H), 1.29 – 1.24 (m, 2H), 1.22 (s, 6H), 0.81 
(t, J = 6.4 Hz, 3H).
13C NMR (126 MHz, DMSO) δ 174.33, 171.74, 129.90, 129.73, 129.48, 128.07, 
128.02, 127.72, 127.66, 127.49, 40.41, 37.98, 35.27, 33.28, 30.89, 28.72, 28.700, 28.68, 26.61, 26.46, 




5-((6Z,9Z,12Z,15Z)-nonadeca-6,9,12,15-tetraenamido)pentanoic acid (2h): Pale yellow solid, 95% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH.  
1H NMR (500 MHz, DMSO) δ 11.99 (s, 
1H), 
1H NMR (500 MHz, DMSO) δ 7.74 (m, 1H), 5.38 – 5.33 (m, 8H), 3.02 (q, J = 6.5 Hz, 2H), 2.83 
– 2.78 (m, 4H), 2.20 (t, J = 7.3 Hz, 2H), 2.06 – 2.00 (m, 6H), 1.51 – 1.47 (m, 4H), 1.40 – 1.35 (m, 2H), 
1.34 – 1.29 (m, 2H), 1.27 –1.25 (s, 2H), 0.88 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
174.77, 172.21, 130.20, 130.13, 128.54, 128.50, 128.19(2C), 128.15, 128.08, 38.43, 35.73, 33.75, 
29.15, 29.13, 26.90, 25.65, 25.43, 22.65, 22.38, 14.01.HRMS (ESI): calculated for C24H38NO3 (M-1) 
388.2857, found 388.2866. 
 
 
3-((6Z,9Z,12Z,15Z)-henicosa-6,9,12,15-tetraenamido)benzoic acid (2i): Pale yellow solid, 81 % 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 12.86 (s, 
1H), 10.01 (s, 1H), 8.21 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 7.9 Hz, 
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1H), 5.37 – 5.29 (m, 8H), 2.79 (dt, J = 17.2, 5.2 Hz, 6H), 2.32 (t, J = 7.4 Hz, 2H), 2.07 (dd, J = 14.1, 
7.0 Hz, 2H), 2.01 (dd, J = 13.8, 6.8 Hz, 2H), 1.61 (dt, J = 15.1, 7.5 Hz, 2H), 1.37 (dt, J = 15.0, 7.6 Hz, 
2H), 1.30 – 1.23 (m, 6H), 0.84 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.27, 167.08, 
139.43, 131.18, 129.85, 129.59, 128.73, 128.00, 127.93, 127.68, 127.65, 127.59, 127.41, 123.63, 
122.99, 119.73, 36.19, 30.77, 28.59(2C), 26.51, 26.40, 25.14, 25.13(2C), 24.63, 21.84, 13.78. HRMS 
(ESI): calculated for C28H37NO3 (M-1) 436.2587, found 436.2866. 
 
 
3-((6Z,9Z,12Z,15Z)-nonadeca-6,9,12,15-tetraenamido)benzoic acid (2j): Pale yellow solid, 98% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 12.87 (s, 
1H), 10.02 (s, 1H), 8.22 (s, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.40 (t, J = 7.9 Hz, 
1H), 5.38 – 5.33 (m, 8H), 2.82 – 2.78 (m, 6H), 2.33 (t, J = 7.4 Hz, 2H), 2.10 – 2.06 (m, 2H), 2.04 (dd, 
J = 13.4, 6.9 Hz, 2H), 1.62 (dt, J = 15.2, 7.5 Hz, 2H), 1.39 – 1.35 (m, 2H), 1.32 (dd, J = 14.7, 7.3 Hz, 
2H), 0.86 (d, J = 7.3 Hz, 3H).
 13C NMR (126 MHz, DMSO) δ 171.27, 167.11, 139.41, 131.35, 129.59, 
128.71, 128.01, 127.95, 127.68, 127.66, 127.66, 127.64, 127.61, 123.64, 122.94, 119.74, 36.19, 28.61, 
28.59, 26.40, 25.14 (2C), 24.63, 22.10, 13.45. HRMS (ESI): calculated for C26H34NO3 (M-1) 
408.2544, found 408.2543. 
 
 
5-((7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenamido)pentanoic acid (2k): Pale yellow solid, 69% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH.
 1H NMR (500 MHz, DMSO) δ 11.98 (s, 
1H), 7.73 (s, 1H), 5.34 – 5.33 (m, 8H), 3.34( s, 6H), 3.02 (dd, J = 12.6, 6.5 Hz, 2H), 2.82 – 2.75 (m, 
2H), 2.20 (t, J = 7.3 Hz, 2H), 2.04 – 2.02 (m, 4H), 1.50 – 1.47 (m, 4H), 1.40 – 1.36 (m, 2H), 1.33 – 
1.25 (m, 10H), 0.86 (t, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 174.76, 172.28, 130.37, 
130.32, 128.52, 128.49, 128.16, 128.13, 127.99, 127.95, 38.42, 35.82, 33.74, 31.32, 29.45, 29.26, 
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29.23, 29.15, 29.12, 28.75, 27.06, 27.02, 27.00, 25.66, 25.064, 22.38, 14.34. HRMS (ESI): calculated 
for C28H37NO3 (M-1) 430.3327, found 430.3323. 
 
 
4-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoic acid (2n): Pale yellow solid, 68% yield, 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 
10.18 (s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 5.37 – 5.31 (m, 7H),  2.80 – 2.76 (m, 
5H), 2.35 (t, J = 7.1 Hz, 2H), 2.10 – 2.08 (m, 2H), 2.01 – 1.98 (m, 3H), 1.67 – 1.64 (m, 2H), 1.30 – 
1.26  (m,  2H), 1.24 – 1.23 (m, 4H), 0.83 (t, J = 6.6 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.54, 
166.91, 143.32, 130.30(2C), 129.91, 129.26, 128.23, 128.07, 127.95, 127.77, 127.63, 127.47, 124.81, 
118.17(2C), 35.80, 30.85, 28.68, 26.57, 26.16, 25.18(3C), 24.81, 21.94, 13.88. HRMS (ESI): 
calculated for C27H36NO3 (M-1) 422.2701, found 422.2690. 
 
 
2-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)benzoic acid (2o): Pale yellow solid, 96% yield, 
eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1
H NMR (300 MHz, CDCl3) δ 10.93 (s, 1H), 
8.76 (d, J = 8.5 Hz, 1H), 8.11 (dd, J = 8.0, 1.5 Hz, 1H), 7.62 – 7.57 (m, 1H), 7.14 – 7.09 (m, 1H), 5.44 
– 5.33 (m, 8H), 2.84 – 2.77 (m, 6H), 2.47 (t, J = 7.8 Hz, 2H), 2.20 – 2.06 (m, 2H), 2.05 – 2.01(m, 2H), 
1.85 (t, J = 7.4 Hz, 2H), 1.37 – 1.25 (m, 6H), 0.88 (t, J = 6.7 Hz, 3H).13C NMR (75 MHz, CDCl3) δ 
172.13, 171.73, 142.11, 135.61, 131.72, 130.49, 128.97, 128.93, 128.56, 128.21, 128.14, 127.85, 
127.53, 122.56, 120.49, 113.74, 37.95, 31.49, 29.30, 27.19, 26.57, 25.64, 25.61(2C), 25.25, 22.55, 





5-((4Z,7Z,10Z,13Z)-nonadeca-4,7,10,13-tetraenamido)pentanoic acid (2q): Pale yellow solid, 64% 
yield, eluent system: 2:1:0.03 hexane-ethyl acetate-AcOH. 
1H NMR (500 MHz, DMSO) δ 11.99 (s, 
1H), 7.78 – 7.74 (m, 1H), 5.36 – 5.31 (m, 7H), 3.04 – 3.00 (m, 2H), 2.83 – 2.75 (m, 4H), 2.20 (t, J = 
7.3 Hz, 2H), 2.08 (dd, J = 8.9, 6.1 Hz, 2H), 2.04 – 2.00 (m, 4H), 1.47 (d, J = 7.3 Hz, 2H), 1.40 – 1.38 
(m, 2H), 1.33 – 1.30 (m, 2H), 1.27 – 1.25 (m, 6H), 0.86 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
DMSO) δ 174.32, 171.16, 129.92, 128.86, 128.08, 128.03, 128.00, 127.75, 127.67, 127.50, 38.02, 
35.21, 33.27, 30.84, 28.68, 28.62, 26.57, 25.18, 25.17, 25.13, 23.16, 21.93, 21.91, 13.88. HRMS (ESI): 




This part of the project was carried out in collaboration with Prof. Chandra S Verma 
(Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR)).  
Protein modeling  
The crystal structure of cPLA2 in its apo form is available,
14 
however the experimental structure has a 
few missing regions (407 to 414, 431 to 462, 498 to 538 and 626-632).  The missing structural regions 
were modeled using homology and loop modeling methods. The homology models were generated by 
program Modeller (version 9.12).
27
 Several models were generated and the models with the best 
stereochemical properties were refined further using all atom MD simulations.   
 
Ligand preparation 
The 3D structures of the test compounds were built using Maestro and minimized using the 
Macromodel module employing the OPLS-2005 force field in Schrodinger 9.0.
28,29
  All the inhibitors 
were then prepared with Ligprep that generates low energy tautomers and enumerates realistic 





Ligand docking  
The prepared inhibitors were docked into the binding pockets of the models of cPLA2 using Glide.
30
 
A box of size 10 x 10 x 10 Ǻ for molecular docking centered on the selected active site residue 
(Ser228) was used to confine the search space of each docked ligand.  For the grid generation, the 
default Glide settings were used.  A rigid receptor docking (RRD) protocol was used which fixes the 
protein conformation while allowing the ligands to be flexible.  All inhibitors were docked into the 
active sites of cPLA2 using this protocol and the docked conformation of each ligand was evaluated 
using the Glide Extra Precision (XP) scoring function.  Docking was carried out on several 
conformational substrates of the Mnk kinases identified by clustering of MD trajectories. 
 
MD simulations 
MD simulations were carried out to refine the homology models of cPLA2 and to generate ensemble 
of receptor conformations for docking. MD simulations were carried out with the Sander module of 
the program Amber11.
31
 The partial charges and force field parameters for each inhibitor were 
generated using the Antechamber module in Amber.  All atom versions of the Amber 03 force field 
(ff03).
32
 The Xleap module was used to prepare the system for the MD simulations. All the simulation 
systems were neutralized with an appropriate number of counterions. Each neutralized system was 
solvated in an octahedral box with TIP3P water molecules, leaving at least 10 Ǻ between the solute 
atoms and the borders of the box.
33
 All MD simulations were carried out in an explicit solvent at 
300K.  During the simulations, the long-range electrostatic interactions were treated with the particle 
mesh Ewald method using a real space cutoff distance of 9 Å.
34
 The Settle algorithm was used to 





Solvent molecules and counterions were initially relaxed using energy minimization with restraints on 
the protein and inhibitor atoms.  This was followed by unrestrained energy minimization to remove 
any steric clashes.  Subsequently the system was gradually heated from 0 to 300 K using MD 




) on protein and inhibitors over 
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a period of 0.25 ns allowing water molecules and ions to move freely.  During an additional 0.25 ns, 
the positional restraints were gradually reduced followed by a 2 ns unrestrained MD simulation to 
equilibrate all the atoms.  For the refinement simulations, three independent MD simulations 
(assigning different initial velocities) were carried out on each equilibrated cPLA2 structure for 100 ns 
with conformations saved every 10 ps.  Cluster analysis of the sampled conformations was performed 
using the Kclust program in MMTSB-tools.
36
 Simulation trajectories were visualized using VMD and 
figures were generated using Pymol.
37, 38 
 
2.13 Experimental - Biology 
2.13.1 Enzchek phospholipase A2 fluorogenic assay (% activity) 
The assay was conducted according to the manufacturer’s instruction (E10217, Molecular Probes) 
with slight modification. Briefly, substrate solution was separately prepared by mixing 5 μL of DOPG, 
5 μL of DOPC and 5 μL of substrate respectively in 1.5 mL of 1X phospholipase A2 reaction buffer. 
The mixture was vortexed vigorously for 3 min before allowing to stand at room temperature for 1 h. 
48 μL of 1X phospholipase A2 reaction buffer were added into each well of a 96-wells plate. This is 
followed by addition of 1 μL of recombinant cPLA2 (P4074-03R, US Biological) and 1 μL of 1 mM 
of the respective compound dissolved in DMSO. The final concentration of the test compound 
achieved is 10 μM. The reaction is initiated by adding 50 μL of the substrate solution and incubating 
at room temperature for 1 h. Fluorescence was measured using a Varioskan plate reader by exciting at 
485 nm, while fluorescence emission was detected at 515 nm. Positive control was performed when 1 
μL of test compound was replaced by vehicle DMSO. 
% activity was calculated by the following formula 
%𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑝𝑜𝑠𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 
 
2.13.2 Enzchek phospholipase A2 fluorogenic assay (IC50) 
The assay was conducted as described above. Instead of adding a fixed concentration of the test 
compound, various concentrations of compound were reconstituted in DMSO.  48 μL of 1X 
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phospholipase A2 reaction buffer were added into each well of a 96-wells plate. This is followed by 
addition of 1 μL of recombinant cPLA2 (P4074-03R, US Biological) and 1 μL of the respective 
concentration of the test compound dissolved in DMSO. The reaction was initiated by adding 50 μL 
of the substrate solution and incubating at room temperature for 1 h. Fluorescence was measured 
using a Varioskan plate reader by exciting at 485 nm, while fluorescence emission was detected at 
515 nm. Positive control was performed when 1 μL of test compound was replaced by vehicle DMSO. 
 
2.13.3 Enzchek phospholipase A2 fluorogenic assay (selectivity) 
The assay was conducted as described above. Instead of adding cPLA2, it was replaced by sPLA2. 48 
μL of 1X phospholipase A2 reaction buffer was added into each well of a 96-wells plate. This is 
followed by addition of 1 μL of sPLA2, human recombinant type V (10009563, Cayman Chemical) 
and 1 μL of 1 mM of the respective compound or thio-etheramidePC dissolved in DMSO [thio-
etheramidePC (62750, Cayman Chemical) is a sPLA2 selective inhibitor]. The reaction was initiated 
by adding 50 μL of the substrate solution and incubating at room temperature for 1 h. Fluorescence 
was measured using a Varioskan plate reader by exciting at 485 nm, while fluorescence emission was 
detected at 515 nm. Positive control was performed when 1 μL of test compound was replaced by 
vehicle DMSO. 
 
% activity was calculated by the following formula: 
%𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑝𝑜𝑠𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 
 
2.13.4 Cell-culture and LPS treatment 
Murine BV-2 cells were cultured in DMEM (11965092, ThermoFisher Scientific) supplemented with 
10% fetal bovine serum, 100 μg/mL streptomycin and 100 units/mL penicillin. Cells were maintained 
in an incubator at 37
o
C, under a 5% CO2 and in a water saturated environment. When performing LPS 
treatment, BV-2 cells were plated on a 10 cm dish in 10 mL DMEM at a density of 1x10
6
 cells per 
dish one day prior to the experiment. After observing that cells are at 90% confluency, 
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lipopolysaccharide (L6529, Sigma) pre-dissolved in DMEM to achieve a concentration of 2 μg/mL 
was added to the dish. Different concentrations of test compounds in DMSO were added to the LPS 
containing medium which was then transferred to the 10 cm dish. DMSO was used as a vehicle 
control and added to the non-LPS treated control. The cells were incubated for the respective hours at 
37
o
C, under a 5% CO2.  After the respective timepoint, cells were washed once with 1xPBS (10 mL) 
and scrapped on ice with 8 mL 1xPBS. Collected cells were spun at 800rpm for 3 min at 4
o
C, before 
discarding the supernatant. Cells were lysed by RIPA buffer, which contain 1 x protease inhibitor and 
1mM PMSF and incubated under ice for 30 min. This was followed by spinning the cell debris at 4
o
C 





2.13.5 MTS cell proliferation assay 
Cells were plated on a 96-wells plate and grown for 24 h to a density of 8000 cells per well for both 
HEK293T and BV-2 cells. Cells were cultured in an incubator at 37
o
C under a 5% CO2 environment 
in 100 μL of DMEM. Thereafter, the compound of interest dissolved in DMEM at a concentration of 
10 μM was added into each well. DMSO was added as vehicle in the control group. 3 biological 
replicates were performed. The plates were then incubated at 37°C with 5% CO2 for 48 h and 72 h. At 
each individual time point, 20 μL of CellTiter 96® AQueous One Solution (MTS reagent) was added 
into each well and re-incubated at 37°C with 5% CO2 without light for 3 h. Colorimetric readings 
were taken at 490 nm using a spectrometer and analysed.  
 
2.13.6 BCA Assay 
BCA assay (23225, Pierce BCA Protein Assay Kit) was performed to quantify the concentration of 
proteins in the cell lysate. 10 µL of test samples (1 µL with 9 µL of lysis buffer) and BSA standards 
(range from 1.25 to 50 μg/ml) were mixed in a 96 well-plate and incubated with 190 µL of working 
reagent mixture (Ratio of Reagent A:B used was 50:1) at 37
o
C for 20 min. The colour intensity that 
was developed was read at 562 nm using a spectrophotometer. A standard curve of different 
concentrations of BSA was plotted using the average blank-corrected readings for each standard vs. its 
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respective concentration (µg/ml). This was then used to determine the protein concentration for 
unknown samples.     
 
2.13.7 Western Blot 
The amount of protein in the lysates were normalized by BCA previously. 25 μg of individual protein 
samples were mixed with an equal volume of 2x Laemmli buffer containing DTT and denatured at 
90
o
C for 10 min.  Lysates were loaded into a 10% Tris-Gly Gel. SDS-PAGE was run at a voltage of 
100 V for 1.5 h in 1x Running Buffer (10% Tris-Gly-SDS buffer). The protein samples on the gel 
were then transferred to PVDF membrane assembled in a sandwich soaked in 1x Transfer Buffer (10% 
Tris-Gly buffer, 10% methanol, 0.1% SDS) at 100V for two hours under ice. The membrane blots 
were then incubated for one hour at room temperature in a Blocking Buffer containing 5% milk in 1x 
Tris-Gly buffer and 0.1% TBST, followed by overnight incubation with the respective primary 
antibody dissolved in 5% milk in 1xTris-Gly buffer and 0.1% TBST at 4°C. After three washes with 
1x Tris-Gly buffer in 0.1% TBST, each of duration 10min, the blot was incubated with a secondary 
horse-radish peroxidase-conjugated antibody (1:10000) dissolved in 5% milk in 1x Tris-Gly buffer 
and 0.1% TBST for one hour at room temperature. Three washes with 1x Tris-Gly buffer in 0.1% 
TBST, each of duration 10min were performed. Enhanced chemiluminescence (ECL) detection of 
protein bands was performed using ECL Plus Western Blotting detecting system (GB Healthcare). 
Antibodies used in western blot include rabbit polyclonal anti-NOS2 (Santa-Cruz, sc-651, 1:100), 
mouse monoclonal anti-cPLA2 primary antibody (Santa Cruz, sc-454, 1:200), mouse anti-gapdh 
(Merck, 1:10000), with secondary horse-radish peroxidase-conjugated antibodies (Santa Cruz, 
1:10000). 
 
2.13.8 ROS assay 
20,000 cells were seeded into a 96-well plate in 100 uL of DMEM and allowed to grow overnight. 
When a 90% cell confluency was observed, lipopolysaccharide pre-dissolved in DMEM to achieve a 
concentration of 2 μg/mL was added to each well of the 96 well. Different concentrations of test 
compounds in DMSO were added to the LPS containing medium and was then transferred to the cells. 
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DMSO was used as vehicle control and added to the non-LPS treated control. The cells were 
incubated for 14 h at 37
o
C, under a 5% CO2 environment. Medium were removed and washed once 
with 1x HBSS. 1mM stock solution of CM-H2DCFDA (C6827, Molecular Probes) in DMSO was 
added into 1x HBSS to achieve a final concentration of 10 μM. 100 μL of CM-H2DCFDA solution 
was added into each well and incubated at 37
o
C for 1 h. Fluorescence detection was done by exciting 
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CHAPTER 3: CHEMICAL SYNTHESIS AND BIOLOGICAL EVALUATION OF 
FLUOROGENIC CYTOSOLIC PHOSPHOLIPASE A2 INHIBITORS AND SUBSTRATE 
 
3.1 Introduction 
Arachidonic acid (AA) is a precursor of a family of lipid mediators, including prostaglandins, that 
regulates a wide variety of physiological responses and disease pathogenesis.
1
 The generation of free 
AA occurs mainly through the activation of phospholipase A2 (PLA2) which catalyzes the hydrolysis 
of the sn-2 acyl ester bond of glycerophospholipids to release AA. Mammalian cells have diverse 
forms of PLA2 including the secreted small molecular weight sPLA2, the larger cytosolic Ca
2+
-
dependent cPLA2 and Ca
2+
-independent iPLA2. Although sPLA2 could participate in the release of 
arachidonate during injury, the main gatekeeper for the enzymatic conversion of arachidonate is 
cPLA2.
2
 Given that cPLA2 is an ubiquitous enzyme which is highly selective for glycerophospholipids 
containing AA, there has been much interest to design and identify cPLA2 inhibitors to better 
understand the molecular mechanism regulating this enzyme and to develop efficacious therapeutics 
for the treatment of cPLA2-upregulated diseases.
3-6  
To this end, we are interested to identify novel 
chemical tools, particularly fluorescent probes which could provide a means to monitor cPLA2 activity. 
To our knowledge, Chiorazzo et al have recently reported a cPLA2 activatable fluorophore for 
imaging cPLA2 in triple negative breast cancer cells.
7
 Herein, we present our works on fluorescent 
inhibitor and substrate probes for the direct detection of cPLA2 at cellular level and for the study of 
cPLA2 inhibition. We herein present the synthesis of inhibitor probes and substrate probe of cPLA2 
and the investigation of these compounds for (i) inhibiton of cPLA2 (ii) cytotoxicity (iii) specific 








3.2 Chemical Synthesis 
3.2.1 Synthetic Strategy 
Figure 3-1: Structure of AACOCF3 and inhibitor probes 
 
Arachidonyl trifluoromethyl ketone (AACOCF3), a potent inhibitor of cPLA2 has been shown to cause 
a reduction in neuronal losses through decreased oxidative stress and inflammation upon inhibiting 
cPLA2 in mouse model of spinal cord injury.
8
 This suggests its ability to penetrate the blood-brain 
barrier and was thus chosen as the scaffold for our cPLA2 inhibitor probe. In the design of our 
fluorogenic inhibitor probe (Figure 3-1), the arachidonyl functionality was used to promote enzyme 
recognition, a trifluoromethylketone moiety was incorporated to inhibit the active site of cPLA2 and a 
fluorogenic group was attached to the distal end of the alkyl chain so that it does not hinder 
interactions with the enzyme’s active site. A representative number of inhibitor probes were 
synthesized and screened for their inhibitory activities. Synthesis of the inhibitor probes mimics the 
synthesis of compounds in chapter 2 by coupling the main triple alkyne intermediate with a 
functionalized alkyne instead of heptyne (Figure 3-1). In this way, the functionalized alkyne could be 
further modified and coupled with various fluorogenic groups to yield inhibitor probes bearing both 
the trifluoromethylketone and arachidonyl moiety after subsequent transformation.  
 
3.2.2 Synthesis of the inhibitor probe 
Similar to the previous chapter, the chemical synthesis of these compounds (Scheme 3-1) involved a 
series of copper-catalyzed coupling and bromination of the alkyne building blocks to achieve a 
quadruple alkyne intermediate 7a and 7b. They were subsequently hydrogenated with Brown’s 
catalyst to form the respective alkene 8a and 8b. Upon bromination of the alcohol present in 8 to 9a 
and 9b, the methyl ester was converted into trifluoromethyl ketone by hydrolyzing the ester (9a and 
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19) to an intermediate carboxylic acid and reacting it with trifluoroacetic anhydride in the presence of 
pyridine. The alkyl tail end of the alkene, functionalized with either a Br or NH2 group could then be 
readily coupled to a fluorophore via Williamson-ether synthesis or an amide coupling reaction 
(Scheme 3-2 and 3-3).  This ensures an efficient synthesis of these relatively complex inhibitor-probes 
where the synthetic route was made divergent. The scheme’s divergence stems from how the various 
inhibitor probes share a common precursor (11a). Six fluorogenic inhibitors (12a-f) were synthesized 
and their inhibitory activities were tested with recombinant cPLA2 via a PLA2 assay. 
Scheme 3-1. Synthesis of common intermediates before coupling with fluorogenic probes. 
 
Scheme 3-2. Synthesis of inhibitor probes 12a-e via amide coupling.  
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Scheme 3-3.Synthesis of inhibitor probe 12f. 
 
3.3 Biological Result of cPLA2 assay and sPLA2 selectivity 
Probe-inhibitors 12a-f were sent for screening, and their respective % enzymatic activity values are 
tabulated in Table 3-1. Probe-inhibitors with O-substituted aromatic rings tended to exhibit higher % 
inhibition and hence higher potency. 7OHCou-AACF3 exhibited the highest potency, with a % 
inhibition value of 95.8 ± 0.8 at a concentration of 10 μM. This also suggests that the hydroxyl-
coumarin fluorophore would have the best interactions with cPLA2 if it was incorporated into the 
substrate-probe at the unsaturated tail. 7OHCou-AACF3 also has an IC50 of 12.5±1.0 μM (Figure 3-
2). This is comparable to AACOCF3 which has an IC50 of 16.5±3.0 μM. Selectivity test with 
recombinant sPLA2 at 10μM showed that 7OHCou-AACF3 did not give an observable bioactivity 
with sPLA2 (Figure 3-3) indicating that it is not sPLA2 selective. 
 
Table 3-1. % activity towards cPLA2 in the presence of different test compounds at 10μM were tested 
in a PLA2 assay at n=4 
 
Entry R % Activity % Inhibition 
1 
 
59.4 ± 4.0 40.6 ± 4.0 
2 
 
42.8 ± 7.2 57.2 ± 7.2 
3 
 





11.9 ± 1.3 88.1 ± 1.3 
5 
 
10.1 ± 1.8 89.9 ± 1.8 
6 
 
19.1 ± 3.6 80.9 ± 3.6 
 
IC50 of 7OHCou-AACF3















































Figure 3-3. Inhibition activity of 7OHCou-AACF3 on sPLA2 at 10 μM compared with sPLA2 
specific inhibitor Thioetheramide-PC (Thio-PC) at 10 μM. Data analyzed by one-way ANOVA with 
Bonferroni's Multiple Comparison Test indicated no statistical difference between control (CTR) and 




3.4 Inhibitory ability of 7OHCou-AACF3  
Next, we evaluated the inhibitory property of 7OHCou-AACF3 on cPLA2 in lipopolysaccharide 
(LPS) stimulated mouse microglial BV-2 cells. Earlier study have shown that BV-2 cells upon LPS 
insult resulted in an increase in inducible nitric oxide synthase (iNOS) which produces excess nitric 
oxide (NO) causing neurotoxicity. Upon application of a cPLA2 specific inhibitor, the protein level of 
iNOS was found to decrease, demonstrating its ability to mediate the effects of NO. Similarly, when 
7OHCou-AACF3 (10 μM) was incubated with BV-2 cells in the presence of LPS, the level of iNOS 
decreased to less than 20% (Figure 3-4) showing its potential neuroprotective ability through the 
inhibition of cPLA2. This is further supported by cell viability assay (vide infra). 
 
Figure 3-4. Western blot of 3 independent experiments showing protein bands of iNOS and GAPDH 
when BV-2 cells were stimulated with 2 μg/mL of LPS in the presence or absence of 10 μM 
7OHCou-AACF3. The procedure used was adapted from Chuang et al.
9 
Data analyzed by one-way 
ANOVA with Bonferroni's Multiple Comparison Test indicate statistical difference between LPS-






3.5 7OHCou-AACF3 as a fluorescent dye for imaging 
To explore the use of 7OHCou-AACF3 as an imaging tool, two cell lines, BV-2 and SHSY5Y, were 
treated with different stimulants and stained with 7OHCou-AACF3 (10μM) (Figure 3-5). The 
cPLA2 levels were found to be not statistically different in the control (untreated BV-2 cells), the 
LPS-stimulated and 7OHCou-AACF3-treated LPS-stimulated BV-2 cells whilst in the SHSY5Y cells, 
the TSA-treated cells were stained more significantly than the non-TSA-treated cells. These results 
corroborated with the Western blot data (Figure 3-5A(i) and 3-5A(ii)) are in agreement with earlier 
study which showed that stimulating BV-2 microglial cells with LPS induces cPLA2 phosphorylation 
but does not increase the cPLA2 level 
9
 whilst treating SHSY5Y with histone deacetylase inhibitor, 
trichlorostatin A (TSA) results in an overexpression of cPLA2.
10








































































Figure 3-5. Western blot and fluorescence imaging of BV-2 and SHSY5Y cells (A)(i)  Representative 
western blot of 3 independent experiments of cPLA2 in BV-2 cells stimulated with 2 μg/mL of LPS 
were normalized with GAPDH. Data analysis by paired t-test indicated no statistical difference 
between the untreated and LPS-treated cells. (ii) Representative western blot of of 3 independent 
experiments of cPLA2 in SHSY5Y cells treated with 0.75μM TSA vs control indicate TSA-treated 
cells have higher level of cPLA2. Data analysis by paired t-test indicated statistical difference 
between the untreated and TSA-treated cells (*P<0.05). (B) Imaging of non-treated BV-2 cells 
vs LPS-treated BV-2 cells after staining with 7OHCou-AACF3 (10μM). No difference in staining 
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was detected. (C) Imaging of non-treated SHYS5Y cells vs TSA-treated cells after staining with 
7OHCou-AACF3 (10μM). TSA-treated cells show a larger extent of staining due to higher level of 
cPLA2 present compared with the non-treated cells. (I) & (V) Grayscale images with excitation at 
358nm. (II) & (VI) Blue pseudo colour images with excitation at 358nm (III) & (VII) Bright-field 
phase contrast of cells. (IV) and (VIII) Merged images of 7OHCou-AACF3 pseudo colour and 
bright-field phase contrast images. Images were captured on a LEICA EMCCD camera. Scale bar 
represent 30μm. 
 
3.6 Design and synthesis of substrate probe Flu7OHCou  
Despite the varied functions 7OHCou-AACF3 could perform, monitoring the activity of active 
cPLA2 would be difficult. Encouraged by the aforementioned results, we decided to expand our 
studies by developing a substrate probe to measure cPLA2 activity. The conventional assay of 
cPLA2 activity uses 1-palmitoyl-2-[
14
C]-arachidonoyl phosphatidylcholine as a substrate.  The 
radiolabeled arachidonate released during the reaction was recovered through aqueous extraction and 
the released radioactivity was determined by liquid scintillation counting.
11-12
 However the use of 
radiometric assays is highly undesirable due to the hazards surrounding radioactive materials. It 
would thus be desirable to develop a simpler assay which does not use radioisotopes for screening 
cPLA2 activities. Various calorimetric and fluorogenic assay kits for the measurement of 
cPLA2 activity are now commercially available. However these assays are not selective to cPLA2 and 
thus there is a need to develop an alternative probe.
13 
 
Since 7OHCou-AACF3 has the highest potency amongst the fluorogenic inhibitor probes synthesized, 
we hypothesized that having the arachidonyl and 7-hydroxycoumarin moieties in the substrate could 
potentially lead to stronger binding with cPLA2. Hence we designed the substrate 
probe Flu7OHCou (Scheme 3-4 to 3-6) to comprise of a glycerylphosphorylcholine (GPC) scaffold 
attached to an arachionyl moiety to confer selectivity towards cPLA2. To enable ratiometric 
measurement, two compatible fluorogenic groups were placed at the alkyl chain end of the fatty acids 
esterified to the GPC moiety. Since 7OHCou-AACF3 possesses an emission maximum at 447 nm, 
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fluorescein was chosen as the other fluorophore since its absorption maximum is at 458 nm, making it 
suitable for Fӧrester resonance energy transfer (FRET) (Figure 3-6). FRET is highly distance-
dependent and is disrupted during subsequent cleavage of the substrate (at the acyl ester bond) by 
cPLA2, which separates the fluorophore donor-acceptor pair. The resulting changes in fluorescent 
signal can be tracked and used to measure cPLA2 activity. FRET substrate-probes showed great 
promise in measuring enzyme activity, and have been successfully used in past work.
14
  Such probes 
have exceedingly high sensitivities, owing to the accumulative nature and the amplification effects of 
the enzymatic catalysis.
14
 As the substrate-probes incorporate the same arachidonyl backbone and 7-
hydroxycoumarin found in 7OHCou-AACF3, synthesis of the inhibitor-probes facilitates synthesis of 
the subsequent substrate-probe. The convergence of the substrate-probe’s synthetic route, could thus 
arises from how the compounds are first prepared in separate fragments – the skipped alkene 
backbone, the phosphate backbone, the fluorophores, and the long alkyl tail – before being coupled 
together to form the final substrate-probe analogue.  
 
 
Figure 3-6. Absorbance and Emission graphs of donor and acceptor of the substrate Flu7OHCou.  
Absorbance (  ̶  ̶̶̶̶̶ ̶ ̶  ) and Emission   (- - -) spectra of 7-hydroxycoumarin (blue) and fluorescein (green) 
in water.  
 
 

















































Scheme 3-4. Synthesis of carboxylic acid 20 
Scheme 3-5.Synthesis of fluorogenic carboxylic acids 24. 
 
Scheme 3-6.Synthesis of substrate probe Flu7OHCou. 
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Flu7OHCou was prepared by separately synthesizing 3 different fragments of the compound 
simultaneously and attaching them together via esterification reactions. The fluorogenic carboxylic 
acid 20 was synthesized by ring opening 13 via a hydrolysis reaction followed by bromination of the 
alcohol present in 14 into 15. In order to yield 20, the ester on 15 needs to be orthogonally hydrolyzed 
in the presence of the ethyl ester present on the fluorescein moiety. In light of this, 15 was converted 
into a tert-butyl ester by hydrolyzing it into the carboxylic acid 16 and protecting the acid with tert-
butanol to form 17. This then allowed the fluorescein 18 to be attached to 17 via a SN2 displacement 
of the Br followed by selective deprotection of the t-butyl ester by refluxing it in TFA to yield 20 
(Scheme 3-4). The unsaturated acid 24 was synthesized by replacing the Br in 9a into an NH2 
followed by an amidation reaction with 7-hydroxycoumarin 22c. Hydrolysis of 23 yielded the 
unsaturated carboxylic acid 24 (Scheme 3-5). To obtain the substrate probe Flu7OHCou, 1,2-
diheptanoyl-sn-glycero-3-phosphocholine 25 was hydrolysed to glycerylphosphorylcholine 26 with 
methanolic sodium hydroxide. Esterification of the hydroxyl groups on 26 with fluorescein 20 gave 
predominantly 27 and some di-esterified product. Treating the mixture of 27 and di-esterified product 
with commercial bee venom PLA2 selectively hydrolyzed the ester on the secondary alcohol, thus 
converting the di-esterified product to 27. Esterification of 27 with 24 provided Flu7OHCou in 30% 
overall yield (Scheme 3-6). 
 
3.7 MTS assay of 7OHCou-AACF3 and Flu7OHCou 
7OHCou-AACF3 and Flu7OHCou were evaluated for their cytotoxicities against the BV-2 cells 
after 48 h and 72 h of treatment. Results showed that more than 80% of the cells survived after both 






















































































Figure 3-7. MTS assay conducted on AACOCF3, 7OHCou-AACF3 and Flu7OHCou on 2 different 
cell lines at different time points. Compounds were adjusted to final concentration of 10 μM. Results 
were obtained from three independent biological repeats (mean ± SEM). Data analyzed by one-way 
ANOVA with Bonferroni's Multiple Comparison Test showed no significant difference among the 









3.8 Flu7OHCou as a substrate for monitoring cPLA2 activity 
 
Figure 3-8. Absorbance ( ̶ ̶  ̶̶̶̶̶ ̶ ̶  ̶ ) and Emission (- - - -) of the substrate probe Flu7OHCou in aqueous 
Tris-buffer, 1% Triton X.  
 
Next, the photophysical property of Flu7OHCou was examined by constituting it in a 20 μM Tris-
HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2) liposomal system containing 1% Triton X-100 
at pH 7.3. The liposomes were formed by mixing 10 mM dioleoylphosphatidylcholine (DOPC), 
10mM dioleoylphosphatidylglycerol (DOPG) and 20 μM of Flu7OHCou together and vigorously 
vortexed in the Triton X-100 containing buffer. Under these conditions, an appreciable blue 
fluorescence (447nm) was detected from the donor 7-hydroxycoumarin while the rest of the emission 
(520nm) came from the green fluorescein acceptor when irradiated at 410 nm (Figure 3-8 and Figure 
3-9A). The addition of Triton X-100 enables the formation of small liposomes which facilitate FRET 
between the 2 fluorophores. When PLA2-rich bee venom (5 units/mL) was added to the liposomal 
system containing Flu7OHCou, the fluorescence intensity changed from a quantum yield of 0.04 to 
0.08. This indicated a successful cleavage of the donor from the substrate, as irradiation at the donor’s 
excitation wavelength lead to successful emission instead of losses due to FRET transfer when the 
acceptor is no longer at close proximity. The reaction was largely completed within 45min and no 
further changes were observed in the emission spectra.  This demonstrates the potential of 
Flu7OHCou to be used as a PLA2 substrate probe. These results are also congruent with earlier 
observations which showed that a membrane-like environment is essential for cPLA2 to recognize the 
substrate, highlighting the need to convert the substrate into liposomes.
11,15
 

















































To investigate if Flu7OHCou is a substrate to cPLA2, the same assay was treated with 0.05 unit/mL 
of recombinant cPLA2. No activity was detected even when the pH of the buffer was increased to 8.9 
to encourage higher PLA2 activity (Figure 3-9B(i)).
16
 This loss of activity was attributed to Triton X-
100 which has been shown previously to abolish cPLA2 activity.
17
 To confirm this hypothesis, a 20 
μM liposomal Tris-HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2, pH 8.9) buffer solution of 
Flu7OHCou without Triton X-100 was prepared and added to 0.05 unit/mL of recombinant cPLA2. 
This led to a significant fluorescence increase from 331 to 554 RFU, confirming that Triton X-100 
had resulted in the loss of cPLA2 activity. (Figure 3-9B(ii)) These results also suggest the possibility 
of developing an assay with Flu7OHCou that uses Triton X-100 to isolate out the cPLA2’s activity 
without the need of an inhibitor. 
 
To investigate the cPLA2-selectivity of Flu7OHCou, 0.05 unit/mL of cPLA2 and sPLA2 were added 
to the liposomal substrate solution without Triton X-100. A large increase in fluorescence intensity 
was observed from the liposomal solution containing cPLA2 while the liposomal solution containing 
sPLA2 exhibited only a smaller increase in fluorescence intensity as time increases (Figure 3-9C(i)). 
The opposite result was observed, where a larger increase in fluorescence intensity for the solution 
containing sPLA2 was detected, when 1% Triton X-100 is present (Figure 3-9C(ii)). These results 
indicate that Flu7OHCou has a higher selectivity to cPLA2 than sPLA2 in the absence of Triton X-
100 while the same result could be reversed in 1% Triton X-100. This suggests the potential of 




Figure 3-9. Photophysical property of Flu7OHCou. (A) - Addition of bee venom (5 units/mL) to 20 
μM Flu7OHCou constituted in a liposome formed by vortexing DOPG and DOPC in a Tris-HCl 
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buffer, pH 7.3 with 1% Triton X-100. Donor peak increases significantly as time increase from 0min 
to 60min while acceptor peak decrease with time. (B) - Addition of recombinant cPLA2 (0.05 unit/mL) 
to 20μM Flu7OHCou constituted in a liposome formed by vortexing DOPG and DOPC in a Tris-HCl 
buffer, pH 8.9 (i) with 1% Triton X-100, (ii) without Triton X-100 (C) - Addition of recombinant 
cPLA2 and sPLA2 (0.05 unit/mL) to 20μM Flu7OHCou constituted in a liposome formed by 
vortexing DOPG and DOPC in a Tris-HCl buffer, pH 8.9 (i) without Triton X-100 (ii) with 1% Triton 
X-100. 
 
To further examine the possible use of Flu7OHCou for inhibitor screening experiments, we 
proceeded to determine the IC50 of AACOCF3 by incubating Flu7OHCou in a liposomal solution 
with recombinant cPLA2 and varying amount of AACOCF3. By plotting a dose-response curve, the 
IC50 was found to be 19.0 ± 1.5 μM which is in good agreement with our experimental data of 16.5 ± 
3.0 μM determined via the commercial PLA2 assay (Figure 3-10). 
 
IC50 of AACOCF3













Figure 3-10. IC50 of AACOCF3 determined from a liposomal substrate solution of Flu7OHCou. IC50 
was determined to be 19.0 ± 1.5 μM from the assay. 
 
In conclusion, 7OHCou-AACF3, a fluorogenic inhibitor of cPLA2 with dual functions of imaging 
and inhibition has been developed. 7OHCou-AACF3 has an IC50 of 12.5±1.0 μM which is 
comparable with AACOCF3. It is able to quench iNOS production via its role as an effective inhibitor 
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and is capable of imaging the increase in cPLA2 protein levels. We have also developed Flu7OHCou, 
a cPLA2-selective fluorogenic substrate and demonstrated its use for inhibitor screening assays. 
 
3.9 Experimental - Chemistry 
All air- and moisture-sensitive reactions were performed in an inert N2 atmosphere, using oven-dried 
glassware sealed with rubber septa. All reaction mixtures and products had the glassware which 
contained them wrapped with aluminium foil, due to their light sensitivity. Technical-grade solvents 
were distilled before use. All commercial-grade reagents and solvents were purchased from Sigma 
Aldrich, Alfa Aesar and Acros, and were used without further purification. All flash column 
chromatography was conducted using Merck silica gel 60 and monitored using TLC. Similarly, the 
progress of all reactions was monitored using TLC. Mass spectra obtained were high resolution mass 
spectrometry (HRMS) via either atmospheric pressure chemical ionization (APCI) or electrospray 
ionization (ESI). Bruker Avance 300 (300 MHz) or 400 (400MHz) or 500 (500 MHz) NMR were 






P spectra. All J values are reported in Hz, while chemical shifts (δ) 
were reported in parts per million. 
 
General cross-coupling procedure used in the syntheses of 3, 5, 7a, and 7b 
The overall synthesis route is shown in Scheme 2, and was adapted from Qi et al.
18
 A mixture of 1 
(1.76 g, 13.9 mmol), 2 (1.21 g, 11.6 mmol), NaI (2.61 g, 17.4 mmol), CuI (3.31 g, 17.4 mmol), and 
K2CO3 (2.41 g, 17.4 mmol) were dissolved in DMF (30.0 mL), and then stirred for 16 h at room 
temperature. Quenching of the reaction was done through the addition of 40 mL of water and 30 mL 
of EA. The bright yellow precipitate that formed upon the addition of water was removed through 
suction filtration. After the first extraction, two more extractions were conducted on the aqueous 
phase using 30 mL of ether. The organic layers were combined, dried using anhydrous Na2SO4, and 
then concentrated. The product was isolated using flash column chromatography with a 3:1 Hex:EA 
eluent to give a yellow oil of 3 at 89% yield (2.01 g). The synthesis of 5 was conducted by reacting 
bromide 4 with propargyl alcohol. The syntheses of 7a and 7b were conducted by reacting bromide 6 
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with 5-pentynol and 6-hexynol respectively; due to 7a and 7b’s instability, they were immediately 
hydrogenated without characterisation in the following step.  
 
 
Methyl 10-hydroxydeca-5,8-diynoate 3: Yellow oil, 89% yield (2.01 g); 
1
H NMR (500 MHz, CDCl3) 
δ 4.22 (t, J = 3.5 Hz 2H), 3.65 (s, 3H), 3.14 (t, J = 3.5 Hz, 2H), 2.43 – 2.37 (m, 2H), 2.23 – 2.17 (m, 
2H), 1.83 – 1.76 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 173.67, 80.30, 79.64, 78.54, 74.43, 51.53, 
51.01, 32.79, 23.72, 18.05, 9.71. 
 
 
Methyl 13-hydroxytrideca-5,8,11-triynoate 5: Dark brown oil, 81% yield (2.41 g); 
1
H NMR (500 
MHz, CDCl3) δ 4.23 (t, J = 2 Hz, 2H), 3.65 (s, 3H), 3.18 – 3.16 (m, 2H), 3.10 – 3.09 (m, 2H), 2.41 (t, 
J = 7.5 Hz, 2H), 2.22 – 2.19 (m, 2H), 1.81 – 1.75 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 173.73, 
79.77, 79.50, 78.74, 75.21, 74.62, 73.82, 51.55, 50.99, 32.79, 23.73, 18.07, 9.77, 9.62. 
 
General bromination procedure used in syntheses of 4, 6, 9a, 9b 
The general protocol was adapted from Qi et al.
18
 3 (5.40 g, 27.8 mmol) and CBr4 (17.58 g, 53.0 
mmol) were dissolved in DCM (106.9 mL) and cooled to -40 °C. PPh3 (13.9 g, 53.0 mmol) was 
dissolved in DCM (53.4 mL) and then added dropwise via a canella to the reaction mixture. Upon 
complete addition of the dissolved PPh3, the reaction mixture was stirred for 2 h at -20 °C. When the 
reaction was completed, hexane was added to the reaction mixture, which caused the precipitation of 
PPh3O. The suspension was filtered through Celite and then concentrated. The product, 4, was then 
isolated using flash column chromatography with a 25:1 hexane-EA system to give a yellow oil, 81% 
yield (5.79 g). The synthesis of 6 was conducted using alcohol 5. The syntheses of 9a and 9b were 





Methyl 10-bromodeca-5,8-diynoate 4: Yellow oil, 81% yield (5.71 g); 
1
H NMR (500 MHz, CDCl3) 
δ 3.90 (t, J = 2.4 Hz, 2H), 3.67 (s, 3H), 3.21 – 3.18 (m, 2H), 2.42 (t, J = 7.2 Hz, 2H), 2.26 – 2.20 (m, 
2H), 1.80(quin, J = 7.2 Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 173.52, 81.80, 79.96, 75.34, 73.83, 
51.51, 32.79, 23.77, 18.10, 14.70, 10.02. 
 
 
Methyl 13-bromotrideca-5,8,11-triynoate 6: Dark brown oil, 85% yield (1.85 g); 
1
H NMR (300 
MHz, CDCl3) δ 3.87 (t, J = 2.4 Hz, 2H), 3.64 (s, 3H), 3.20 – 3.18 (m, 2H), 3.10 – 3.08 (m, 2H), 2.39 
(t, J = 7.2 Hz, 2H), 2.22 – 2.16 (m, 2H), 1.77 (quin, J = 7.2 Hz, 2H); 13C NMR (126 MHz, CDCl3): δ 
173.56, 81.14, 79.49, 75.50, 75.40, 74.44, 73.21, 51.48, 32.71, 23.70, 18.02, 14.62, 9.98, 9.59. 
 
 
(5Z,8Z,11Z,14Z)-methyl 18-bromooctadeca-5,8,11,14-tetraenoate 9a: Brown oil, 88% yield (1.80 
g); 
1
H NMR (500 MHz, CDCl3) δ 5.42 – 5.30 (m, 8H), 3.66 (s,  3H), 3.41 (t, J = 6.5 Hz, 2H), 2.84 – 
2.79 (m, 6H), 2.32 (t, J = 7.5 Hz, 2H), 2.23 (t, J = 7.3 Hz, 2H), 2.10 (t, J = 7.0 Hz, 2H), 1.91 (q, J = 
7.0 Hz, 2H), 1.70 (q, J = 7.5 Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 173.82, 129.35, 128.81, 128.70, 
128.11, 128.05, 128.00, 127.93, 127.83, 51.31, 33.28, 33.14, 32.35, 26.43, 25.58 (2C), 25.53, 25.50, 




(5Z,8Z,11Z,14Z)-methyl 19-bromononadeca-5,8,11,14-tetraenoate 9b: Brown oil, 83% yield 
(0.100 g); 
1
H NMR (500 MHz, CDCl3) δ 5.40 – 5.36 (m, 8H), 3.67 (s, 3H), 3,43 – 3.40 (m, J = 6.8 Hz, 
2H), 2.85 – 2.80 (m, 6H), 2.33 (t, J = 7.5 Hz, 2H), 2.14 – 2.10 (m, 4H), 1.87 (q, J = 7.3 Hz, 2H), 1.72 
(quint, J = 7.5 Hz, 2H), 1.55 – 1.54 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 173.86, 129.28, 128.85, 
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128.72, 128.32 (2C), 128.15, 128.13, 127.98, 51.34, 33.56, 33.32, 32.20, 27.97, 26.46, 26.21, 25.54 
(2C), 25.52, 24.67. HRMS (ESI): calculated for C20H32O2Br (M+1) 383.1580, found 383.1577.
 
 
General hydrogenation procedure used in the syntheses of 8a and 8b 
The general protocol was adapted from Qi et al.
18
 95% Ethanol (31.1 mL) was added to 
Ni(OAc)2.4H2O (1.27 g, 5.12 mmol) in a sealed round-bottom flask, and was flushed with H2 gas for 
10 min. 1 M Ethanolic NaBH4 solution (6.15 mL, 6.15 mmol) was then added, followed by bubbling 
with H2 gas for 10 mins. Subsequently, ethylenediamine (2.45 mL, 36.88 mmol) was added, followed 
by bubbling with H2 gas for 20 mins. 7a (1.53 g, 5.12 mmol) was then added, and the mixture was left 
to stir for 3 h at room temperature, with constant bubbling H2 gas. A filtration using Celite was 
conducted, followed by preparative thin layer chromatography using a 4:1 Hex:EA eluent system to 
afford a yellow oil of 8a, 39% yield (0.61 g). This protocol was used to synthesise 8b from 8b. 
 
 
(5Z,8Z,11Z,14Z)-methyl 18-hydroxyoctadeca-5,8,11,14-tetraenoate 8a: Yellow oil, 39% yield 
(0.61 g); 
1
H NMR (500 MHz, CDCl3) δ 5.42 – 5.38 (m, 8H), 3.68 – 3.66 (m, 5H), 2.85 – 2.81 (m, 6H), 
2.34 (t, J = 7.0 Hz, 2H), 2.20 – 2.12 (m, 4H), 1.75 – 1.63 (m, 4H); 13C NMR (126 MHz, CDCl3): δ 
174.11, 129.42, 128.89, 128.82, 128.40, 128.26, 128.18, 128.06, 128.03, 62.38, 51.45, 33.40, 32.44, 





(5Z,8Z,11Z,14Z)-methyl 19-hydroxynonadeca-5,8,11,14-tetraenoate 8b: Yellow oil, 45% yield 
(0.11 g); 
1
H NMR (300 MHz, CDCl3) δ 5.43 – 5.35 (m, 8H), 3.67 – 3.62 (m, 5H), 2.84 – 2.64 (m, 5H), 
2.35 – 2.31 (m, 2H), 2.27 – 2.04 (m, 7H), 1.73 – 1.62 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 174.20, 
129.7, 128.94, 128.84, 128.41, 128.32, 128.00, 127.88, 127.68, 58.31, 51.55, 33.46 (2C), 26.54, 25.67, 
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25.65, 25.62, 24.77, 24.33, 18.39. HRMS (ESI): calculated for C20H32NaO3 (M+Na) 343.2224, found 
343.2239. 
 
General trifluoromethylation procedure used in the syntheses of 10a and 10b 
Ester 9a (0.44 g, 1.2 mmol) dissolved in MeOH (50 mL) was hydrolysed to its corresponding 
carboxylic acid the addition of 1M LiOH (34 mL). The solution was stirred at room temperature for 
12 h and quenched with 1M HCl. After concentrating the mixture was diluted with water and 
extracted with EA. Organic phase was dried and concentrated to afford a brown liquid without 
subsequent purification. The acid (1.2 mmol) was dissolved in DCM (35.0 mL), followed by addition 
of trifluoroacetic anhydride (1.52 mL, 10.7 mmol) and pyridine (1.15 mL, 14.2 mmol).
19
 The solution 
was then stirred at room temperature for 2 h, before being quenched through addition of saturated 
NaHCO3 solution (40.0 mL).  Extraction was conducted with DCM (3 x 30.0 mL). The organic layers 
were combined and dried using anhydrous Na2SO4, before being concentrated to afford the crude 
product. The crude product was further purified through flash column chromatography using a 3:1 
Hex-EA eluent system to afford a yellow oil of 10a, 78% yield (0.36 g). This protocol was used to 
synthesise 10b from 9b. 
 
 
(6Z,9Z,12Z,15Z)-19-bromo-1,1,1-trifluorononadeca-6,9,12,15-tetraen-2-one 10a: Dark brown oil, 
78% yield (0.36 g); 
1
H NMR (500 MHz, CDCl3) δ 5.44 – 5.31 (m, 8H), 3.39 (t, J = 6.5 Hz, 2H), 2.85 
– 2.79 (m, 6H), 2.71 (t, J = 7.5 Hz, 2H), 2.20 (q, J = 7.0 Hz, 2H), 2.13 (q, J = 7.0 Hz, 2H), 1.91 (quint, 
J = 7.0 Hz, 2H), 1.75 (quint, J = 7.5 Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 191.19 (q, J = 34 Hz, 
1C), 129.46, 129.33, 128.14, 128.08, 127.95, 127.86, 127.82, 118.95, 115.55 (q, J = 290 Hz, 1C), 
35.47, 33.09, 32.37, 25.89, 25.59, 25.54, 25.51, 25.49, 22.04. HRMS (ESI): calculated for 





(6Z,9Z,12Z,15Z)-20-bromo-1,1,1-trifluoroicosa-6,9,12,15-tetraen-2-one 10b: Pale yellow  oil, 58% 
yield (65 mg); 
1
H NMR (500 MHz, CDCl3) δ 5.41 – 5.38 (m, 8H), 3.45 – 3.35 (m, 2H), 2.86 – 2.81 
(m, 1H), 2.72 (t, J = 7.0 Hz, 4H), 2.17 – 2.10 (m, 2H),  (m, 2H), 1.87 (t, J = 7.5 Hz, 2H), 1.76 (t, J = 
7.5 Hz, 2H), 1.51 (t, J = 7.5 Hz, 2H); 
13
C NMR (126MHz, CDCl3): δ 191.24 (t, J = 35 Hz), 129.99, 
129.57, 129.38, 128.35, 128.32, 128.30, 128.26, 128.17, 128.14, 127.94, 127.90, 127.87, 127.85, 
127.80, 115.53 (q, J = 292.1 Hz, 1C)., 72.70, 58.44, 35.56, 33.61, 29.21, 29.18, 28.03, 27.08, 26.98, 
26.27, 26.10, 25.97, 25.60. HRMS (ESI): calculated for C20H29BrF3O (M+1) 421.1348, found 
421.1346. 
 
General amination protocol used in the synthesis of 11a, and 21 
9a (1.60 g, 4.33 mmol) was dissolved in a 7N methanolic solution of NH3 (50.0 mL), and heat in a 
sealed tube for 12 h. The solvent was removed, and flash column chromatography was conducted 
using a 80:20:1 DCM:MeOH:TEA eluent system to afford a yellow oil  of 21, 71% yield (0.940 g). 




Yellow oil, 91% yield (0.30 g), eluent system: 98:2 DCM-MeOH; 
1
H NMR (500 MHz, CDCl3) δ 5.98 
(s, 3H), 5.36 – 5.35 (m, 8H), 3.47 – 3.44 (m, 3H), 2.97 (t, J = 7.5 Hz, 2H), 2.82 – 2.71 (m, 6H), 2.18 – 
2.12 (m, 4H), 1.98 – 1.84 (m, 2H), 1.78 – 1.77 (m, 4H); 13C NMR (126 MHz, CDCl3): δ 191.43 (d, J 
= 35 Hz), 129.52, 129.49, 128.26, 128.17, 128.12, 127.99, 127.88, 127.69, 115.52 (d, J = 287.9 Hz, 
1C), 50.25, 39.51, 35.53, 27.41, 27.08, 25.92, 25.54, 25.52, 24.16, 22.08. HRMS (ESI): calculated for 





(5Z,8Z,11Z,14Z)-methyl 18-aminooctadeca-5,8,11,14-tetraenoate 21: Yellow oil, 71% yield (0.94 
g), eluent system: 90:10:1 DCM:MeOH:TEA; 
1
H NMR (500 MHz, CDCl3) δ 6.98 (s, 5H), 5.36 – 5.31 
(m, 8H), 3.62 (s, 3H), 2.96 (s, 2H), 2.80 – 2.76 (m, 6H), 2.28 (t, J = 7.5 Hz, 2H), 2.14 (q, J = 6.8 Hz, 
2H), 2.05 (q, J = 7.0 Hz, 2H), 1.82 (t, J = 7.3 Hz, 2H), 1.69 (s, 2H); 
13
C NMR (126 MHz, CDCl3): δ 
173.88, 129.26, 128.72, 128.61, 128.14 (2C), 128.08, 127.78, 127.72, 51.30, 39.72, 33.22, 26.32, 
25.46, 25.45 (2C), 25.42, 25.40, 24.55. HRMS (ESI): calculated for C19H32O2N (M+1) 306.2428, 
found 306.2434. 
 
General amidation procedure used in syntheses of 12a-f 
 11a (10.0 mg, 0.03 mmol), the respective carboxylic acid (0.03 mmol), EDC.HCl (7.6 mg, 0.04 
mmol), HOBt (6.0 mg, 0.04 mmol) and TEA (5.5 μL, 0.04 mmol) were dissolved in DMF (1.2 mL). 
The mixture was stirred for 12 h at room temperature, and then quenched with brine. Extraction with 
EA was performed twice on the aqueous layer; the organic layers were combined, dried, and then 




tetraen-1-yl)-2H-chromene-3-carboxamide 12a: Yellow solid, 89% yield (14 mg), eluent system: 
3:1 hexane-EA; 
1H NMR (500 MHz, DMSO) δ 8.64 (s, 1H), 7.67 (d, J = 14 Hz, 1H), 6.81 – 6.79 (m, 
1H), 6.60 (s, 2H), 5.39 – 5.28 (m, 8H), 3.46 (q, J = 6.5 Hz, 4H), 3.28 (d, J = 7.0 Hz, 2H), 2.79 – 2.73 
(m, 4H), 2.10 – 2.03 (m, 2H), 2.02 – 1.99(m, 2H), 1.60 – 1.54 (m, 2H), 1.51 – 1.46 (m, 2H), 1.31 – 
1.23 (m, 4H), 1.14 (t, J = 7.0 Hz, 6H); 
13
C NMR (126 MHz, DMSO): δ 162.07, 161.76, 157.14, 
152.36, 147.54, 131.47 (2C), 129.57, 129.11, 128.08, 127.98, 127.75, 127.69, 127.66, 110.07, 109.46, 
107.62, 95.81, 44.26 (2C), 38.34, 34.59, 28.96, 26.65, 25.40 (2C), 25.11, 24.14, 21.53, 12.24 (2C). 






yl)-2H-chromene-3-carboxamide 12b: Pale yellow solid, 68% yield (10 mg), eluent system: 2:1 
hexane-EA; 
1H NMR (500 MHz, DMSO) δ 8.83 (s, 1H), 8.74 (s, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.46 
(d, J = 9.0 Hz, 1H), 7.36 -7.34 (m, 1H), 6.61 (s, 1H), 5.41 – 5.30 (m, 8H), 3.84 (s, 3H), 2.85 – 2.76 (m, 
5H), 2.16 (s, 2H), 2.12 – 2.06 (m, 3H), 2.03 – 1.98 (m, 3H), 1.62 – 1.59(m, 2H), 1.24 (m, 6H); 13C 
NMR (126 MHz, DMSO): δ 162.88, 160.33, 155.93, 148.31, 147.15, 129.58, 129.12, 128.65, 128.12, 
127.98, 127.81, 127.75, 127.71, 121.88, 118.89, 117.19 (2C), 111.80, 55.79, 38.62, 35.48, 28.96, 






2H-chromene-3-carboxamide 12c: Pale yellow, 42% yield (6.0 mg), eluent system: 1:1 hexane-EA; 
1H NMR (500 MHz, DMSO) δ 11.04 (s, 1H), 8.77 (s, 1H), 8.64 (t, J = 5.5 Hz, 1H), 7.80 (d, J = 9.0 
Hz, 1H), 6.88 (dd, J = 8.5, 2.0 Hz, 1H), 6.80 (s, 1H), 5.40 – 5.28 (m, 8H), 3.30 (d, J = 6.5 Hz, 2H), 
2.85 – 2.69 (m, 6H), 2.15 – 2.09 (m, 2H), 2.07 – 2.00 (m, 2H), 1.62 – 1.55 (m, 4H), 1.31 – 1.26 (m, 
2H); 
13
C NMR (126 MHz, CDCl3): δ 163.52, 161.40, 161.02, 156.18, 147.84, 131.87, 129.63, 129.08, 
128.64, 128.57, 128.08, 127.96, 127.79, 127.66, 114.26, 113.70, 111.07, 101.72, 38.50, 35.41, 28.88, 










yl)benzamide 12d: Pale yellow liquid, 87% yield (12 mg), eluent system: 3:1 hexane-EA; 
1
H NMR 
(500 MHz, DMSO) δ 8.79 (d, J = 5.1 Hz, 1H), 8.62 (dd, J = 7.2, 2.0 Hz, 1H), 8.28 – 8.25 (m, 1H), 
7.70 (dd, J = 11.0, 8.8 Hz, 1H), 5.40 – 5.29 (m, 8H), 3.31 – 3.27 (m, 2H), 2.86 – 2.75 (m, 6H), 2.15 – 
2.04 (m, 4H), 2.03 – 1.99 (m, 2H), 1.64 – 1.57 (dd, J = 14.1, 7.0 Hz, 2H), 1.30 – 1.23 (m, 2H); 13C 
NMR (126 MHz, DMSO) δ 163.03, 156.07 (d, J = 265.7 Hz, 1C), 136.59, 135.04 (d, J = 9.9 Hz, 1C), 
131.38 (d, J = 3.7 Hz, 1C), 129.25, 128.64 (d, J = 11.5 Hz, 1C), 128.00, 127.79 (d, J = 9.5 Hz, 1C), 
127.68, 125.11, 125.10, 125.09, 118.67 (d, J = 21.3 Hz, 1C), 39.02, 35.43, 28.81, 25.43, 25.14 (2C), 




1-yl)acetamide 12e: Brown solid, 94% yield (12 mg), eluent system: 99:1 DCM-MeOH; 
1
H NMR 
(500 MHz, DMSO) δ 9.18 (s, 1H), 7.88 (s, 1H), 7.01 (d, J = 7.9 Hz, 2H), 6.64 (d, J = 13.4 Hz, 2H), 
5.37 – 5.32 (m, 8H), 3.24 (s, 2H), 3.04 – 3.00 (m, 2H), 2.87 – 2.70 (m, 6H), 2.08 – 2.01 (m, 4H), 1.63 
– 1.60 (m, 2H), 1.46 – 1.30 (m, 2H), 1.23 (s, 2H); 13C NMR (126 MHz, DMSO) δ 170.35, 155.76, 
129.70 (2C), 129.61, 129.27, 128.69, 128.60, 128.00, 127.85, 127.70, 126.59, 115.02, 114.87(2C), 
41.56, 38.20, 35.41, 29.05, 25.42 (2C), 25.12, 25.09, 24.15, 21.63. HRMS (ESI): calculated for C27H33 




chromen-2-one 12f: 10b (25 mg, 0.06mmol) was dissolved in DMF (0.5 mL) and added with 4-
methylumbelliferone (8.7 mg, 0.049) and K2CO3 (20.5 mg, 0.15 mmol). The mixture was refluxed for 
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4 h and allowed to cool to room temperature. Mixture was quenched by addition of brine and 
extraction was performed with EA. The organic phase was separated and dried and concentrated. 
Flash column chromatography was conducted using a 2:1 Hexane:EA eluent system to afford a brown 
liquid, 26% yield (8.0 mg); 
1H NMR (500 MHz, DMSO) δ 7.68 (d, J = 8.5 Hz, 1H), 6.96 (m, 2H), 
6.21 (s, 1H), 5.38 – 5.33 (m, 8H), 4.09 (t, J = 6.5 Hz, 2H), 2.81 – 2.78 (m, 6H), 2.40 (s, 3H), 2.11 – 
2.05 (m, 2H), 2.03 – 2.02 (m, 2H), 1.77 – 1.74 (m, 2H), 1.50 – 1.48 (m, 2H), 1.24 (m, 4H); 13C NMR 
(126 MHz, DMSO): δ 162.03, 160.09, 154.73, 153.33, 130.29, 129.55, 129.38, 127.99, 127.93, 
127.85, 127.68, 126.36 (2C), 112.97, 112.35, 111.00, 101.08, 68.05, 28.96, 28.82, 28.63, 28.54, 27.96, 




Scheme 3-7. Synthesis of Coumarin analogues 
 
General procedure used in the synthesis of 30a and c  
The synthesis of 30c was adapted from Ma et al.
20
 Aldehyde 29c (1.51 g, 10.9 mmol), diethyl 
malonate (2.47 mL, 16.3 mmol), and piperidine (0.80 mL, 8.15 mmol) were dissolved in ethanol (15.6 
mL), and then refluxed for 1 h. After that, the reaction mixture was stirred at room temperature for 16 
h. The ethanol was removed, and recrystallization was performed using a bi-solvent system of hexane 
and EA to afford yellow crystals of 30c, 88% yield (2.26 g). This protocol was used to synthesise 30a 







Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate 30a: Brown powder, 87% yield (0.65 g); 
1
H NMR (500 MHz, CDCl3) δ 8.39 (s, 1H), 7.33 (d, J = 9.5 Hz, 1H), 6.59 (dd, , J = 9.5, 2.0 Hz, 1H), 
6.42 (d, J = 2.0 Hz, 1H), 4.35 (q, J = 7.0 Hz, 2H), 3.42 (q, J = 7.0 Hz, 4H), 1.37 (t, J = 7.3 Hz, 3H), 
1.21 (t, J = 7.0 Hz, 6H); 
13
C NMR (126 MHz, CDCl3): δ 164.03, 158.29, 158.13, 152.74, 149.00, 
130.90, 109.44, 108.73, 107.51, 96.52, 60.93, 44.95 (2C), 14.22, 12.27 (2C). HRMS (ESI): calculated 




Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate 30c: Yellow solid, 88% yield (2.26 g); 
1
H 
NMR (300 MHz, DMSO) δ 11.09 (s, 1H), 8.67 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 6.84 (dd, J = 8.6 Hz, 
J = 2.3 Hz, 1H), 6.73 (d, J = 2.1 Hz,  1H), 4.26 (q, J = 6.9 Hz, 2H), 1.29 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(75 MHz, DMSO): δ 164.04, 162.93, 157.09, 156.39, 149.42, 132.10, 113.99, 112.08, 110.41, 101.78, 
60.79, 14.12. HRMS (ESI): calculated for C12H9O5 (M-1) 233.0455, found 233.0446.  
 
 
Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate 30b The synthesis of 30b was adapted from 
Ma et al.
20
 29b (0.500 g, 2.59 mmol), diethyl malonate (0.59 mL, 3.88 mmol), and piperidine (0.19 
mL, 1.94 mmol) were dissolved in ethanol (5.2 mL), and then refluxed for 1 h. After that, the reaction 
mixture was stirred at room temperature for 24 h. The ethanol was removed, and the solid was re-
dissolved in EA (30.0 mL). Extraction was carried out using EA (3 x 40.0 mL) and H2O (30.0 mL), 
and the organic layer was combined and dried using Na2SO4. The solvent was removed and flash 
column chromatography was conducted using a 1:1 Hex:EA eluent system to afford a yellow solid of 
30b, 87% yield (0.65 g); 
1
H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 7.25 (d, , J = 9.5 Hz, 1H), 7.21 – 
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7.18 (m, 1H), 6.99 (d, J = 7.5 Hz, 1H), 4.39 (q, , J = 7.0 Hz, 2H), 3.84 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 163.02, 156.81, 156.20, 149.62, 148.23, 122.50, 118.43, 118.05, 
117.73, 110.62, 61.83, 55.82, 14.13. HRMS (ESI): calculated for C13H12NO5Na (M+Na) 271.0577, 
found 271.0576. 
 
General basic hydrolysis procedure used in the syntheses of 22a-c 
30b (0.65 g, 0.26 mmol) was dissolved in a 0.5M methanolic solution of NaOH (6.0 mL), and left to 
stir at room temperature for 16 h. Solvent was removed from the reaction mixture and then 1M HCl 
was added (4.0 mL). The resulting mixture was refrigerated for 24 h, and then filtered and dried to 
afford a brown powder of 22b, 79% yield (0.40 g). This protocol was used to synthesise 22a and 22c 
from 30a and 30c respectively. 
 
 
7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid 22a: Brown powder, 94% yield (0.55 g); 
1H NMR (500 MHz, DMSO) δ 12.47  (s, 1H), 8.56 (s, 1H), 7.60 (d, J = 9 Hz, 2H), 6.76 (d, J = 8. 9Hz, 
1H), 6.50 (d, J = 2.1 Hz, 1H), 3.46 (q, J = 6.9 Hz, 4H), 1.25 (t, J = 7.2 Hz, 6H); 
13
C NMR (126 MHz, 
CDCl3): δ 164.40, 159.63, 157.82, 152.86, 149.36, 131.78, 110.00, 107.35, 107.04, 95.87, 44.35 (2C), 
12.25 (2C). HRMS (ESI): calculated for C14H15NO4Na (M+Na) 284.0893, found 284.091. 
 
 
7-methoxy-2-oxo-2H-chromene-3-carboxylic acid 22b: Yellow crystals, 79% yield (0.40 g); 
1
H 
NMR (500 MHz, DMSO) δ 13.22 (s, 1H), 8.69 (s, 1H), 7.47 (d, , J = 2.5 Hz, 1H), 7.38 (d, J = 9 Hz, 
1H)7.32 (dd, J = 9.0, 2.8 Hz, 1H), 3.81 (s, 3H); 
13C NMR (126 MHz, DMSO): δ 164.43, 157.43, 
156.18, 149.37, 148.52, 122.47, 119.03, 118.84, 117.70, 112.33, 56.26. HRMS (ESI): calculated for 




7-hydroxy-2-oxo-2H-chromene-3-carboxylic acid 22c: Yellow crystals, 84% yield (1.89 g); 
1
H 
NMR (300 MHz, DMSO) δ 12.87 (s, 1H), 11.09 (s, 1H), 8.69 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 6.87 – 
6.83 (m, 1H), 6.74 (d, J = 1.8 Hz, 1H); 
13C NMR (75 MHz, DMSO): δ  164.29, 164.00, 157.67, 
157.04, 149.49, 132.08, 114.07, 112.48, 110.67, 101.85. HRMS (ESI): calculated for C10H5O5 (M-1) 
205.0142, found 205.0137. 
 
 
Scheme 3-8. Synthesis of fluorescein 18 
 
 
Ethyl 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoate 18: 31 (1.0 g, 3.0 mmol) was dissolved in 
EtOH (20.0 mL), followed by addition of H2SO4 (1.5 mL, 28.1 mmol) to the solution. The solution 
was refluxed for 16 h. Solid Na2CO3 was added to the solution, which was then filtered. The filtrate 
was concentrated and the resulting solids that formed were re-dissolved in boiling ethanol. 
Recrystallization followed by filtration and drying afforded an orange solid of 18, 80% yield (0.865 g); 
1
H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 7.5 Hz, 1H), 7.85 (t, , J = 7.3 Hz, 1H), 7.77 (t, J = 7.5 Hz, 
1H), 7.48 (d, J = 7.5 Hz, 1H), 6.80 (d, J = 9.5 Hz, 2H), 6.57 (d, J = 7.5 Hz, 4H), 3.95 (q, J = 7.0 Hz, 
2H), 0.86 (t, , J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 165.48, 150.90, 134.04, 133.38, 
131.09 (2C), 131.00 (2C), 130.55, 130.37, 115.20, 103.75, 61.31, 13.75. HRMS (ESI): calculated for 





Methyl 15-hydroxypentadecanoate 14: ω-pentadecalactone 13 (5.0 g, 20.8 mmol) was dissolved in 
MeOH (50.0 mL), and 30% methanolic sodium methoxide (1.54 mL, 8.3 mmol) was added to the 
solution, which immediately turned from clear to cloudy. The solution was stirred for 16 h at room 
temperature. Quenching was conducted through addition of water and 3M HCl. The methanol was 
removed through heating the solution under reduced pressure, which left behind a suspension of solids. 
The solids were filtered and recrystallized with EA to afford  a white solid of 14, 99% yield (5.64 g); 
1
H NMR (500 MHz, CDCl3) δ 4.85 (s, 1H), 3.64 (s, 3H), 3.61 (t, J = 6.8 Hz, 3H), 2.28 (t, , J = 7.5 Hz, 
2H), 1.60 (t, J = 7.0 Hz, 2H), 1.54 (t, J = 7.5 Hz, 2H), 1.27 (m, 20H); 
13
C NMR (126 MHz, CDCl3): δ 
174.37, 62.97, 51.38, 34.07, 32.74, 29.55 (2C), 29.51 (2C), 29.38 (2C), 29.19 (2C), 29.09, 25.69, 
24.90. HRMS (ESI): calculated for C16H32O3Na (M+Na) 295.2244, found 295.2246. 
 
 
Methyl 15-bromopentadecanoate 15: 14 (4.84 g, 17.8 mmol) was added with CBr4 (11.2 g, 33.8 
mmol) and dissolved in DCM (250 mL). The mixture was cooled to 0 
o
C and PPh3 (8.85 g, 33.8 mmol) 
was added in portion to the mixture. The reaction was allowed to warm to room temperature and 
stirred for 16 h. When the reaction was completed, hexane was added to the reaction mixture, which 
caused the precipitation of PPh3O. The suspension was filtered through celite and then concentrated. 
Flash column chromatography with a 99:1 hexane-EA system to give a pale yellow solid 15, 53% 
yield (3.16g), eluent system: 9:1 hexane-EA; 
1
H NMR (500 MHz, CDCl3) δ 3.69 (s, 3H), 3.43 (t, J = 
7.0 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 1.87 (quin, J = 7.0 Hz, 2H), 1.65 – 1.62 (m, 2H), 1.46 – 1.43 (m, 
2H), 1.26 (m, 20H); 
13
C NMR (126 MHz, CDCl3): δ 174.31, 51.40, 34.11, 33.99, 32.85, 29.58, 29.57, 
29.55, 29.51 (2C), 29.42, 29.24, 29.14, 28.76, 28.17, 24.95. HRMS (ESI): calculated for C16H31O2Br 





15-bromopentadecanoic acid 16: 15 (1.62 g, 4.8 mmol) was dissolved in THF (50 mL) and add with 
1M LiOH (24 mL). The solution was stirred at room temperature for 16 h and quenched with 1M HCl. 
After concentrating the mixture was diluted with water and extracted with DCM. Organic phase was 
dried and concentrated to afford a white solid 16 with no additional purification, 97% yield (1.51 g); 
1
H NMR (500 MHz, CDCl3) δ 3.39 (t, J = 6.9 Hz, 2H), 2.33 (t, J = 7.5 Hz, 2H), 1.87 – 1.81 (m, 2H), 
1.63 – 1.60 (m, 2H), 1.42 – 1.39 (m, 2H), 1.27 – 1.25 (m, 18H); 13C NMR (126 MHz, CDCl3) δ 
180.37, 34.06, 33.95, 32.79, 29.54 (2C), 29.51, 29.48, 29.38, 29.36, 29.18, 29.00, 28.72, 28.13, 24.61. 
HRMS (ESI): calculated for C15H28O2Br (M-1) 319.1278, found 319.1283. 
 
 
tert-butyl 15-bromopentadecanoate 17: 16 (1.51 g, 4.7 mmol) was dissolved in DCM (15.0 mL) 
and cooled to 0 
o
C. Trifluoroacetic anhydride (1.47 mL, 10.4 mmol) was added dropwise to the 
mixture and the solution was allowed to warm to room temperature for 2 h. Tert-butanol (1.62 mL, 
16.9mmol) was added and stirred for an additional 3 h. When no more starting material was detected, 
the mixture was quenched with water and extracted with diethyl ether. Organic phase was dried and 
concentrated, flash column chromatography was conducted using a 19:1 Hex:EA eluent system to 
afford a white solid 17, 95% yield (1.68g), eluent system: 19:1 hexane-EA; 
1
H NMR (500 MHz, 
CDCl3) δ 3.39 (t, J = 6.9 Hz, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.87 – 1.81 (m, 2H), 1.58 – 1.55 (m, 2H), 
1.43 (s, 9H), 1.27 – 1.25 (m, 20H); 13C NMR (126 MHz, CDCl3) δ 173.14, 79.69, 35.52, 33.77, 32.77, 
29.51 (2C), 29.49, 29.45, 29.38, 29.35, 29.21, 29.01, 28.69, 28.10, 28.03(3C), 25.03. HRMS (ESI): 






Ethyl 2-(6-((15-(tert-butoxy)-15-oxopentadecyl)oxy)-3-oxo-3H-xanthen-9-yl)benzoate 19: 17 
(0.65 g, 1.72 mmol) was dissolved in DMF (5.6 mL) and added with 18 (0.5 g, 1.39 mmol) and 
DIPEA ( 0.87 mL, 5.0 mmol). The mixture was refluxed for 2 h and was cooled to room temperature. 
Following which, the reaction was quenched by the addition of brine while extraction was performed 
using EA. The organic phase was then dried and concentrated. Flash column chromatography was 
conducted using a 19:1 DCM:MeOH eluent system to afford an orange solid 19, 84% yield (0.77 g); 
1
H NMR (500 MHz, CDCl3) δ 8.20 (dd, J = 7.8, 1.2 Hz, 1H), 7.69 (td, J = 7.5, 1.4 Hz, 1H), 7.63 (td, J 
= 7.7, 1.3 Hz, 1H), 7.27 (dd, J = 7.5, 1.1 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.87 – 6.82 (m, 2H), 6.70 
(dd, J = 8.9, 2.3 Hz, 1H), 6.49 (dd, J = 9.7, 1.9 Hz, 1H), 6.40 (d, J = 1.9 Hz, 1H), 4.03 – 3.95 (m, 4H), 
2.15 (t, J = 7.5 Hz, 2H), 1.79 – 1.76 (m, 2H), 1.54 – 1.51 (m, 2H), 1.43 – 1.40 (m, 11H), 1.31 – 1.30 
(m, 18H), 0.92 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 185.20, 173.02, 165.09, 163.61, 
158.72, 154.12, 150.39, 134.01, 132.32, 130.97, 130.52, 130.17, 130.08, 129.44 (2C), 128.77, 117.26, 
114.54, 113.64, 105.39, 100.51, 79.58, 68.76, 61.06, 35.37, 29.37(2C), 29.34 (2C), 29.29, 29.22, 
29.08, 29.05, 28.84, 28.70, 27.90 (3C), 25.70, 24.87, 13.37. HRMS (ESI): calculated for C41H52O7 
(M+Na) 679.3605, found 679.3608. 
 
 
15-((9-(2-(ethoxycarbonyl)phenyl)-3-oxo-3H-xanthen-6-yl)oxy)pentadecanoic acid 20: 19 (0.46 g, 
0.7 mmol) was dissolved in TFA (5.0 mL) and heated at 70 
o
C for 1 h. When no more starting 
material was observed, TFA was removed under reduced pressure. Flash column chromatography was 
conducted using a 19:1 DCM:MeOH eluent system to afford an orange solid 20, 88% yield (0.37g); 
1
H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 7.7 Hz, 1H), 7.74 (dt, J = 28.2, 7.5 Hz, 2H), 7.32 (d, J = 
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7.5 Hz, 1H), 6.99 (s, 1H), 6.94 (t, J =10.5 Hz, 2H), 6.78 (d, J = 9.0 Hz, 1H), 6.65 (d, J = 10 Hz, 1H), 
6.61 (s, 1H), 4.11 – 4.02 (m, 4H), 2.36 (t, J = 7.5 Hz, 2H), 1.87 – 1.84 (m, 2H), 1.67 – 1.64 (m, 2H), 
1.50 – 1.47 (m, 2H), 1.28 (s, 18H), 0.97 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 185.25, 
177.84, 165.15 (2C), 164.16, 159.16, 154.55, 133.98, 132.45, 131.12, 130.55, 130.48, 130.21, 129.67, 
129.07 (2C), 117.20, 114.71, 114.32, 105.28, 100.54, 69.00, 61.27, 34.13, 29.48, 29.46, 29.41, 29.37, 
29.32, 29.17, 29.14, 29.02, 28.75, 25.81, 25.78, 24.76, 13.47. HRMS (ESI): calculated for C37H45O7 




tetraenoate 23: 21 (58.6 mg, 0.19 mmol) was dissolved in DMF (7.7 mL) and added with 22c (36.0 
mg, 0.17 mmol), EDC.HCl (50.0 mg, 0.26 mmol), HOBt (35.0 mg, 0.26 mmol) and TEA (36.5 μL, 
0.26 mmol). The reaction was stirred at room temperature for 12 h and quenched with the addition of 
brine. Extraction was performed with EA with 1% AcOH. The organic layer was separated, dried and 
concentrated. Flash column chromatography was conducted using a 2:1 Hexane:EA eluent system to 
afford a pale yellow solid 23, 60% yield (52mg);  
1
H NMR (500 MHz, CDCl3) δ 9.01 (s, 1H), 8.79 (s, 
1H), 7.53 (d, J = 8.5 Hz, 1H), 6.94 (dd, J = 11.7, 2.9 Hz, 2H), 5.41 – 5.30 (m, 8H), 3.67 (s, 3H), 3.48 
– 3.45 (m, 2H), 2.81 – 2.75 (m, 5H), 2.32 (t, J = 7.5 Hz, 2H), 2.19 – 2.15 (m, 2H), 2.11 – 2.08 (m, 2H), 
1.74 – 1.66 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 174.57, 163.57, 162.85, 162.08, 156.72, 148.61, 
131.43, 128.90 (2C), 128.80, 128.73, 128.22, 128.15, 128.11, 128.09, 114.94, 113.45, 111.80, 102.83, 
51.62, 39.51, 33.48, 29.13, 26.49, 25.58 (2C), 25.55, 24.76, 24.62. HRMS (ESI): calculated for 







tetraenoic acid 24: 23 (39 mg, 0.08 mmol) was dissolved in a solution of THF:MeOH: H2O-1:1:1 
(0.6 mL) and added with 1M LiOH (60 μL). The mixture was stirred for half an hour at room 
temperature and quenched with 1M HCl. Extraction was performed using EA with 1% AcOH and the 
subsequent organic phase was separated, dried and concentrated.  Flash column chromatography was 
conducted using a 2:1:0.03 Hexane:EA:AcOH eluent system afford 24 as a pale yellow solid, 45% 
yield (17 mg); 
1
H NMR (500 MHz, CDCl3) δ 9.04 (d, J = 5.5 Hz, 1H), 8.74 (d, J = 6.8 Hz, 1H), 7.46 
(d, J = 8.3 Hz, 1H), 6.89 – 6.84 (m, 2H), 5.40 – 5.34 (m, 8H), 3.45 (d, J = 6.3 Hz, 2H), 2.81 – 2.77 (m, 
4H), 2.37 (dd, J = 15.0, 7.6 Hz, 2H), 2.24 – 2.10 (m, 2H), 2.00 (d, J = 6.2 Hz, 2H), 1.74 – 1.62 (m, 
4H), 1.31 (m, 2H);
 13
C NMR (126 MHz, CDCl3) δ 177.70, 163.38, 162.00, 156.60, 148.74, 131.46, 
130.89, 129.02, 128.95, 128.73, 128.69, 128.42, 128.15, 128.09, 128.05, 114.92, 113.22, 111.79, 
102.79, 39.67, 33.32, 29.67, 29.10, 26.48, 25.64, 24.57, 22.67, 14.08. HRMS (ESI): calculated for 
C28H33NO6 (M+Na) 502.2200, found 502.2201. 
 
 
(S)-2,3-dihydroxypropyl (2-(trimethylammonio)ethyl) phosphate  26: 1,2-diheptanoyl-sn-glycero-
3-phosphocholine 25 (0.5 g, 1.0 mmol) was dissolved in methanol (180 mL) and added with 1 M 
NaOH (20 mL). The solution was refluxed for 2 h and cooled to room temperature. 2M HCl (10 mL) 
was added to quench the reaction and the mixture was concentrated. Extraction was performed using 
EA and water and the aqueous layer was separated and concentrated. Methanol was then added to 
dissolve the resulting solids in which the residual solids were filtered and discarded while the filtrate 
was concentrated to afford a white solid 26, 90% yield (0.24 g); 
1H NMR (500 MHz, MeOD) δ 3.99 
(s, 2H), 3.61 (m, 2H), 3.47 (m, 2H), 3.42 (m, 1H), 3.24 (m, J = 7.5 Hz, 3H), 3.10 (m, 1H), 3.07 (s, 9H); 





hydroxypropyl(2-(trimethylammonio) ethyl) phosphate 27 : Synthesis of 27 was adapted from G. 
Borsotti et al.
22
 20 (177 mg, 0.22 mmol) was first dissolved in THF (2.0 mL) and stirred with CDI (62 
mg, 0.38 mmol) at room temperature for 2 h. The mixture was then concentrated and redissolved in 
DMF (7.0 mL). At the same time, 26 (52 mg, 0.20 mmol) was added into DMF (3.0mL) and sonicated 
to dissolve the solids before adding into the solution of 20. K2CO3 (54mg, 0.45 mmol) was added and 
the reaction was heated at 40 
o
C for 12 h. After the reaction was complete, the solution was extracted 
with chloroform and water. Organic phase was re-extracted with water and combined aqueous phase 
was concentrated under reduced pressure. The crude mixture was dissolved in DMSO (20 μL) and 
added with 20 μL of 1,2-Dioleoyl-sn-glycero-3-phosphocholine(10mM in EtOH), 20 μL of 1,2-
Dioleoylphosphatidylglycerol (10mM in EtOH). The mixture was then added to a Tris-buffer solution 
(6.0 mL), pH 8.9, and stirred vigorously. 60 μL of Bee venom PLA2 (500 units/mL) was subsequently 
added and the reaction was stirred at room temperature for 8 h and concentrated. Preparative TLC was 
performed with the eluent 9:1 DCM:MeOH to afford an orange solid 27, 55% yield (94 mg); 
1
H NMR 
(500 MHz, MeOD) δ 8.30 (d, J = 8 Hz, 1H), 7.87 (td, J = 7.5, 1.3 Hz, 1H), 7.80 (td, J = 7.7, 1.2 Hz, 
1H), 7.45 (d, J = 7.5 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 7.06 (dd, J = 9.3, 5.6 Hz, 2H), 6.95 (dd, J = 
9.0, 2.3 Hz, 1H), 6.60 (dd, J = 9.6, 2.0 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.32 (d, J = 2.3 Hz, 2H), 
4.21 – 4.18 (m, 3H), 4.14 – 4.11 (m, 1H), 4.06 – 3.98 (m, 3H), 3.95 -3.91 (m, 2H), 3.67 (dd, J = 5.7, 
3.2 Hz, 2H), 3.25 (s, 9H), 2.37 (t, J = 7.5 Hz, 2H), 1.87 – 1.84 (m, 2H), 1.63 – 1.61 (m, 2H), 1.52 – 
1.51 (m, 2H), 1.41 – 1.31 (m, 18H), 0.95 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, MeOD) δ 187.21, 
175.36, 166.73, 166.56, 161.50, 156.42, 156.26, 135.15, 133.99, 132.59, 132.20, 131.94, 131.65, 
131.29, 130.85, 129.32, 118.12, 116.15, 116.02, 105.46, 101.90, 70.43, 69.89, 67.87, 67.54, 66.24, 
62.44, 60.47, 54.71, 34.92, 30.73 (2C), 30.71, 30.64 (2C), 30.59, 30.41, 30.38, 30.22, 30.02, 26.99, 
25.99, 13.92; 
31P NMR (202 MHz, MeOD) δ 0.37. HRMS (ESI): calculated for C45H63NO12P (M+1) 






tetraenoyl)oxy)propyl (2-(trimethylammonio)ethyl) phosphate   Flu7OHCou: 24 (17.0 mg, 0.04 
mmol) was first dissolved in THF (1.0 mL) and stirred with CDI (6.2mg, 0.04mmol) at room 
temperature for 2 h. The mixture was then concentrated and redissolved in DMF (2.0 mL). At the 
same time, 27 (40 mg, 0.05 mmol) dissolved in DMF (0.5 mL) and added into the solution of 24. 
K2CO3 (5.8mg,0.04 mmol) was added and the reaction was heated at 40 
o
C for 12 h. The reaction was 
extracted with chloroform and water. Organic phase was re-extracted with water and combined 
aqueous phase was concentrated under reduced pressure. Preparative TLC was performed with the 
eluent 9:1 DCM:MeOH to afford an orange solid, 60 % yield  (27.3 mg); 
1
H NMR (500 MHz, MeOD) 
δ 9.03 (s, 1H), 8.74 (s, 1H), 8.30 (d, J = 7.0 Hz, 1H), 7.87 (dt, J = 7.6, 3.8 Hz, 1H), 7.80 (dt, J = 7.7, 
6.6 Hz, 1H), 7.74 (dd, J = 5.7, 3.3 Hz, 1H), 7.67 – 7.63 (m, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.21 (d, J = 
2.3 Hz, 1H), 7.06 – 7.04 (m, 2H), 6.93 (dd, J = 9.0, 2.3 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 
6.60 – 6.58 (m, 1H), 6.51 (d, J = 1.6 Hz, 1H), 5.44 – 5.26 (m, 8H), 4.44 (dd, J = 12.0, 3.1 Hz, 1H), 
4.29 (s, 2H), 4.24 (dd, J = 5.5, 2.9 Hz, 1H), 4.20 – 4.17 (m, 3H), 4.05 – 3.98 (m, 4H), 3.67 – 3.66 (m, 
2H), 3.44 – 3.42 (m, 2H), 3.25 (s, 9H), 2.87 – 2.77 (m, 4H), 2.37 – 2.30 (m, 5H), 2.23 – 2.19 (m, 2H), 
2.11 – 2.05 (m, 4H), 1.88 – 1.82 (m, 2H), 1.73 – 1.67 (m, 4H), 1.53 – 1.50 (m, 3H), 1.36 – 1.31 (m, 
20H), 0.97 (t, J = 7.5 Hz, 3H); 
13
C NMR (101 MHz, MeOD) δ 185.82, 173.53, 173.00, 167.95, 165.34, 
165.12, 163.16, 162.00, 160.07, 157.15, 154.99, 154.76, 148.17, 133.75, 132.57, 132.22, 131.48, 
131.17, 130.98, 130.80, 130.56, 130.27, 129.87, 129.48, 129.42, 128.58, 128.52, 128.46, 127.97, 
127.91, 127.81, 127.76, 127.67, 116.74, 114.75, 114.61, 112.19, 110.96, 104.11, 100.51, 70.47, 69.03, 
67.76, 66.14, 63.54, 62.27, 61.04, 59.06, 53.39, 53.35, 53.31, 38.81, 35.14, 33.52, 33.11, 31.65, 30.24, 




31P NMR (243 MHz, MeOD) δ -0.43. HRMS (ESI): calculated for C73H92N2O17P (M-1) 
1299.6139, found 1299.6137. 
 
3.10 Experimental - biology 
3.10.1 Enzchek Phospholipase A2 Fluorogenic Assay (% Activity) 
The assay was conducted according to the manufacturer’s instruction (E10217, Molecular Probes) 
with slight modification. Briefly, substrate solution was separately prepared by mixing 5 μL of DOPG, 
5 μL of DOPC and 5 μL of substrate respectively in 1.5 mL of 1X reaction buffer. The mixture was 
vortexed vigorously for 3 min before allowing to stand at room temperature for an hour. 48 μL of 1X 
reaction buffer was added into each well of a 96-wells plate. This was followed by addition of 1 μL of 
recombinant cPLA2 (P4074-03R, US Biological) and 1 μL of 1 mM of the respective inhibitor/test 
compound dissolved in DMSO. The final concentration of the test compound achieved was 10 μM. 
The reaction was initiated by adding 50 μL of the substrate solution and incubating at room 
temperature for an hour. Fluorescence was measured using a Varioskan Flash plate reader 
(ThermoFisher Scientific) at 485 nm excitation and 515nm emission. Positive control was performed 
when 1 μL of the test compound was replaced by vehicle DMSO. % cPLA2 activity was calculated by 
the following formula 
 
% 𝑐𝑃𝐿𝐴2 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑝𝑜𝑠𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 
 
3.10.2 Enzchek Phospholipase A2 Fluorogenic Assay (IC50) 
The assay was conducted as described above. Instead of adding a fixed concentration of the 
inhibitor/test compound, various concentration of 7OHCou-AACF3 was reconstituted in DMSO.  48 
μL of 1X reaction buffer were added into each well of a 96-wells plate. This is followed by addition 
of 1 μL of recombinant cPLA2 (P4074-03R, US Biological) and 1 μL of the respective concentration 
of 7OHCou-AACF3 dissolved in DMSO. The reaction was initiated by adding 50 μL of the substrate 
solution and incubating at room temperature for an hour. Fluorescence was measured using a 
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Varioskan Flash plate reader (ThermoFisher Scientific) at 485 nm excitation and at 515 nm emission. 
Positive control was performed when 1 μL of 7OHCou-AACF3 was replaced by vehicle DMSO. 
 
3.10.3 Enzchek Phospholipase A2 Fluorogenic Assay (Selectivity) 
The assay was conducted as described above. Instead of adding cPLA2, it was replaced by sPLA2. 48 
μL of 1X reaction buffer was added into each well of a 96-wells plate. This is followed by addition of 
1 μL of sPLA2, human recombinant type V (Cat no. 10009563, Cayman Chemical) and 1 μL of 1 mM 
of the respective test compound dissolved in DMSO. Thio-etheramidePC is a sPLA2 selective 
inhibitor and was purchased from Cayman Chemical (Cat no. 62750). The reaction was initiated by 
adding 50 μL of the substrate solution and incubating at room temperature for an hour. Fluorescence 
was measured using a Varioskan Flash plate reader (ThermoFisher Scientific) by exciting at 485 nm, 
while fluorescence emission was detected at 515 nm. Positive control was performed when 1 μL of 
tested compound was replaced by vehicle DMSO. 
 
% sPLA2 activity was calculated by the following formula: 
% 𝑠𝑃𝐿𝐴2𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑




SHSY5Y human neuroblastoma cells (ATCC CRL-2266) were cultured in DMEM full medium 
(ThermoFisher Scientific, 11995-065) supplemented with 10% Fetal Bovine Serum, 100 μg/mL 
streptomycin and 100 units/mL penicillin. Cells were maintained in an incubator at 37 
o
C, under a 5% 
CO2, water saturated environment. When performing trichostatin A (TSA)-treatement, SHSY5Y cells 
were plated on 12 wells with density of 0.15x10
6
 cells per well. After observing a 70% confluency, 
TSA pre-dissolved in DMEM to achieve a final concentration of 0.75 μM was added to each well and 
incubated for 24 hours. Cells were then washed once with 1xPBS (1.0 mL) and scrapped on ice with 
RIPA buffer, which contain 1 x Protease Inhibitor (Roche, 11836153001) and 1 mM PMSF and 
incubated on ice for 30 min. This was followed by centrifuging the cell debris at 4 
o
C for 30 min at 
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Murine BV-2 cells (ATCC CRL-2540) were cultured in DMEM (ThermoFisher Scientific, 11965092) 
supplemented with 10% Fetal Bovine Serum, 100 μg/mL streptomycin and 100 units/mL penicillin. 
Cells were maintained in an incubator at 37 
o
C, under a 5% CO2, water saturated environment. When 
performing LPS treatment, BV-2 cells were plated on 10 cm dish in 10 mL DMEM at a density of 
1x10
6
 cells per dish one day prior to the experiment. After observing that cells are at 90% confluency, 
lipopolysaccharide (Sigma, L6529) pre-dissolved in DMEM to achieve a concentration of 2 μg/mL 
was added to the dish. 10 μM of 7OHCou-AACF3 were added to the LPS containing medium which 
was then transferred to the 10 cm dish. DMSO was used as vehicle control and added to the non-LPS 
treated control. The cells were incubated for 14 hours at 37 
o
C, under a 5% CO2.  After the respective 
timepoint, cells were washed once with 1xPBS (10 mL) and scrapped on ice with 8 mL 1xPBS. 
Collected cells were spun at 800 rpm for 3 min at 4 
o
C, before discarding the supernatant. Cells were 
lysed in RIPA buffer, which contains 1 x Protease Inhibitor and 1 mM PMSF and incubated on ice for 
30 min. This was followed by spinning the cell debris at 4 
o
C for 30 min at 13200 rpm before 
transferring the supernatant to a clean tube and storing the sample at -20 
o
C for future analyses. 
 
3.10.5 MTS assay 
Cells were plated on 96-wells plate and grown for 24 h at a density of 8000 cells per well for both 
HEK293T (ATCC CRL-3216) and BV-2 cells (ATCC CRL-2540). Cells were cultured in an 
incubator at 37 
o
C under a 5% CO2 environment in 100 μL of DMEM. Thereafter, the compound of 
interest dissolved in DMEM at a concentration of 10 μM was added into each well. DMSO was added 
as vehicle in the control group. 3 biological replicates were performed. The plates were then incubated 
at 37 °C with 5% CO2 for 48 h and 72 h. At each individual time point, 20 μL of CellTiter 96® 
AQueous One Solution (MTS reagent) was added into each well and re-incubated at 37 °C with 5% 




3.10.6 BCA Assay 
BCA assay (Pierce BCA Protein Assay Kit, 23225) was performed to quantify the concentration of 
proteins in the cell lysate. 10 µL of sample (1 µL lysate with 9 µL of lysis buffer) and BSA standards 
(range from 1.25 to 50 μg/ml) were mixed in a 96 well-plate and incubated with 190 µL of working 
reagent mixture (ratio of Reagent A:B used was 50:1) at 37 
o
C for 20 mins. The colour intensity that 
was developed was read at 562 nm using a spectrophotometer. A standard curve of different 
concentrations of BSA was plotted using the average blank-corrected readings for each standard vs. its 
respective concentration (µg/ml). This was then used to determine the protein concentration for 
unknown samples.     
 
3.10.7 Western Blot 
The amount of protein in the lysates were normalized by BCA previously. 25 μg of individual protein 
samples were mixed with an equal volume of 2x Laemmli buffer containing DTT and denatured at    
90 
o
C for 10 mins.  Lysates were loaded into a 10% Tris-Gly Gel. SDS-PAGE was ran at a voltage of 
100 V for 1.5 hours in 1x Running Buffer (10% Tris-Gly-SDS buffer). The protein samples on the gel 
were then transferred to PVDF membrane assembled in a sandwich soaked in 1x Transfer Buffer (10% 
Tris-Gly buffer, 10% methanol, 0.1% SDS) at 100 V for 2 hours under ice. The membrane blots were 
then incubated for one hour at room temperature in a blocking buffer containing 5% milk in 1xTris-
Gly buffer and 0.1% TBST, followed by overnight incubation with the respective primary antibody 
dissolved in 5% milk in 1xTris-Gly buffer and 0.1 % TBST at 4 
o
C. After three washes with 1xTris-
Gly buffer in 0.1% TBST, each of duration 10 min, the blot was incubated with a secondary horse-
radish peroxidase-conjugated antibody (1:10000) dissolved in 5% milk in 1xTris-Gly buffer and 0.1% 
TBST for one hour at room temperature. Three washes with 1xTris-Gly buffer in 0.1% TBST, each of 
duration 10 min were performed. Enhanced Chemiluminescence (ECL) detection of protein bands 
was performed using ECL Plus Western Blotting detecting system (GB Healthcare). Antibodies used 
in western blot include rabbit polyclonal anti-NOS2 (Santa-Cruz, sc-651, 1:100), mouse monoclonal 
anti-cPLA2 primary antibody (Santa Cruz, sc-454, 1:200), mouse anti-GAPDH (Merck, 1:10000), 
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with secondary horse-radish peroxidase-conjugated antibodies (Santa Cruz, 1:10000). GAPDH was 
used as the control protein to normalize loading quantity in each lane of the blot. 
 
3.10.8 Cell-staining 
The respective treatments were performed as described in the cell-treatment experiment. For these 
experiments, cells were grown on coverslip coated with 0.1mg/ml PDL. After the respective hours of 
treatment, 10 μM of 7OHCou-AACF3 were dissolved in DMEM and incubated with the cells at 37 
o
C for 1 h to stain the cells. Medium was then removed from individual wells and cells were rinse 
once with 1xPBS (1 mL). 4% formaldehyde (500 μL) were added for 10 min at room temperature for 
fixation before rinsing the cells twice with 1xPBS(1 mL). Coverslips were dried for 1 min before 
mounting it on glass-slides using Prolong Gold Antifade Mountant,(Thermofisher, P36930). 
 
3.10.9 Photophysical property of 7OHCou-AACF3  
Quantum yields were measured and calculated by using the following equation and referencing with 






























































3.10.10 Assay with positive control bee venom PLA2 
6 μL of 10 mM Flu7OHCou was mixed with 10 μL of DOPG, 10 μL of DOPC and added into 3 mL 
of Tris-HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2,1% Triton X, pH 7.3) buffer solution. 
The solution was vortexed vigorously for 3 min before allowing it to stand at room temperature for 
one hour. 100 μL of the liposomal solution was added into a 96-wells plate. The reaction was initiated 
by adding 1 μL of Bee venom (E10217), 5 units/ml from EnzChek PLA2 Assay. Fluorescence was 
measured using a Varioskan Flash plate reader (ThermoFisher Scientific) by exciting at 410 nm, and 
measuring the emission spectra at every 5 min intervals. Negative control was performed when 1 μL 
of bee venom was replaced by the buffer solution. 
 
3.10.11 Assay for cPLA2 enzyme with and without Triton X-100 
6 μL of 10 mM Flu7OHCou was mixed with 10 μL of DOPG, 10 μL of DOPC and added into 3 mL 
of either Tris-HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2, pH 8.9) or (50 mM Tris-HCl, 100 
mM NaCl, 20 mM CaCl2, 1% Triton X-100, pH 8.9) buffer solution. The solution was vortexed 
vigorously for 3 min before allowing it to stand at room temperature for one hour. 100 μL of the 
liposomal solution was added into each well of a 96-wells plate. The reaction was initiated by adding 
1 μL of recombinant cPLA2 (P4074-03R, US Biological). Fluorescence was measured using a 
Varioskan Flash plate reader(ThermoFisher Scientific) by exciting at 410 nm, and measuring the 
emission spectra at every 5 min intervals. Negative control was performed when 1 μL of bee venom 
was replaced by the buffer solution. 
 
3.10.12 Assay for selectivity test with Flu7OHCou 
6 μL of 10 mM Flu7OHCou was mixed with 10 μL of DOPG, 10 μL of DOPC and added into 3 mL 
of Tris-HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2, pH 8.9) or (50 mM Tris-HCl, 100 mM 
NaCl, 20 mM CaCl2, 1% Triton X-100, pH 8.9) buffer solution. The solution was vortexed vigorously 
for 3 min before allowing it to stand at room temperature for one hour. 100 μL of the liposomal 
solution was added into each well of a 96-wells plate. The reaction was initiated by adding 1 μL of 
recombinant cPLA2 (P4074-03R, US Biological) as well as 1 μL of reconstituted sPLA2 (10009563, 
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Cayman Chemicals) each having activity of 0.05 unit/mL. Fluorescence was measured using a 
Varioskan Flash plate reader (ThermoFisher Scientific) by exciting at 410 nm, while fluorescence 
emission was detected at 447 nm at 5 min intervals. Negative control was performed when 1 μL of 
enzyme was replaced by the buffer solution. 
 
3.10.13 Assay to determine IC50 of AACOCF3 with Flu7OHCou 
6 μL of 10 mM Flu7OHCou was mixed with 10 μL of DOPG, 10 μL of DOPC and added into 3 mL 
of Tris-HCl (50 mM Tris-HCl, 100 mM NaCl, 20 mM CaCl2, pH 8.9) buffer solution. The solution 
was vortexed vigorously for 3 min before allowing it to stand at room temperature for one hour. 100 
μL of the liposomal solution was added into each well of a 96-wells plate. This is followed by adding 
1 μL of the respective concentration of AACOCF3 dissolved in DMSO. The reaction was initiated by 
adding 1 μL of recombinant cPLA2 (P4074-03R, US Biological) and incubating at room temperature 
for one hour. Fluorescence was measured using a Varioskan Flash plate reader (ThermoFisher 
Scientific) by exciting at 410 nm, while fluorescence emission was detected at 447 nm. Positive 
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CHAPTER 4: CONCLUSION AND FUTURE PERSPECTIVE 
4.1 Conclusion 
In this thesis, we have developed a new class of inhibitors of cPLA2 basing it on AACOCF3 as 
scaffold. By devising a synthetic route that is divergent, common intermediates could be identified 
and used for the synthesis of the compounds. A total of 33 compounds including AACOCF3 was 
synthesized and structure activity relationship studies was performed. Among these 33 compounds, 
we identified one compound, 2i to be the most potent, non-cytotoxic and a selective and effective 
inhibitor of cPLA2. By testing the compound in potential neuroinflammatory model involving LPS-
stimulated BV-2 microglial cells, 2i was able to reduce ROS and iNOS production. In addition, 
PAMPA assay showed that 2i is brain penetrant, further enhancing the potential of 2i to be a 
neurological agent for inhibition of cPLA2 in the CNS. We have also developed 7OHCou-AACF3 as 
a non-cyotoxic and selective fluorogenic inhibitor of cPLA2 with dual functions of imaging and 
inhibition. With an IC50 of 12.5±1.0 μM which is comparable with AACOCF3, it was demonstrated to 
quench iNOS production via its role as an inhibitor and is capable of imaging the increase in cPLA2 
protein levels. In addition, Flu7OHCou, a cPLA2-selective fluorogenic substrate was synthesized and 
demonstrated its use for inhibitor screening assays.  
 
4.2 Future Perspectives 
Further modification on the inhibitor scaffold could be directed on the alkyl chain end  region, such as 
changing it to bulky aromatic derivatives to see how flexible the enzyme is at this pocket. In addition, 
the use of 2i could be expanded to other neurodegenerative models such as Alzheimer’s disease or 
multiple sclerosis to see the effect it has on disease reversal by reducing cPLA2’s activity. This could 
determine the potential of 2i as a neurological inhibitor of cPLA2, with upon further studies on its 
pharmacokinetic properties could assess the feasibility of upgrading 2i into potential clinical trial. 
 
In terms of developing inhibitor and substrate probe for cPLA2, a wider range of fluorophore could be 
attached to the tail end of arachidonyl trifluoromethylketone. The current probe 7-hydroxycoumarin 
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could potentially be deprotonated at higher pH leading to the formation of a charged moiety. Having a 
neutral fluorophore allows pH effects to be reduced, hence giving a more stable response. More 
applications could be performed using the substrate probe Flu7OHCou including the use of it to track 
cPLA2 activity in tissue slices eg. brain slices. This would pave the path for potential in vivo 
applications.  
 
Lastly, potential functionalization of the alkyl chain end of 2i could allow the installation of a 7-
hydroxycoumarin moiety. The resulting inhibitor probe formed could be more specific to cPLA2 and 
the applications similar to what 7OHCou-AACF3 could perform may also be explored. 
